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Abstract 
Apolipoprotein E (APOE) is a major genetic risk factor for Alzheimer’s disease (AD) and has been 
shown to influence amyloid-β (Aβ) clearance from the brain in an isoform-specific manner. Our 
prior work showed Aβ transit across the blood-brain-barrier was reduced by apoE4, compared to 
other apoE isoforms, due to elevated lipoprotein receptor shedding in brain endothelia. Recently, 
we demonstrated matrix metallopeptidase 9 (MMP-9) induces lipoprotein receptor proteolysis in 
an apoE isoform-dependent manner, which impacts Aβ elimination from the brain. The current 
studies interrogated the relationship between apoE and MMP-9 and found apoE dose-dependently 
reduced MMP-9 activity in a cell-free assay, with apoE4 showing a significantly weaker ability to 
inhibit MMP-9 function than apoE2 or apoE3.  Moreover, these effects may be due to the reduced 
binding affinity of apoE4 for MMP-9 compared to apoE2 and apoE3 as revealed by kinetic binding 
studies. Elevated MMP-9 expression and activity was observed in the cerebrovasculature of both 
human and animal AD brain specimens with an APOE4 genotype. The apoE isoforms also lead 
to altered levels of MMP-9 secreted from brain endothelia cultures (apoE2<apoE3=apoE4). Both 
the expression and secretion of MMP-9 were more pronounced upon insult, suggesting a 
combined influence of AD and APOE genotype. Collectively, these findings suggest a role for 
apoE in regulating MMP-9 disposition in the brain, which could have profound consequences for 
a variety of neurodegenerative diseases. With respect to AD, genetic deletion of the MMP-9 gene 
in 5xFAD mice rescued deficits in sociability, social recognition memory and anxiety disinhibition, 
signifying an important role for MMP-9 in the behavioral dysfunction inherent in AD. These 
observations did not appear to be due to changes in brain Aβ levels or lipoprotein receptor 
shedding, suggesting the behavioral improvements resulting from MMP-9 gene removal were 
mediated through alternative mechanisms. In total, modulating MMP-9 may represent a promising 
therapeutic strategy for the treatment of AD and other neurological disorders. 
 
~ 3 ~ 
 
Acknowledgements 
 
It is a pleasure to thank the following people, without whom I would not have been able 
to complete this research. 
First of all, I would like to express my sincere gratitude to my supervisor Dr. Corbin Bachmeier 
for the continuous encouragement and support throughout my Ph.D. study. His guidance greatly 
facilitated all the planning and conducting of experiments and in the writing of this thesis. I count 
myself very lucky to have had such a supervisor for my Ph.D. 
I wish to express my special appreciation and thanks to my secondary supervisor, Dr. Laila 
Abdullah, who has provided a great deal of guidance and feedback over the course of my Ph.D. I 
am exceptionally grateful for her help and expertise with statistical analysis and the apoE lipidation 
studies. 
Thank you both for guiding me through the research and the preparation of both this thesis and 
the published manuscript. 
Of course, I am extremely indebted to Dr. Fiona Crawford and Dr. Mike Mullan for their support 
of me and all the other Ph.D. students. I am thankful for Mike’s comprehensive knowledge and 
his encouragement for us to take the time to deliberate over decisions and to consider the bigger 
picture. Thank you to Fiona for always being willing to make time to help and for being an 
unstoppable force of good for the institute. I would like to say an extra thanks to you both for all 
the measures you have put in place with regards to the current unprecedented situation caused by 
COVID-19, to ensure that the Roskamp Institute remains a safe haven in amongst the turmoil. 
Thank you to Robert and Diane Roskamp for co-founding the Roskamp Institute and for 
providing a place for scientists to conduct research with the aim to combat neurological diseases. 
Thank you to the Roskamp foundation, to the Bay Pines Veteran’s Affairs Healthcare system and 
to the National Institute of Health for funding this research. 
I would like to say a big thank you to the other PIs at the Roskamp Institute, in particular Dr. 
Daniel Paris and Dr. Ghania Ait-Ghezala, for their individual expertise and help in various aspects 
of my project. I would also like to acknowledge and thank Dr. Ben Shackleton for his prior research 
which provided the foundation for these studies. Thank you to Max Eisenbaum for lending a hand 
whenever I needed it and for always being ready with a joke. I would also like to thank the other 
current and past students and staff that have helped me and who have made my overall experience 
enjoyable. In particular, Alex Morin, Claire Huguenard, Adam Cseresznye, Heather Langlois and 
Nicole Saltiel. 
My special thanks to my family for their continued encouragement and support of my education 
and of the choices that I make for my life. Thank you for your visits to the U.S. during my Ph.D. 
and for always enquiring about my progress. 
And finally, thank you to my brilliant husband and fellow Ph.D. student, Dr. Jonas Schweig. You 
have always been my support from the beginning, happy to share your knowledge and experience 
and willing to give up your free time to help me solve a problem. Thank you for supporting me 
both in the laboratory and at home. 
 
 
~ 4 ~ 
 
I would also like to thank the scientists that actively contributed to this thesis: 
 
The binding analysis of apoE to MMP-9 displayed in Chapter 3.3.1 was performed by Dr. Daniel 
Paris. 
 
The cell-free activity assay, showing the regulation of MMP-9 activity by apoE, displayed in 
Chapter 3.3.3, was conducted by Dr. Ben Shackleton. 
 
The confocal analysis of EFAD tissue displayed in Chapter 2.3.2 and Chapter 3.3.4 was conducted 
by Dr. Jonas Schweig. 
 
The ELISA analysis of lipoprotein receptor levels in human brain tissue displayed in Chapter 3.3.5 
were derived from the Ph.D. thesis of Dr. Ben Shackleton. 
 
 
This work was supported by Merit Review award number I01BX002839 from the United States 
(U.S.) Department of Veterans Affairs (VA) Biomedical Laboratory Research and Development 
Program. The research in this publication was also supported by the National Institute on Aging 
of the National Institutes of Health under award number R01AG041971. I am grateful to the 
Banner Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona 
for providing the human brain specimens. The Brain and Body Donation Program is supported 
by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain 
and Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute on 
Aging (P30 AG19610 Arizona Alzheimer’s Disease Core Center), the Arizona Department of 
Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical 
Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson’s Disease 
Consortium) and the Michael J. Fox Foundation for Parkinson’s Research. Human brain tissue 
specimens were also obtained from the University of Maryland Brain and Tissue Bank which is a 
Brain and Tissue Repository of the NIH NeuroBioBank (Baltimore, MD) and the Mount Sinai 
NIH Brain and Tissue Repository (New York, NY). I would also like to thank Dr. Mary Jo LaDu 
(University of Illinois at Chicago) for providing the mixed glial cultures and EFAD animals, and 
Dr. Hussein Yassine (University of Southern California) for his guidance and assistance with the 
apoE lipidation studies. 
 
 
 
 
~ 5 ~ 
 
Table of Contents 
Abstract ........................................................................................................................................................ 2 
Chapter 1: Introduction ........................................................................................................................... 11 
1.1 Alzheimer’s disease .................................................................................................................. 11 
1.1.1 Incidence and impact of Alzheimer’s disease .............................................................. 11 
1.1.2 Amyloid pathology........................................................................................................... 12 
1.1.3 Tau Pathology ................................................................................................................... 18 
1.1.4 Neuroinflammation ......................................................................................................... 19 
1.1.5 Apolipoprotein E ............................................................................................................. 21 
1.2 Blood brain barrier dysfunction ............................................................................................. 24 
1.2.1 Cerebrovasculature and blood brain barrier deterioration ......................................... 24 
1.2.2 Lipoprotein receptors ...................................................................................................... 26 
1.2.3 Matrix metallopeptidase 9 ............................................................................................... 28 
1.3 Mouse models of Alzheimer’s disease................................................................................... 32 
1.4 Clinical trials for Alzheimer’s disease .................................................................................... 34 
1.5 Aims of the studies .................................................................................................................. 40 
Chapter 2: Effect of apoE on the expression and secretion of MMP-9 in human and mouse brain 
tissue ........................................................................................................................................................... 42 
2.1 Introduction .............................................................................................................................. 42 
2.2 Materials and methods ............................................................................................................. 45 
2.2.1 Materials ............................................................................................................................ 45 
2.2.2 Human cortex samples .................................................................................................... 45 
2.2.3 Animals .............................................................................................................................. 46 
2.2.4 Isolation of brain fractions ............................................................................................. 47 
2.2.5 Measurement of active and total MMP-9 levels in mouse and human 
cerebrovasculature ........................................................................................................................... 47 
2.2.6 AB-42 injected apoE-TR mice ....................................................................................... 48 
2.2.7 Zymographic analysis of EFAD spleen samples ......................................................... 48 
2.2.8 Collection and enrichment of human lipidated apoE ................................................ 49 
2.2.9 Effect of APOE genotype on total secreted MMP-9 and secreted active MMP-9 in 
vitro  ............................................................................................................................................ 50 
2.2.10 Effect of APOE genotype on total secreted MMP-9 ex vivo ................................... 50 
2.2.11 Tissue processing ............................................................................................................. 50 
2.2.12 Immunofluorescence ....................................................................................................... 51 
2.2.13 Statistical analysis ............................................................................................................. 52 
2.3 Results ........................................................................................................................................ 53 
2.3.1 MMP-9 expression and activity across APOE genotype in human 
cerebrovasculature ........................................................................................................................... 53 
2.3.2 MMP-9 expression across APOE genotype in EFAD mice ..................................... 55 
2.3.3 MMP-9 expression across APOE genotype in apoE-TR mice ................................. 59 
2.3.4 Effect of apoE isoform on MMP-9 secretion in HBMECs and apoE-TR mice ... 59 
2.4 Discussion ................................................................................................................................. 63 
Chapter 3: Functional regulation of MMP-9 by apoE: conversion, binding, colocalisation and 
enzymatic activity ...................................................................................................................................... 71 
~ 6 ~ 
 
3.1 Introduction .............................................................................................................................. 71 
3.2 Materials and methods ............................................................................................................. 74 
3.2.1 Materials ............................................................................................................................ 74 
3.2.2 Human cortex samples .................................................................................................... 74 
3.2.3 Animals .............................................................................................................................. 74 
3.2.4 Isolation of brain fractions ............................................................................................. 74 
3.2.5 Collection and enrichment of human lipidated apoE ................................................ 75 
3.2.6 Artificial lipidation of apoE ............................................................................................ 75 
3.2.7 Zymographic analysis of the impact of apoE on MMP-9 conversion to the active 
form  ............................................................................................................................................ 76 
3.2.8 Cell-free activity assay...................................................................................................... 76 
3.2.9 Binding studies ................................................................................................................. 76 
3.2.10 Tissue processing ............................................................................................................. 77 
3.2.11 Immunofluorescence ....................................................................................................... 77 
3.2.12 Statistical analysis ............................................................................................................. 78 
3.3 Results ........................................................................................................................................ 79 
3.3.1 Binding interactions between apoE and MMP-9 ........................................................ 79 
3.3.2 Effect of apoE isoform on pro MMP-9 conversion to activated MMP-9 .............. 79 
3.3.3 Effect of apoE isoform on MMP-9 activity................................................................. 82 
3.3.4 Localisation of apoE and MMP-9 in brain endothelia ............................................... 82 
3.3.5 Differences in lipoprotein receptor levels in human brain tissue ............................. 85 
3.3.6 Differences in lipoprotein receptor levels in EFAD mouse brain ........................... 85 
3.4 Discussion ................................................................................................................................. 88 
Chapter 4: Modulation of MMP-9 activity and expression in AD mice ........................................... 95 
4.1 Introduction .............................................................................................................................. 95 
4.2 Materials and methods ............................................................................................................. 97 
4.2.1 Materials ............................................................................................................................ 97 
4.2.2 Animals .............................................................................................................................. 97 
4.2.3 In vivo treatment with SB-3CT in E4FAD mice ...................................................... 100 
4.2.4 Study design .................................................................................................................... 100 
4.2.5 Behavioural analysis ....................................................................................................... 101 
4.2.6 Isolation of brain fractions ........................................................................................... 103 
4.2.7 Guanidine extraction ..................................................................................................... 104 
4.2.8 Zymographic analysis of EFAD spleen samples ....................................................... 104 
4.2.9 Statistical analysis ........................................................................................................... 104 
4.3 Results ...................................................................................................................................... 105 
4.3.1 Pharmacological inhibition of MMP-9 activity with SB-3CT in E4FAD mice .... 105 
4.3.2 Genetic manipulation of MMP-9 in 5xFAD mice .................................................... 114 
4.4 Discussion ............................................................................................................................... 124 
Chapter 5: Conclusions .......................................................................................................................... 131 
Chapter 6: Future directions .................................................................................................................. 136 
Chapter 7: References ............................................................................................................................ 138 
 
~ 7 ~ 
 
Table of Figures 
Figure 1.1: Processing of β-amyloid precursor protein by the sequential processing of secretases.
 ..................................................................................................................................................................... 13 
Figure 1.2: The amyloid cascade hypothesis describing the sequence of major pathogenic events 
leading to AD. ........................................................................................................................................... 16 
Figure 1.3: Schematic diagram depicting the proposed regulatory mechanisms of MMP-9 by which 
apoE could be influencing MMP-9 disposition.................................................................................... 41 
Figure 2.1: APOE genotype effect on total MMP-9 levels in the cerebrovasculature of human brain 
tissue in AD and control subjects. .......................................................................................................... 53 
Figure 2.2: APOE genotype effect on active MMP-9 levels in the cerebrovasculature of human 
brain tissue in AD and control subjects. ............................................................................................... 54 
Figure 2.3: MMP-9 expression in mouse homogenate tissue from EFAD mice at 10, 40 and 70 
weeks of age. .............................................................................................................................................. 55 
Figure 2.4: MMP-9 expression in mouse cerebrovasculature tissue from EFAD mice at 10, 40 and 
70 weeks of age. ........................................................................................................................................ 56 
Figure 2.5: MMP-9 immunoreactivity in cortices of E3FAD and E4FAD mice. ........................... 57 
Figure 2.6: Levels of proMMP-9 in spleens of E3FAD and E4FAD mice. .................................... 58 
Figure 2.7: MMP-9 expression in mouse cerebrovasculature tissue from apoE-TR mice following 
intracranial injection with DMSO or Aβ-42. ........................................................................................ 58 
Figure 2.8: ApoE isoform differences in MMP-9 secretion in conditioned media from apoE-
treated HBMECs. ..................................................................................................................................... 61 
Figure 2.9: Impact of apoE isoform on MMP-9 secretion. ................................................................ 62 
Figure 3.1: Activation of the gelatinase, MMP-9. ................................................................................. 71 
Figure 3.2: Kinetic binding studies of MMP-9 and apoE2, apoE3 or apoE4 using Bio-Layer 
Interferometry. .......................................................................................................................................... 80 
Figure 3.3: Figure 14: Kinetic binding studies of MMP-9 and artificially lipidated apoE3 using Bio-
Layer Interferometry. ............................................................................................................................... 81 
Figure 3.4: Effect of apoE isoform on the conversion of MMP-9 to the active form................... 81 
Figure 3.5: Differential modulation of MMP-9 activity by apoE isoforms. ..................................... 83 
Figure 3.6: MMP-9 and apoE immunoreactivities in cortices of E3FAD and E4FAD mice. ...... 84 
Figure 3.7: Expression of LRP1 in human cortex samples. ............................................................... 86 
Figure 3.8: Expression of LRP1 and LDLR in 40-week-old and 70-week-old EFAD mouse brain.
 ..................................................................................................................................................................... 87 
~ 8 ~ 
 
Figure 3.9 ApoE isoforms differentially regulate MMP-9 disposition. ............................................. 94 
Figure 4.1: Study design for the 4-week pharmacological MMP-9 inhibition and MMP-9 gene 
deletion in vivo analysis. ........................................................................................................................ 100 
Figure 4.2: Anxiety-related behaviour and locomotor activity in the OFT and the EPM. .......... 106 
Figure 4.3: Testing social interaction and social memory using the three-chamber test. ............. 107 
Figure 4.4: Spatial memory testing using the RAWM. ...................................................................... 108 
Figure 4.5: Spatial memory testing of male mice using the RAWM. ............................................... 109 
Figure 4.6: Analysis of Aβ-40 and Aβ-42 levels in the cerebrovasculature, whole parenchyma and 
the GS and GI parenchyma brain fractions. ....................................................................................... 111 
Figure 4.7: Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain 
fraction...................................................................................................................................................... 112 
Figure 4.8: Analysis of MMP-9 levels in SB-3CT and vehicle-treated E4FAD mice. .................. 113 
Figure 4.9: Anxiety-related behaviour and locomotor activity in the OFT and the EPM. .......... 115 
Figure 4.10: Testing social interaction and social memory using the three-chamber test. ........... 117 
Figure 4.11: Testing social interaction and social memory of male mice using the three-chamber 
test. ............................................................................................................................................................ 118 
Figure 4.12: Testing spatial memory using the RAWM. ................................................................... 120 
Figure 4.13: Analysis of Aβ-40 levels in the cerebrovasculature, plasma, whole parenchyma and 
the GS and GI parenchyma brain fractions. ....................................................................................... 121 
Figure 4.14: Analysis of Aβ-42 levels in the cerebrovasculature, whole parenchyma and the GS and 
GI parenchyma brain fractions. ............................................................................................................ 122 
Figure 4.15: Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain 
fraction...................................................................................................................................................... 123 
 
 
 
 
 
 
~ 9 ~ 
 
Abbreviations 
AD Alzheimer’s disease 
ADAM10 A desintegrin and metalloproteinase domain containing protein 10 
AICD APP intracellular domain 
ANOVA Analysis of variance 
APMA 4-aminophenylmercuric acetate 
APOE Apolipoprotein E 
ApoE-TR ApoE targeted replacement 
APP Amyloid precursor protein 
ARIA Amyloid-related imaging abnormalities 
Aβ Amyloid beta 
BACE β-site amyloid precursor protein cleaving enzyme 
BBB Blood brain barrier 
BCA Bicinchoninic acid 
BKY Two-stage step-up method of Benjamini, Krieger and Yekutieli 
C1q Complement component 1q 
CNS Central nervous system 
CSF Cerebrospinal fluid 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
EOAD Early-onset Alzheimer’s disease 
EPM Elevated plus maze 
FAD Familial Alzheimer’s disease 
FBS Foetal bovine serum 
FDA U.S. Food and Drug Administration 
GI Guanidine insoluble 
GS Guanidine soluble 
HBMECs Human brain microvascular endothelial cells 
HBSS Hanks Balanced Salt Solution 
HDL High-density lipoprotein 
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol 
Ig Immunoglobulin 
IL Interleukin 
~ 10 ~ 
 
KD Dissociation constant 
KO Knockout 
LDLR Low-density lipoprotein receptor 
LOAD Late-onset Alzheimer’s disease 
LRP1 Low density lipoprotein receptor-related protein 1 
LTP Long-term potentiation 
MAPT Microtubule associated protein tau 
MCI Mild cognitive impairment 
MMP Matrix metallopeptidase 
MMP9KO MMP-9 knockout 
MPER Mammalian Protein Extraction Reagent 
NFTs Neurofibrillary tangles 
NFκB Nuclear factor κ-light-chain-enhancer of activated B cells 
OFT Open field test 
PBS Phosphate-buffered saline 
PEG Polyethylene glycol 
PET Positron emission tomography 
PFA Paraformaldehyde 
PKC-α Protein kinase C-α 
PMA Phorbol-12-myristate-13-acetate 
PMSF Phenylmethylsulphonyl fluoride 
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
PS1 Presenilin 1 
PS2 Presenilin 2 
RAGE Receptor for advanced glycation end products 
RAWM Radial arm water maze 
SB-3CT 2-[[(4-Phenoxyphenyl)sulfonyl]methyl]thiirane) 
SEM Standard error of the mean 
TBI Traumatic brain injury 
TGF-β Transforming growth factor β 
TIMP Tissue inhibitor of metallopeptidases 
TNF-α Tumour necrosis factor α 
TREM2 Triggering receptor expressed on myeloid cells 2 
VCAM1 Vascular cell adhesion molecule-1 
WT Wild type 
α-CTF α-C-terminal fragment 
β-CTF β-C-terminal Fragment 
 
~ 11 ~ 
 
Chapter 1: Introduction 
1.1 Alzheimer’s disease 
1.1.1 Incidence and impact of Alzheimer’s disease 
Dementia is an umbrella term for diseases and conditions characterised by a gradual loss in 
memory and cognitive ability [1]. Today (2020), it is estimated that there are over 50 million people 
living dementia. With the rapid growth in the number of individuals developing dementia, this 
figure is set to triple to 152 million by 2050 [2], largely due to the aging population. Indeed, age is 
the most influential known risk factor; it is estimated that 25% to 45% of people older than 85 
years have some form of dementia, the most common being Alzheimer’s disease (AD), accounting 
for more than half of all cases [1], [3]. However, AD can also develop earlier, with symptoms 
appearing between the ages of 30 and 60. Based on the age of onset, AD is subdivided into either 
early-onset AD (EOAD), which is usually linked to causative genes, or the more prevalent form, 
late-onset AD (LOAD), also referred to as sporadic AD, where the cause is unknown but 
associated with gene-environment interactions. Typically, EOAD tends to have a more aggressive 
disease progression and a shorter relative survival time [4]. 
Neurofibrillary tangles of hyperphosphorylated tau (NFTs), accumulation of amyloid beta (Aβ) 
and neuroinflammation are the classic hallmark pathologies that characterise AD and were first 
described by Alois Alzheimer in 1907 [5]. Although the definitive diagnosis of the disease requires 
post-mortem examination of the brain and the identification of Aβ plaques, diagnosis in living 
patients can be assisted by certain clinical criteria and cerebrospinal fluid (CSF) and positron 
emission tomography (PET) biomarkers [6]–[8]. Current validated CSF biomarkers for AD are 
low Aβ-42 levels, high total tau and high phosphorylated tau protein levels [9], [10]. As it is a 
progressive and currently irreversible neurodegenerative disorder, symptoms of AD usually 
develop gradually and worsen over time, becoming debilitating and interfering with daily activities. 
They progress from mild loss of memory in the early stages of AD to being unable to respond to 
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the environment and carry on conversations, as is often the case in late-stage AD. The most 
common early symptom of AD is having problems retaining new information. As the disease 
develops through the brain, the symptoms become increasingly severe and may manifest as mood 
and behaviour changes such as confusion about events, time and place or becoming suspicious 
about family and friends. People with AD may also have difficulty speaking, swallowing and 
walking [2]. 
1.1.2 Amyloid pathology 
1.1.2.1 APP processing 
The amyloid precursor protein (APP), located on chromosome 21, is thus named because it was 
demonstrated to be the precursor protein to Aβ peptides, which are the building blocks of the 
extracellular plaques central to AD [11]–[17]. The production of Aβ requires the double cleavage 
of APP via the amyloidogenic pathway. First, β-secretase, also known as β-site amyloid precursor 
protein cleaving enzyme (BACE), cleaves APP within the luminal domain generating membrane-
tethered β-C-terminal fragment (β-CTF) and the soluble ectodomain sAPPβ [18]. Next, the β-
terminal fragments are cleaved by γ-secretase within the transmembrane domain to release Aβ. 
Both Aβ and sAPPβ are released into the extracellular milieu following exocytosis [19]. 
Alternatively, APP can also be processed via the nonamyloidogenic pathway which involves α-
secretase as opposed to BACE, and cleaves APP within the Aβ sequence, thus preventing its 
production. In this pathway, γ-secretase then cleaves the α-C-terminal fragments (α-CTF) resulting 
in the formation of p3 peptides instead of Aβ (Figure 1.1). The accumulation of soluble Aβ and 
the subsequent aggregation into Aβ plaques seen in AD can be attributed in part to a shift in the 
equilibrium of the APP processing towards the amyloidogenic pathway [20]. 
 
 
~ 13 ~ 
 
 
Figure 1.1: Processing of β-amyloid precursor protein by the sequential processing of secretases. 
A) Nonamyloidogenic processing of APP by α-secretase followed by γ-secretase releasing the p3 peptide. 
B) Amyloidogenic processing of APP by β-secretase and subsequently γ-secretase resulting in the 
production of the Aβ protein. Both α-secretase and β-secretase generate soluble ectodomains (sAPPα and 
sAPPβ respectively) and in both instances intracellular C-terminal fragments (AICD) are produced 
following γ-secretase cleavage (as described by O’Brien and Wong (2011) [21]). 
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1.1.2.2 Mutations in genes involved in APP processing 
Epidemiological studies provided the first direct evidence to implicate the considerable 
involvement of genetic factors in AD pathology. AD can be divided into a familial and sporadic 
forms based on whether the disease can be traced to a clear family history [22]. While the majority 
of AD cases are classed as sporadic, the clinical course and pathology of familial AD (FAD) is 
similar to sporadic AD and thus has been used extensively to study the disease as a whole and to 
conduct clinical trials (discussed in 1.4). Thus, it is crucial to study and define the molecular 
mechanisms that give rise to AD in individuals with FAD [23]. Three causative genes have been 
linked to autosomal dominant FAD: APP, PS1, and PS2. The first mutations of these genes that 
were found to cause AD were discovered in the early 1990s and include point/missense mutations 
of the APP protein, e.g. APP V717I (London) and APP KM670/671NL (Swedish) [24], [25]. 
These mutations were the first of many implicating APP in the development of EOAD [26]. One 
variant (APP A673T (Icelandic)), uncovered in 1993, was demonstrated not to cause AD but to 
be protective against the disease and cognitive decline in the elderly without AD [27], [28]. In vitro, 
it was associated with a 40% reduction in the formation of amyloidogenic peptides which was 
attributed to the mutation being in close proximity to, and inhibiting the cleavage of, BACE [27]. 
Further mutations that affect the cleavage of APP were detected in genes encoding subunits of the 
γ-secretase, presenilin 1 and 2 (PS1, PS2) [4], [29]–[35]. When these mutations were identified, PS1 
mutations were found to occur more frequently than PS2 mutations and now over 200 different 
PS1 mutations have been recognised [35], [36], accounting for up to 70% of all EOAD cases [37]. 
Presenilin gene mutations typically result in the elevated production of Aβ-42, causing a higher 
ratio of Aβ-42:Aβ-38 and a consequently greater formation of Aβ aggregates [38]–[40].  
1.1.2.3 The amyloid hypothesis 
Glenner and Wong (1984b) first isolated and sequenced the Aβ protein and proposed that it could 
be a causative factor in AD [12]. The subsequent discovery that pathogenic mutations of APP, 
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PS1 and PS2 lead to the aberrant cleavage of APP and hence distort the normal processing of the 
Aβ protein, has provided impetus to the reigning amyloid cascade hypothesis. This postulates that 
Aβ is imperative to the pathogenesis of AD and positions it at the beginning of the pathological 
cascade for the disease process: “beta-amyloid deposition----tau phosphorylation and tangle 
formation----neuronal death” [41]–[44]. More genetic evidence that supports this hypothesis arises 
from the finding that the extra copy of chromosome 21 and the ensuing overexpression of the 
APP gene in individuals with Trisomy 21 (Down's syndrome) results in elevated Aβ deposits which 
precede further pathology characteristic of AD [45].  
Accumulation of Aβ occurs early in the disease pathology, and besides the increased production 
of Aβ contributing to the increased levels, there is also thought to be an imbalance in the clearance 
of the peptide (discussed in 1.2). While FAD presents with mutations that encourage the increased 
production of Aβ, the impaired clearance is deemed to be of more consequence in the sporadic 
forms of AD, where the failure of clearance mechanisms gives rise to the gradual accrual of the 
toxic amyloidogenic proteins [45]. Yet, according to the amyloid cascade hypothesis, in both cases 
the oligomerisation of Aβ affects synaptic health and the deposition of Aβ oligomers into diffuse 
plaques elicits inflammatory responses and neuronal dyshomeostasis. This leads to changes in 
kinase and phosphatase activity and the formation of NFTs comprised of the protein tau 
(discussed in more detail in 1.1.3). Ultimately this leads to extensive neuronal dysfunction and 
death, resulting in dementia (Figure 1.2) [45]. 
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Figure 1.2: The amyloid cascade hypothesis describing the sequence of major pathogenic events 
leading to AD. 
The curved yellow arrow signals that Aβ oligomers may also contribute to downstream processes such as 
activating microglia and astrocytes and directly injuring synapses and neurons (as described by Selkoe and 
Hardy (2016) [45]). 
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Although this linear hypothesis has been met with considerable scepticism since its conception, 
Aβ still remains entwined in AD pathology and represents a compelling target for treatment of the 
disorder [46]–[50]. In their reviews 10 and 25 years after, the authors discuss the research that has 
been conducted since which has supported the hypothesis and provide counterarguments for the 
findings that highlight discrepancies in it [45], [51]. One such disparity concerns the poor 
correlation of amyloid plaque burden with the degree of cognitive impairment compared to tau 
tangles. Indeed, tau has been shown to correlate well with cognitive impairment over the course 
of AD pathogenesis [52]. Nevertheless, Aβ deposits typically appear very early in the disease 
pathology and have been shown to lead to the downstream cellular and molecular changes such as 
neuroinflammation and aggregation of misfolded hyperphosphorylated tau, that are more causal 
to neuronal dysfunction [45], [53]–[55]. Accumulating research suggests that amyloid is present at 
the disease onset and precipitates the spread of tau, allowing it to cause further damage to neurons 
[56]–[59]. This is one of the ways that Aβ can impact cognition while not exhibiting a linear 
correlation with cognitive impairment.  
Furthermore, the solubility of Aβ, the composition and quantity of it in specific, disease-related 
forms can determine the degree of cell death and may better correlate with the clinical stage [7], 
[60]. Studies have marked soluble oligomeric Aβ as being a particularly noxious form [61], [62]. 
These can exist both extracellularly and intracellularly and can harm neurons by causing pore 
formation, thereby disrupting cellular calcium balance and leading to the loss of membrane 
potential, and can encourage apoptosis [63]. Soluble Aβ oligomers have been demonstrated to 
adopt a nonstandard secondary structure termed α-sheet, which forms early in aggregation and 
strongly correlates with toxicity [62].  
The location and emergence of amyloid deposits is important to the presentation of cognitive 
function; some regions are more susceptible to Aβ than others. Human functional studies have 
suggested that the default-mode network could be one of the earliest networks affected by amyloid 
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burden and alterations in its activity were demonstrated in asymptomatic individuals with high 
levels of Aβ. This indicates that this network is particularly vulnerable to early Aβ deposition in 
addition to being among the first to exhibit aberrant activity [64], [65]. However, by using whole-
brain immunolabeling in 5xFAD mice, Gail Canter et al. (2019) recently identified that while Aβ 
aggregates were detected in the default-mode network at 4 months of age, the mammillary bodies, 
septum and subiculum exhibited Aβ accumulation even earlier at 2 months of age, with some Aβ 
deposits being detected in the mammillary bodies at 1 month [66]. They showed that in this mouse 
model, which is based on FAD mutations, the subcortical memory structures show initial 
vulnerability to Aβ and that aggregates develop in progressively complex networks with age [66]. 
The mammillary bodies, septum and subiculum are regions that connect the hippocampus to the 
rest of the Papez memory circuit, which is known to be impaired in early stages of AD [67]. 
1.1.3 Tau Pathology 
NFTs represent another of the main pathologies characteristic of AD described by Alois 
Alzheimer in 1907 [5]. These were discovered to be comprised primarily of the microtubule 
associated protein tau (MAPT) [68]–[71] which is misfolded and abnormally hyperphosphorylated 
[72]–[74]. Although many mutations can exist in the MAPT gene that encodes tau, these are 
associated with other neurodegenerative diseases such as frontotemporal dementia and other 
tauopathies, but not AD [75], [76]. There is no tau mutation that has been identified to cause AD, 
indicating that tau does not directly cause AD and emphasises the fundamental role of Aβ in the 
pathologic mechanisms underlying AD. 
Alternative splicing of exons, 2, 3, and 10 of the MAPT gene, located on chromosome 17, 
generates the six recognised isoforms of tau. These vary by the number of inserts in the N-terminal 
region and by the number of C-terminal repeats (3R or 4R) [77]. In tauopathies, an imbalance in 
the amount of 3R-tau and 4R-tau exist as opposed to the equal amounts seen in healthy individuals 
[78], [79]. In the AD brain, equal amounts of 3R-tau and 4R-tau constitute the NFTs [79]. The 
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aberrant activity of tau in AD is instead deemed to be resultant of its post-translational 
modifications, specifically the changes in the tau phosphorylation pattern [80]. This 
phosphorylation at specific phospho-sites modifies the conformation of tau, promoting 
aggregation into an insoluble form, also known as paired helical filaments [72], [81], [82].  
As discussed above, the amount of tau correlates with cognitive decline to a better degree than 
Aβ. The progression of NFTs through the brain is similarly less erratic. For this reason, the Braak 
stages which characterise the pathogenesis of AD focus on the location of NFTs. There are six 
stages. The first two stages (Braak I and II) describe NFTs limited to the transentorhinal region of 
the brain, dysfunction of which is evident in early AD [52], [83], [84]. When tau spreads to the 
limbic regions including the hippocampus, this is defined as stages III and IV. The last stages, V 
and VI, represent extensive NFTs in the neocortical regions of the brain [52]. 
1.1.4 Neuroinflammation 
The third major contributor to AD pathogenesis is the failure of the inflammatory response to 
cease. Under normal conditions, it is a protective response that removes detrimental stimuli such 
as invasive external pathogens or misfolded proteins and aids in recovery and the restoration of 
homeostasis. However, in neurodegenerative diseases such as in AD, the prolonged activation of 
inflammation contributes to neurodegeneration [85]. In general, gliosis and neuroinflammation 
appear to have complicated effects that could be helpful or detrimental [86]. Many central nervous 
system (CNS) diseases exhibit neuroinflammation and reactive gliosis [87]. In AD, specifically, Aβ 
deposition results in the activation of glial cells such as astrocytes and microglia and the 
accompanying release of pro-inflammatory mediators [88]. These include cytokines, chemokines 
and reactive oxygen species, such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour 
necrosis factor α (TNF-α). These in turn can cause further activation of astrocytes and microglia 
in addition to extra Aβ production, resulting in a vicious cycle thought to exacerbate the 
pathological progression of AD, causing cell damage and apoptosis and furthering neuronal 
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dysfunction [89]. Furthermore, reactive microglia and astrocytes induce the deterioration of the 
blood brain barrier (BBB), which is vital for CNS function. If the BBB is compromised, peripheral 
blood leukocytes can enter the CNS, intensifying the existing neuroinflammation and other AD 
pathologies [90]–[92] .  
Liddelow and colleagues demonstrated that reactive astrocytes, termed “A1” astrocytes, are 
induced through the secretion of interleukin 1α (IL-1α), TNF-α, and complement component 1q 
(C1q) by classically activated microglia. A1 astrocytes are regarded as more toxic compared to the 
more beneficial A2 astrocytes, mirroring the M1 and M2 phenotypes for microglia [93]. They do 
not retain the ability to support neuronal survival, outgrowth, synaptogenesis and phagocytosis, 
but instead prompt the death of neurons and oligodendrocytes. This occurs in AD and other 
neurodegenerative disorders including Parkinson’s and Huntington’s disease, amyotrophic lateral 
sclerosis and multiple sclerosis [93]. Considerable research has also linked neuroinflammation to 
the aggregation of phosphorylated tau [94]–[96]. 
Glia are typically regarded as responders to insult, rather than instigators of the disease processes. 
However, a more direct influence of inflammatory factors in the initial phases of pathogenesis has 
been proposed, implicating the role of glia in synaptic dysfunction. Disruptions in neuron-glia 
signalling may impact synaptic health leading to the loss of normal neuronal function and 
subsequent deficits in cognition [87], [97]. Furthermore, the stimulation of the inflammatory 
response by infectious diseases, particularly chronic or accumulative infections, have been linked 
to AD aetiopathogenesis. High levels of neuroinflammation can create a toxic environment leading 
to pathological changes in the brain [92], [98], [99]. Age, one of the major risk factors for AD, 
increases the body’s susceptibility to infection and may help transform the normal acute response 
into a chronic one [100]. 
As discussed above, the sporadic form of AD is not driven by the three causative genes that affect 
the cleavage of APP as is the case in FAD [101]. In this form, the cause of the disease is far more 
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elusive. However, there is still a significant genetic involvement. A number of genes involved in 
the immune response have been connected to AD including CR1, SPI1, the MS4As, TREM2, 
ABCA7, CD33, and INPP5D [102]–[104]. In microglia, TREM2 (triggering receptor expressed on 
myeloid cells 2) regulates two branches of signalling which have influence on the reactive 
phenotype. One is associated with the promotion of the seemingly protective activation state of 
microglia and modulates phagocytosis; TREM2 has been reported to promote phagocytosis of Aβ 
by microglia [103, p. 2], [105]. The other moderates the inflammatory reactivity, suppressing the 
production and release of cytokines [103]. Variants of TREM2 can heighten AD risk by 2-4-fold, 
heavily implicating the role of microglia in AD pathogenesis [106]. The effect of TREM2 on tau 
pathology continues to be debated, with studies reporting contrasting findings regarding whether 
tau pathology is aggravated or alleviated by TREM2 [107], [108]. 
1.1.5 Apolipoprotein E 
In 1993, it was discovered that polymorphic alleles of apolipoprotein E (APOE) represent a major 
genetic determinant of developing AD [109], [110]. ApoE is a 299-amino acid glycoprotein which 
regulates lipid homeostasis by transporting cholesterol and lipids between cells through the 
bloodstream [111]. It is expressed primarily by the liver and macrophages in the periphery and by 
astrocytes and other glial cells in the CNS [112]–[115]. ApoE has been established as a ligand of 
TREM2, binding with high affinity and thus connecting two major genetic risk factors of AD 
[116], [117]. The three main variants of the gene encoding the apoE protein are apoE2, apoE3, 
and apoE4. These variants differentially influence AD risk [114]; the presence of the ε4 allele 
increases the risk of an individual developing AD and at an earlier age compared to the more 
common ε3 allele, remaining to date the highest genetic risk factor for the disease [109], [118], 
[119]. The prevalence of the ε2, ε3 and ε4 isoforms are 8%, 77% and 15% respectively in the 
general population, however the prevalence of the ε4 allele in the AD population rises to ~40% 
[119]. This is because the presence of one ε4 allele increases the risk of developing AD by three to 
four-fold compared to ε3 homozygotes. That risk is magnified in individuals with two ε4 alleles, 
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putting them at an 8-fold greater risk and indicating a potential dose response of the apoE4 isoform 
[109], [118]. Conversely, apoE2 is regarded as protective against AD pathology [114], [119], [120]. 
A recent large scale study found that individuals with the APOE2/2 genotype had a 66%, 87% 
and 99.6% lower AD odds ratio than those with the APOE2/3, APOE3/3 and APOE4/4 
genotypes respectively [121]. 
The detrimental effect of the apoE4 isoform in the progression of AD is well-defined, however 
the underlying mechanism is yet to be fully established. It has been determined that apoE isoforms 
vary in their regulation of Aβ clearance to a greater degree than Aβ synthesis with apoE4 being 
associated with a lower rate of clearance from the brain [122]–[126]. Indeed, as mentioned above, 
in the typically later onset, sporadic forms of AD, the build-up of Aβ is considered to be more of 
a consequence of defects in the clearance of amyloid from the brain, either by cellular uptake or 
transport across the BBB, rather than aberrant Aβ production [127], [128]. Investigation into the 
BBB clearance of Aβ after intracranial administration of human Aβ-42 to wild type (WT), apoE 
knockout (KO), and apoE3 and apoE4 targeted replacement (apoE-TR) mice revealed that the 
presence of apoE3 resulted in a greater clearance of Aβ from the brain; the amount of Aβ 
appearing in the plasma following intracranial administration was 5-fold greater than WT or apoE 
KO mice. A 2-fold increase in plasma Aβ levels was also seen in apoE4-TR mice compared to WT 
or apoE KO mice [122]. ApoE has been discovered immunohistochemically in amyloid plaques 
and NFTs [129], [130] and studies have indicated that apoE4 is associated with a higher neuritic 
plaque density [131]–[133]. Furthermore, APP transgenic mice that express human apoE isoforms 
display an isoform-specific effect on both the degree of Aβ build-up and deposition (apoE4 > 
apoE3 > apoE2) [134]. 
To explain how apoE isoforms differentially affect the amount of Aβ in the brain and consequently 
influence the risk of developing AD, several studies have been conducted. ApoE has been 
demonstrated to bind to Aβ, with apoE4 binding with a higher affinity than apoE3 [135] and apoE, 
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in particular apoE4, was reported to promote the formation of Aβ fibrils [136]. Other research 
provides an alternative explanation. Verghese et al. (2013) reported that apoE and soluble Aβ show 
little interaction in the extracellular environment and instead compete for low-density lipoprotein 
receptor-related protein 1 (LRP1)-dependent uptake in astrocytes. They propose that this is how 
apoE can differentially affect the metabolism of soluble Aβ [137]. 
Independently of amyloid, apoE has also been demonstrated to influence tau pathology, 
neuroinflammation and tau-mediated neurodegeneration in vivo in an isoform specific manner, with 
apoE4 being associated with worse pathology [138]. Homozygotes for APOE2 are at a lower risk 
for AD, as having two copies of the APOE2 isoform has been reported to be protective against 
AD, particularly against tau pathology. Far fewer tau tangles are observed in APOE2/2 carriers 
compared to the other APOE genotypes [121]. The magnitude of APOE’s influence on tau 
pathology can be surmised from the recent study investigating an extremely rare mutation on the 
APOE3 allele, termed the Christchurch mutation (APOE3ch), which conferred protection against 
the autosomal dominant PS1 mutation, E280A [139]. In this paper, the authors describe the case 
of a Colombian woman who inherited the E280A mutation, which normally causes 
neurodegeneration and cognitive decline in an individual by their 40’s, as a result of aberrant Aβ 
production. However, this woman also inherited two copies of the Christchurch mutation, and it 
is thought to be because of this that she is currently in her 70’s experiencing short-term memory 
loss but remaining independent. The researchers credited this to the mutation’s ability to disrupt 
the binding of lipoprotein receptors and other proteoglycans because of the location of the R136S 
mutation in the APOE gene. It was discovered that the mutation causes apoE3ch to behave in a 
similar manner to apoE2. Low-density lipoprotein receptor (LDLR) binding was reduced by 
apoE2 and apoE3ch by 98% and 60% respectively, compared to apoE3. Furthermore, both apoE2 
and apoE3ch bind poorly to heparan sulphate proteoglycans which have been implicated in the 
promotion of Aβ aggregation and the uptake of extracellular tau [139], [140]. They found that 
apoE3ch demonstrated the lowest heparin binding ability relative to the other apoE isoforms, 
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while apoE4 displayed the highest [139], [141]. In the case study, PET imaging revealed that the 
woman showed very little tau pathology in her brain yet displayed a massive build-up of amyloid 
plaques [139]. 
 
1.2 Blood brain barrier dysfunction 
1.2.1 Cerebrovasculature and blood brain barrier deterioration 
Aβ can also be cleared from the brain to the systemic circulation through the BBB. Increasing 
evidence implicates BBB dysfunction in the pathogenesis of AD, due to altered Aβ clearance 
across the BBB [142], [143]. BBB damage is greater in individuals with the APOE4 isoform, 
contributing to the development of AD pathology [144]–[146]. APOE4 carriers exhibit augmented 
degeneration of pericytes compared to APOE3 carriers and non-demented controls. This 
correlates with the degree of loss of BBB integrity [144]. In general, cerebrovascular abnormalities 
are greater in APOE4 carriers resulting in further impairment of BBB function [124]. APOE4 has 
been implicated in hyperlipidaemia and hypercholesterolemia, which are cerebrovascular risk 
factors for AD [114], [147], [148]. Vascular disease has been implicated as a co-factor in AD; a 
considerable amount of AD cases exhibit cerebrovascular pathology, which encompasses 
components of the BBB [149]. Cerebral amyloid angiopathy, periventricular white matter lesions 
and microvascular degeneration affecting the cerebral endothelium are widespread vascular 
abnormalities that affect most instances of AD [150]. AD overlaps neuropathologically with 
cardiovascular disease and the two diseases share several risk factors in addition to APOE such as 
diabetes mellitus, obesity, diet, age, hypercholesterolaemia and hypertension [151].  
AD can lead to structural and function changes in cerebral blood vessels. The brain demands a 
well-regulated supply of blood to function properly. Therefore, any structural abnormalities that 
hinder the supply of oxygen and the removal of toxins from the brain could exacerbate neuronal 
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dysfunction [152]. Ischaemic brain damage is also known to further cognitive impairment and has 
been linked to an elevated production of Aβ-42 [151], [153], [154]. 
The brain also requires a functioning BBB to be a highly specialised barrier dividing it from the 
peripheral nervous system and preventing potentially hazardous substances from entering the 
brain. The BBB also preserves the chemical composition of the neuronal “milieu” which is 
necessary for routine neuronal tasks, its disruption leading to dysfunction of neurons and synapses 
[128]. In the early 1900’s, Goldmann demonstrated the existence of a barrier separating the brain 
and CSF with the rest of the body by injecting trypan blue dye systemically and observing its 
exclusion from the brain, and vice versa [155], [156]. Davson and colleagues expanded upon these 
original studies with dyes by describing how the brain endothelium regulates the active transport 
of ions [157]. Since then, many more studies have characterised the mechanisms of the BBB. It is 
now known that in the brain, the endothelium of cerebral blood vessels forms the BBB. This, 
along with associated pericytes, basement membranes, astrocytes, and microglial cells defines the 
neurovascular unit. Transport across the BBB is tightly regulated; tight junctions exist between the 
brain endothelial cells producing a diffusion barrier which impedes the paracellular influx of most 
blood-borne substances into the brain but allows the diffusion of small, lipid-soluble molecules in 
and out of the brain [158]–[160]. Large peptides require specific receptors for their transcytosis 
through the brain endothelium [161], including Aβ. The principal receptors for Aβ transport out 
of the brain are LDLR and LRP1 (discussed below). Studies have indicated that this transport 
through the BBB represents a major elimination route of Aβ from the brain [123], [162]–[165].  
The basement membrane underlying the vasculature is comprised of the extracellular matrix 
(ECM), a highly structured, multifaceted complex of proteins and polysaccharides, and contributes 
to the structural integrity of the BBB [166]. Several factors are associated with the preservation of 
the ECM’s integrity and that of the tissue it supports. However, in a pathological setting the 
functioning of the ECM becomes impaired, disrupting the integrity of the BBB. Increasing 
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evidence implicates the disruption of the BBB in the pathogenesis of AD, coexisting with Aβ 
deposition and the formation of NFTs. These disruptions include the degradation of basement 
membrane proteins and tight junctions and loss of pericytes [149], [167]. Dysfunction of the 
cerebral microvascular endothelium or other components of the neurovascular unit can affect Aβ 
elimination and escalate Aβ accumulation in the brain by increasing the permeability of the BBB, 
causing brain hypoperfusion and inducing inflammatory responses [128], [142], [143]. This in turn 
may further disturb the function of the BBB, forming a vicious cycle and exacerbating the 
development of AD [168], [169]. Transporters that carry peptides across the BBB can be 
additionally affected. As mentioned above, LRP1 and LDLR are the principal receptors for Aβ 
transport out of the brain. As such they have received a lot of attention for their role in AD 
pathogenesis.  
1.2.2 Lipoprotein receptors 
LDLR and LRP1 belong to the LDLR family of transmembrane receptors required for the uptake 
and removal of lipoproteins [162]. Both receptors are responsible for the clearance of Aβ from the 
brain [163]. The dysregulation of LRP1 and LDLR is associated with AD pathogenesis. 
Impairment of LRP1 function has been linked to an increase in AD risk [170], [171]. Conditional 
knockout of LRP1 in the brain endothelial cells lowered the clearance of Aβ injected into the brain 
of WT mice, increased soluble brain Aβ and reduced plasma Aβ, resulting in worsened spatial 
learning and memory impairment in 5xFAD mice [161]. Selective deletion of LRP1 in forebrain 
neurons in the APP/PS1 mouse model of AD resulted in elevated Aβ levels and intensified plaque 
deposition in the cortex. The authors attributed this to diminished LRP1-mediated neuronal Aβ 
uptake and degradation [172]. LDLR function is likewise implicated in AD pathogenesis. 
Overexpression of LDLR enhanced the extracellular clearance of Aβ, increased the vesicular 
transport to lysosomes and the cellular degradation of Aβ, reduced Aβ deposition and diminished 
plaque-associated neuroinflammatory responses [173], [174], while the elimination of LDLR in 
~ 27 ~ 
 
5xFAD mice has been shown to increase Aβ deposition and decrease Aβ cellular uptake [173], 
[175]. 
LRP1 and LDLR are the major apoE receptors, demonstrating distinct binding affinity to apoE 
[119]. When human apoE is complexed with Aβ or when Aβ exists in oligomeric form, the 
clearance of Aβ through the BBB is diminished relative to unbound monomeric Aβ [123], [125], 
[176]. Moreover, Aβ complexed with apoE4 is cleared at a slower degree compared to apoE2 and 
apoE3 [125] and is able to penetrate the BBB via the receptor for advanced glycation end products 
(RAGE) transporter more readily than Aβ bound to apoE3 [122]. 
Lipoprotein receptors are also present in a soluble form; the soluble receptor is produced at the 
cell surface through proteolytic cleavage in a process called ectodomain shedding, releasing the 
515kda ectodomain into the extracellular space. The soluble receptor is still able to bind to ligands 
but loses the capability to internalise or transport ligands intracellularly [177]–[181]. Previously, 
our team found a strong inverse correlation between the shedding of these receptors in the brain 
and Aβ transit across the BBB [182]. Following the administration of Aβ, lipoprotein receptor 
shedding was increased in our in vitro and in vivo prior studies, thereby further impairing the 
clearance of Aβ [182]. Proteolysis of receptors depletes the population of endocytic transporters 
available for BBB clearance and in addition increases the concentration of soluble forms of these 
receptors in the extracellular space, which can bind Aβ thereby extending its half-life in the brain 
and intensifying its detrimental effects [183], [184]. These data suggest that Aβ clearance across 
the BBB is mediated at least in part by lipoprotein receptor proteolysis. 
Considering the close relationship between apoE and its lipoprotein receptors, it is conceivable to 
imagine that the manner by which apoE affects Aβ efflux through the BBB may be due to some 
extent to its influence on lipoprotein receptor proteolysis. Previously, our team has shown that 
apoE influences the extent of ectodomain shedding in an isoform-specific manner [182]. The 
presence of apoE2 and apoE3 attenuated Aβ-induced receptor shedding however apoE4 was less 
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adept at protecting the receptors than apoE2 and apoE3, the result of which was reduced clearance 
of Aβ across the BBB [182]. 
While our prior studies observed a correlation between lipoprotein receptor shedding and Aβ 
removal from the brain, the factors driving lipoprotein receptor proteolysis have yet to be fully 
explored. The mechanism by which apoE may be modulating lipoprotein receptor shedding may 
be due to its influence on specific enzymes. One group of protease enzymes implicated in receptor 
shedding is the matrix metallopeptidases (MMPs) [185]. MMP-9, in particular, has been identified 
as a ligand for LRP1 [186], [187] and prior studies have suggested a role for MMP-9 in the shedding 
of LRP1 [181], [188].  
 
1.2.3 Matrix metallopeptidase 9 
1.2.3.1 The functions of the matrix metallopeptidase family 
It has been nearly 60 years since the first member of the matrix metallopeptidase family was 
discovered by Gross and Lapiere [189], [190]. Since then, there has been considerable research to 
attempt to piece together the puzzle of their assorted roles and their individual contributions to 
various pathological processes. It has since been found that MMPs are a family of zinc-dependent 
endopeptidases involved in the degradation of structural elements of the ECM such as collagen, 
gelatin, and elastin. This protease activity is required for physiological tissue remodelling, such as 
that required for embryo implantation, angiogenesis and to preserve cardiac function and integrity 
[191]–[193]. However, MMPs also have a well-recognised role in pathophysiological tissue 
remodelling and have been implicated in the pathology behind many neurodegenerative disorders 
and other disease states [194]. Unregulated expression of MMPs can lead to tissue injury and 
inflammation [195]. Currently, there are 10 different MMPs found in the mammalian CNS which 
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are classified into four main subgroups based on function and domain structure. These are 
collagenases, gelatinases, stromelysins, and film sort (MT)-MMPs [192]. 
1.2.3.2 MMP-9 in health and disease 
MMP-9, also referred to as gelatinase B, is a member of the gelatinases group so-named due to its 
high specific activity for gelatins over other components of the ECM. One of its major 
physiological functions is to degrade proteins in the basal lamina of blood vessels in order to 
promote angiogenesis and is accordingly upregulated during development and wound healing 
[196]–[198]. However, it has received a lot of attention for its role in disease. Typically only present 
at low levels, it becomes substantially upregulated during many inflammatory pathologies including 
AD, arthritis, diabetes and cancer in which it contributes to the stimulation of the immune 
response and has been shown to be highly destructive [199], [200]. Indeed, there were a number 
of non-specific MMP inhibitors tested clinically for potential cancer treatments including BAY 12-
9566 (tanomastat), a small molecular MMP-2, MMP-3 and MMP-9 inhibitor and doxycycline, a 
U.S. Food and Drug Administration (FDA) approved broad-spectrum MMP inhibitor currently 
used to treat infections such as periodontitis [201], [202]. 
The proteolytical activity of MMP-9 may further tissue damage following acute brain injury such 
as traumatic brain injury (TBI) and ischemia. MMP-9 levels are elevated after ischemia in WT mice, 
predominantly in vascular endothelium [203]. The degradation of components of the ECM by 
MMP-9 resulted in neuronal apoptosis in a transient focal cerebral ischemia model in mice [204] 
and MMP-9 knockout (MMP9KO) mice have been shown to be protected against both TBI and 
ischemia and exhibit a reduced BBB disruption [205], [206]. Research shows that MMP-9 deletion 
or inhibition offers favourable outcomes in multiple animal models of cardiovascular disease [193], 
which is a risk factor associated with the development of dementia [207]. 
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1.2.3.3 MMP-9 in Alzheimer’s disease 
Overall, studies illustrate that AD patients exhibit elevated MMP-9 levels compared to control 
subjects. Circulating MMP-9 levels in the plasma of AD patients were found to be increased 
compared to controls however, levels did not differ between APOE genotype [208]. MMP-9 levels 
have been found to be elevated in the hippocampus and the cerebral cortex in individuals with 
AD [209], [210]. In the CSF of individuals with AD, MMP-9 levels were found to be higher 
compared with CSF from cognitively healthy elderly individuals [211]. In addition, levels of tissue 
inhibitor of metallopeptidases 1 (TIMP-1), a glycoprotein and natural inhibitor of MMP-9, were 
correspondingly lower in AD patients indicating less inhibition of MMP-9. The cognitively healthy 
controls carrying the APOE4 allele had elevated CSF MMP-9 levels compared to those without 
APOE4 [211]. As discussed above, helpful validated CSF biomarkers for AD are low Aβ-42 levels, 
high total tau and high phosphorylated tau protein levels [9], [10]. These biomarkers are also good 
for predicting AD in patients with mild cognitive impairment (MCI). In the cognitively healthy 
controls, higher MMP-9 levels were seen in subjects with these AD biomarkers, indicating that 
MMP-9 might be involved in early pathogenesis of AD [99], [211]. 
Increased MMP-9 expression and activity in the hippocampus has been linked to Aβ-induced 
cognitive dysfunction [212]. Following intracerebroventricular injection of Aβ, cognitive 
impairment was induced and MMP-9 levels in the hippocampus were increased. This cognitive 
impairment was attenuated in MMP9KO mice. Furthermore Aβ-induced neurotoxicity in primary 
cultured cortical neurons was diminished upon treatment with an MMP-9 inhibitor as well as in 
cultured neurons of MMP9KO mice compared to those from WT mice [212]. This suggests that 
the increase in MMP-9 expression in the hippocampus may be implicated in the development of 
Aβ-induced cognitive impairment. 
Studies into the role of MMP-9 in AD progression have revealed that MMP-9 diminishes the 
integrity of the BBB by the degradation of the ECM [144], [200], [213], [214]. MMP-9 is able to 
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bind and proteolyse lipoprotein receptors prompting ectodomain shedding in in vitro and ex vivo 
studies [215]–[218]. In terms of apoE, there has been a few experiments which have investigated 
the relationship between MMP-9 and apoE. ApoE2 and apoE3, but not apoE4 have been reported 
to control the levels of certain inflammatory molecules that activate MMP-9 [219], [220], and these 
effects were mediated through LRP1 signalling [144], [219], [221]. Confocal microscopic analysis 
showed that MMP-9 accumulated in brain endothelial cells as well as pericytes in AD brains, with 
APOE4 carriers displaying greater levels than APOE3 carriers and non-demented controls. 
Correspondingly, levels of LRP1 were similarly diminished [144]. MMP-9 expression was found 
to be increased in apoE-TR mice in a model of TBI, with apoE4-TR mice showing higher MMP-
9 expression than apoE3-TR and WT mice but less than apoE KO mice. This was associated with 
a loss of BBB integrity and tight junction proteins [220]. Our recent work implicated MMP-9 in 
lipoprotein receptor shedding and that MMP-9 function was influenced by APOE genotype [222]. 
MMP-9 induced lipoprotein receptor shedding in a dose-dependent manner in brain endothelial 
cells and freshly isolated mouse cerebrovessels. Moreover, treatment with SB-3CT, an MMP-9 
inhibitor, diminished Aβ-induced lipoprotein receptor shedding in brain endothelial cells and the 
brains of apoE4-TR mice. SB-3CT treatment also resulted in significantly greater Aβ clearance 
from the brain to the periphery following intracranial administration of Aβ in apoE4-TR mice 
[222]. These prior studies suggest apoE influences MMP-9 function and may describe the impact 
of apoE isoforms on lipoprotein receptor shedding and Aβ clearance across the BBB. 
1.2.3.4 MMP-9 regulation 
Like other MMPs, MMP-9 is precisely regulated at several stages [223]. Under normal conditions, 
MMP-9 is present at low levels, however it has been found to be upregulated in many disease 
states, prompting its intensive scrutiny [199], [200]. MMP-9 has been found to be upregulated in 
endothelial cells, pericytes, neurons and glia in AD [144], [224]–[227]. MMP-9 is secreted from 
cells as an inactive 92 kDa proenzyme (zymogen) which is activated when cleaved by extracellular 
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proteinases, in an important regulatory step [228], [229]. Several activators of MMP-9 exist. These 
include MMP-2 [230], MMP-3 [231], MMP-7 [232], MMP-10 [233], MMP-13 [234], and the serine 
protease trypsin [235].  
 
1.3 Mouse models of Alzheimer’s disease 
Numerous mouse models of AD that recapitulate some of the pathological features of AD have 
been generated. Three of these mouse models were used in the present studies, which are described 
here. 
1.3.1.1 5XFAD mice 
Mutations in the genes encoding APP and the presenilins, PS1, PS2, result in a heightened 
production of Aβ-42 and cause FAD. 5xFAD mice are APP/PS1 double transgenic mice that co-
express five FAD mutations and additively increase Aβ-42 production resulting in a mouse model 
of AD with accelerated plaque development and elevated levels of cerebral Aβ-42. The five 
mutations are the Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations in 
APP, and the M146L and L286V mutations in the PS1 gene, PSEN1 [236]. Of the three lines 
originally generated, the Tg6799 line expresses the highest levels of mutant APP and is the most 
widely used. The mice used in the studies presented in Chapter 4 were on a congenic C57BL/6 
background as opposed to the original hybrid B6SJL background and were hemizygous for the 
APP and PSEN1 transgenes. 
Extracellular amyloid plaques can be detected in the hippocampus, cortex and thalamus of these 
mice at 2 months of age and thioflavin-S-positive plaques appear between 2 and 4 months of age 
in the frontal, parietal and entorhinal cortices and the dentate gyrus [237], [238]. Mice exhibit 
progressive cerebral amyloid angiopathy from around 3 months of age [237]. Amyloid pathology 
is more severe in female compared to male mice [236], [239]. Spatial working memory as assessed 
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by the cross-maze test is impaired starting from 3-6 months of age and is exacerbated with age. 
Anxiety decreases progressively with age from 3-6 months in this strain of mice as determined by 
the elevated plus maze [240]. 
1.3.1.2 ApoE-TR mice 
Given that APOE polymorphic alleles are the main genetic determinants of AD [109], [118], [119], 
mice expressing the human APOE genes are a valuable mouse model to study the role of human 
APOE polymorphisms in AD. In apoE-TR mice, the endogenous murine APOE gene is replaced 
with the human APOE2, APOE3 or APOE4 genes by gene targeting. Mice are homozygous for 
the APOE gene and are on a C57BL/6 Background [241]–[243]. The mice retain the endogenous 
regulatory sequences required for apoE production and express the human apoE protein at 
physiological levels. ApoE4-TR mice exhibit impaired spatial learning and memory compared to 
apoE3-TR mice at 3 months of age. This is attributed to defects in synaptic function rather than 
other aspects of AD pathology such as gliosis, amyloid deposition or NFTs, which are not different 
between apoE3-TR and apoE4-TR mice [244]–[246]. 
1.3.1.3 EFAD mice 
The E2FAD, E3FAD and E4FAD mouse models were created by crossing 5xFAD mice (Tg6799 
line) with apoE2-TR, apoE3-TR, and apoE4-TR mice, respectively. 5xFAD mice on the original 
hybrid B6SJL background were used to cross with the apoE-TR mice. This strain of 5xFAD mice 
develop severe amyloid pathology; elevated levels of intraneuronal Aβ (1-42) are detected at 
approximately 6 weeks of age followed by amyloid deposition beginning at about 2 months. 
Amyloid plaques rapidly develop from 2 months of age and memory impairment is apparent [236]. 
The EFAD animals used in the current studies were provided by Dr. Mary Jo LaDu (University 
of Illinois at Chicago). The EFAD mouse models were generated to study the role of APOE 
isoforms within the context of AD pathology. The mice remain homozygous for the APOE allele 
and heterozygous for the 5xFAD mutations. Overall, the EFAD mice display a less severe AD 
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phenotype compared to the 5xFAD line; they develop plaques in the subiculum and cortex at four 
months of age as opposed to two months in the 5xFAD line [247]. Early changes in the levels of 
Aβ are detected from 2-6 months demonstrating an age-specific effect on Aβ pathology [247]–
[249]. Furthermore, EFAD mice exhibit APOE-specific effects on Aβ accumulation; the 
development of Aβ pathology was greater in mice carrying the APOE4 isoform compared to the 
APOE2 or APOE3 isoforms [247]. At 4 and 6 months, E4FAD mice exhibit significantly more 
plaques than the E2FAD and E3FAD models. E2FAD and E3FAD have predominantly diffuse 
plaques contrasting with the compact plaques in E4FAD mice [247]. Amyloid pathology is greater 
in female mice than male mice [250]. E4FAD mice displayed decreased levels of apoE4 in the 
detergent-soluble fraction suggesting that less apoE4 is lipoprotein-associated relative to apoE2 
and apoE3. E4FAD mice demonstrate the most age-dependent deficits in cognitive function 
compared to E3FAD and E2FAD mice [251]. Liu et al. (2015) tested spatial recognition memory 
in E2FAD, E3FAD and E4FAD mice at 2, 4 and 6 months of age using the two-trial Y-maze and 
the Morris Water Maze [251]. These tests demonstrated a significant age effect for the E4FAD 
mice from 2-4 and 2-6 months. A significant genotype effect was observed for E4FAD mice 
compared to E2FAD and E3FAD mice at both 4 and 6-months of age. There were no genotype 
effects at 2 months [251]. The EFAD mouse model is useful for exploring the mechanisms 
underlying the apoE-modulated symptoms of AD pathology [252]. 
 
1.4 Clinical trials for Alzheimer’s disease 
There has not been a new drug approved by the FDA for treatment of AD since 2003 [253]. At 
present, the drugs used for treatment of AD include cholinesterase inhibitors (donepezil, 
galantamine and rivastigmine) and an N-methyl-D-aspartate receptor antagonist (memantine), 
which aim to sustain neuronal communication by enhancing the chemical pathways that are 
disrupted following neurodegeneration [254]–[257]. However, these can merely inhibit the 
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symptoms of dementia and only for a limited amount of time [257], [258]. The goal is to find 
disease-modifying treatments that prevent, stop or reverse AD progression [259]. Owing to the 
compelling nature of the amyloid cascade hypothesis, many clinical trials have been conducted on 
the premise of reducing amyloid plaques and overall amyloid load in the hope that this will improve 
downstream pathologies. 
As of February 2020, there were 121 anti-AD candidates being evaluated in 136 trials. While some 
of these compounds aim to enhance cognition (12/121) or treat neuropsychiatric and behavioural 
symptoms (12/121), 97 aim to be disease modifying. Of these, amyloid remains the most popular 
target followed by tau [260]. Due to the aberrant production of Aβ observed in FAD as a result of 
mutations involved in APP processing (discussed above), a major attempt of anti-AD therapies 
has been to reduce the production of Aβ. As discussed above, the amyloidogenic pathway 
encompasses BACE. Accordingly, inhibitors of this enzyme have been thoroughly investigated. 
Previously tested BACE inhibitors include verubecestat and lanabecestat, which were discontinued 
due to lack of efficacy in mild to moderate AD clinical trials. Trials with atabecestat, evaluated for 
its effects in preclinical AD, were also halted when raised liver enzymes were detected in some 
individuals [261], [262]. The last BACE inhibitors remaining in the pipeline were cancelled last year 
(2019), including two phase III trials (NCT02956486, NCT03036280) and one phase II trial 
(NCT02322021) investigating elenbecestat, previously shown to cause a 70% reduction of CSF 
Aβ. The cited reason for the termination was an unfavourable risk/benefit ratio determined by its 
data safety monitoring board [263]. Clinical trials of CNP520, also known as umibecestat, 
(NCT03131453, NCT02565511) were cancelled due to a worsening of cognitive function 
following treatment as measured during a planned interim analysis [264]. 
Therapeutic antibodies represent another major category Aβ reducing drugs. The aim of these is 
to utilise the immune response, neutralising or enhancing the clearance of Aβ [265]. In 2019, four 
monoclonal antibodies were tested: aducanumab, crenezumab, gantenerumab, and solanezumab. 
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Aducanumab specifically targets aggregated Aβ in the parenchyma and was shown to reduce 
amyloid deposition in treatment groups [266], [267]. Although, aducanumab was reported to slow 
cognitive decline in prodromal or mild AD, it was cancelled since it did not fulfil the primary 
endpoint criteria [261]. Nevertheless, further analysis of additional data of the EMERGE and 
ENGAGE trials revealed a statistically significant effect in the highest doses of aducanumab 
leading Biogen to submit a Biologics License Application in early 2020 [259], [268]. At the Clinical 
Trials on Alzheimer’s Disease conference in November 2019, Biogen stated that cognitive decline 
was reduced by 27% in subjects receiving the highest dose of aducanumab in the ENGAGE trial. 
While the antibody still requires further testing along with approval from the FDA, these initial 
results give support to the amyloid cascade hypothesis and the idea the amyloid can be druggable 
[269]. 
Solanezumab, a humanised immunoglobulin G1 (IgG1) monoclonal antibody against the central 
region of Aβ, was unsuccessful in both reducing amyloid deposits in the brain and preventing 
cognitive decline in mild to moderate AD [270], [271]. Both gantenerumab, a human recombinant 
monoclonal IgG1 antibody that targets both the amino-terminal and central regions of Aβ, and 
crenezumab, a humanised anti-Aβ monoclonal immunoglobulin G4 (IgG4), have a higher 
specificity for oligomeric and fibrillary Aβ [259], [272]. While crenezumab testing was terminated 
following futility analysis, trials of gantenerumab are still ongoing [273], [274]. Futility analyses 
evaluate data before the trial is complete and predict whether continuing the trial is worthwhile 
[275]. 
BAN2401 is a humanised IgG1 monoclonal antibody developed from the mouse mAb158 
antibody and is based on the 'Arctic' APP mutation (E693G). It is selective for the large soluble 
Aβ protofibrils typical of this mutation [276], [277]. Previous studies in mice found that mAb158 
may be neuroprotective and lower Aβ protofibril induced toxicity [278]. BAN2401 was first shown 
to be well tolerated in a phase I trial [279] and was enrolled in an 18-month phase II trial for early 
~ 37 ~ 
 
stage AD and MCI (NCT01767311) [280]. Although after 12 months the antibody showed no 
cognitive benefit, futility analysis determined that it would continue for the full 18 months [281]. 
BAN2401 was reported to lower brain Aβ by up to 93% and slow cognitive decline by 47% on 
the ADAS-Cog and by 30% on the ADCOMS with a dose of 10 mg/kg twice monthly [282]. The 
antibody is now being evaluated in an extension to the phase 2b trial and additionally in a phase 3 
trial (NCT03887455) [274]. A common issue in these antibody-based trials is amyloid-related 
imaging abnormalities (ARIA), a side effect in which individuals present with vasogenic oedema 
caused by the rapid movement and clearance of amyloid deposits. It occurs mostly in APOE4 
carriers and in receivers of the highest drug doses, which is the reason that a significant number 
of APOE4 carriers were removed from the highest dose of BAN2401. Since APOE4 carriers 
exhibit a faster progression of AD, this action has caused some to have reservations about the 
positive results from this trial [274], [283]. 
Nilvadipine is a dihydropyridine-type calcium channel blocker and anti-hypertensive drug found 
to increase cerebral blood flow in rats, mouse models of AD and humans [284]–[286]. Previously, 
anti-hypertensive drugs have been linked to a reduced incidence of AD [287]. Nilvadapine has 
been previously demonstrated to inhibit Aβ production in vitro, reduce Aβ deposits in vivo and 
promote elimination of Aβ across the BBB [288], [289]. Hyperphosphorylation of tau has also 
been shown to be diminished by nilvadipine in vivo [290]. The Roskamp Institute team was involved 
in the evaluation of nilvadipine in mild to moderate AD disease in an 18-month phase III trial 
[291]. The primary outcome measures did not indicate any treatment benefit, possibly due to 
limitations in the study such as a too low dose and the recruitment of subjects with fully established 
dementia or potentially non-AD individuals due to the lack of biomarker confirmation. However, 
the sub-group analysis showed less cognitive decline in the mild AD group compared to placebo 
[291]. Further exploratory analysis suggested that very mild AD subjects responded positively to 
nilvadipine on both the ADAS-Cog 12 and the ADCOMS and that very mild and mild AD patients 
treated with nilvadipine showed beneficial effects on memory and language traits, respectively 
~ 38 ~ 
 
[292]. Moreover, APOE4 carriers exhibited less cognitive decline compared to non-carriers after 
treatment with nilvadipine [291]. 
Numerous trials directed at non-amyloid based mechanisms have also proved futile. These include 
anti-tau-based therapies, natural substances such as vitamins, fish oils or botanical compounds, 
hormones and anti-inflammatory drugs [293]–[295]. An inhibitor of tau aggregation was found to 
provide no treatment benefit in mild to moderate AD [296]. A trial investigating pioglitazone, an 
insulin sensitising agent, in preclinical AD was cancelled and an inhibitor of the tyrosine kinase, 
Fyn, showed no differences upon treatment in any clinical measure [261]. 
Even with the relative success of aducanumab and BAN2401, many anti amyloid therapies have 
failed to meet their endpoint criteria, which has led many to doubt the suitability of this approach. 
However, a closer evaluation points towards technical limitations as opposed to Aβ being an 
erroneous treatment target [253], [295], [297]. There are several reasons postulated to explain these 
failures, including not intervening early enough, incorrect drug doses, flawed treatment targets and 
not comprehending in depth the contribution of Aβ and other factors in AD [259], [296]. Indeed, 
many drugs were reported not to have passed biochemical effect thresholds necessary for clinical 
improvement [295]. It is important for drugs to be tested at the stage of the disease where they 
would be predicted to be most effective in addition to being assessed at a dose that has been pre-
determined in early trials to have sufficient target engagement [298]. This has been recently 
highlighted by the exploratory analysis following treatment with nilvadipine in AD, demonstrating 
differential responses related to disease severity at the beginning of treatment [292]. 
To enhance future clinical trials, technical and methodological improvements and revised 
diagnostic criteria are required. For example, including prodromal or pre-symptomatic individuals 
at high risk of developing the disease and using better biomarkers will help in developing 
preventative treatments [299]. Both objective subtle cognitive difficulties and tau-PET have been 
reported to be predictive of future AD pathology such as Aβ accumulation, neurodegeneration 
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and atrophy [300], [301]. In humans, the pre-symptomatic phase of AD can last for many years, 
until it is thought that the accumulation of Aβ reaches the point where it elicits the activation of 
neurotoxic cascades which ultimately lead to cell death and dementia [302]. High levels of cortical 
Aβ are detected in cognitively healthy individuals as well as those with dementia, signifying that 
extensive Aβ deposition, at least in the cortex, can precede cognitive impairment [303]. Early stage 
pathology including neuroinflammation and tau pathology can also occur before the manifestation 
of clinically defined dementia [302]. Once clinical symptoms arise, Aβ has accumulated over many 
years and extensive neurodegeneration has already occurred, potentially rendering the treatment 
ineffective [298]. This suggests that early intervention may be necessary for AD treatment. 
Furthermore, due to the heterogenous nature of AD, clinical trial simulators or longer duration of 
treatment, although costly, may be necessary to overcome variability in measurements and detect 
efficacy from drug candidates [297]. 
With the lack of success that was apparent in many of the AD trials, there has been a rising 
appreciation of just how complex and diverse the pathology is. There is a dynamic interplay 
between the different components and signalling pathways of the disorder which seem to vary a 
great deal between individuals [304], [305]. Accordingly, it may be necessary to focus on more than 
one target, opting for combination therapies for the treatment of AD [306], [307]. The elimination 
of Aβ, tau, neuroinflammation or any other AD pathology alone after homeostasis has already 
been severely disrupted may not be sufficient to halt or reverse cognitive decline. Future treatments 
may need to also act downstream of the main pathologies, working to restore normal brain 
function. Hence it is vital to understand AD pathology in depth, filling in the necessary gaps about 
the mechanisms involved in order to assist the development of potential therapies [308]. 
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1.5 Aims of the studies 
APOE is a significant risk factor for the development of AD, however the underlying mechanisms 
are not well defined [109], [110]. Prior work by our group suggested that apoE may be regulating 
MMP-9 disposition [222]. Since MMP-9 can be regulated at multiple levels [223], this thesis 
examined the effect of apoE isoforms on different aspects of MMP-9 regulation with the 
hypothesis that apoE4 is less efficient than other apoE isoforms in modulating MMP-9 function. 
In addition, since MMP-9 has been previously implicated in AD pathology [208], the targeting of 
MMP-9 in mice with an AD phenotype is anticipated to have a beneficial effect on cognitive 
function. 
This thesis can be divided into 2 major parts: 
Part 1: To delineate the molecular mechanisms by which the apoE isoforms can 
differentially modulate MMP-9 function using in vitro and ex vivo methods. 
As discussed above, MMP-9 is precisely regulated at several levels including induction and 
secretion of a proenzyme, activation of the proenzyme by proteolytic cleavage of the pro domain 
and modulation of active MMP-9 [223]. The purpose of Chapters 2 and 3 was to examine the 
relationship between apoE and MMP-9 and further our understanding of the role of apoE in AD 
pathophysiology. The proposed mechanisms by which apoE could be regulating MMP-9 
disposition which were investigated in Chapters 2 and 3 are summarised in Figure 1.3. 
Part 2: To further elucidate the role of MMP-9 in the pathology of AD and to investigate 
MMP-9 as a possible target for the treatment of AD. 
The aims of Chapter 4 were to inhibit MMP-9 in vivo and investigate the effects on behaviour, in 
particular cognitive function, Aβ-40 and Aβ-42 levels in the brain and plasma and LRP1 and LRP2 
levels in the brain. 
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Figure 1.3: Schematic diagram depicting the proposed regulatory mechanisms of MMP-9 by which 
apoE could be influencing MMP-9 disposition. 
MMP-9 can be regulated at multiple levels including the modulation of MMP-9 levels, secretion of the 
proenzyme from the cell, conversion of the proenzyme to the active form and enzymatic activity. Since 
MMP-9 exerts its detrimental effects at the blood-brain-barrier, endothelial cells were focused on as a source 
of MMP-9 production and release. 
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Chapter 2: Effect of apoE on the expression and secretion of MMP-9 in 
human and mouse brain tissue 
2.1 Introduction 
As discussed in Chapter 1, elevated MMP-9 levels have been reported in numerous inflammatory 
disease states including AD [200], [208], [309]. In AD, patients have been reported to exhibit 
elevated MMP-9 expression and activity in the plasma, hippocampus and frontal cortex compared 
to control subjects [208]–[210], [309], [310]. Moreover, Aβ has been shown to directly induce the 
expression and gelatinolytic activity of MMP-9 [310], [311]. Increased MMP-9 levels in AD have 
also been attributed to the heightened levels of proinflammatory cytokines and oxidative damage 
present in AD [222], [224], [312]–[315]. 
Our group and others have shown that apoE isoforms vary in their ability to remove Aβ from the 
brain with apoE4 being associated with reduced BBB clearance from the brain [122]–[126]. Our 
team also found an isoform-specific effect of apoE on lipoprotein receptor shedding (LRP1 and 
LDLR) with a rank order of apoE4>apoE3>apoE2 [182]. Collectively, these findings showed an 
inverse relationship between lipoprotein receptor shedding in the brain and Aβ elimination across 
the BBB, one that is APOE-genotype specific [182]. Our previous studies suggest that the effect 
of apoE on these processes may be mediated through MMP-9 [222]. MMP-9 is able to bind and 
proteolyse lipoprotein receptors prompting ectodomain shedding based on in vitro and ex vivo 
studies [215]–[218]. The proteolytic shedding of LRP1 and LDLR by MMP-9 impairs their ability 
to transport Aβ out of the brain [182], [222]. For this reason, coupled with the known secretion of 
MMP-9 from endothelial cells [316]–[318], the investigation of MMP-9 expression was focused to 
the cerebrovasculature. Parts of the data and conclusions presented in this Chapter have been 
peer-reviewed and published [319]. 
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While our previous studies indicated that apoE differentially regulates MMP-9 disposition [222], 
the mechanism by which this occurs is not yet known. Considering the above data, one potential 
way in which apoE may influence MMP-9 disposition could be the modulation of MMP-9 
expression levels. Studies indicate that there are considerable differences in gene expression 
patterns associated with different APOE isoforms which contribute to the risk conferred by each 
genotype [320], [321]. It has previously been demonstrated by confocal microscopic analysis that 
MMP-9 accumulated in brain endothelial cells as well as pericytes in human AD compared to 
control subjects. Within the AD samples, APOE4 carriers displayed greater levels of MMP-9 in 
these cerebrovascular cells than APOE3 carriers [144]. Furthermore, brain MMP-9 levels have 
been reported to be increased in apoE4-TR mice relative to apoE3-TR and apoE2-TR mice [219]. 
To expand upon these studies, in this Chapter, MMP-9 levels in AD across the APOE genotypes, 
both heterozygous and homozygous (APOE2/2, APOE2/3, APOE3/3, APOE3/4, APOE4/4) 
were investigated. The effect of APOE genotype on MMP-9 levels in non-demented controls was 
also examined to assess any APOE effects in the absence of AD pathology. 
In addition to increasing the expression levels of MMP-9, Aβ has been shown to be a potent 
stimulator of MMP-9 secretion from endothelial cells, neurons and glial cells [224]–[227]. Since 
the primary function of MMP-9 is to degrade proteins in the basal lamina of blood vessels in order 
to promote angiogenesis [196]–[198], [318], it follows that there would be a high production and 
secretion of the protease in endothelial cells and the surrounding cerebrovasculature [318]. In the 
current studies phorbol-12-myristate-13-acetate (PMA) was used to stimulate the secretion of 
MMP-9 from cells since it is a known stimulator of MMP-9 secretion [316], [317], [322]. PMA is a 
phorbol ester which induces MMP-9 expression via a protein kinase C-α (PKC-α)-dependent 
signalling cascade, thereby promoting angiogenesis [323]–[325]. 
TNF-α [326], [327], transforming growth factor β (TGF-β) [326], [328], IL-1α [316], IL-1β [329] 
and angiogenic factors including fibroblast growth factor-2 and vascular endothelial growth factor 
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[318] have also been reported to induce MMP-9 secretion from cells. The induction of MMP-9 
can be attenuated; in some cell types forskolin has been reported to suppress MMP-9 induction 
[316]. MMP-9 is typically secreted from the cytosol as a proenzyme which is activated outside the 
cell. Following stimulation of human cultured mast cells with PMA, proMMP-9 was detected at 
the earliest measured time point of 12 hours post stimulation, increasing up to 96 hours, however 
active MMP-9 was only detected 24 hours after stimulation [322]. However, both pro and active 
MMP-9 have also been detected within vesicles shed from human umbilical vein endothelial cells, 
being released into the extracellular environment as early as 4 hours following stimulation by 
angiogenic factors [318]. 
The cellular regulation of MMP-9 is complex and strictly controlled, and MMP-9 levels can be 
regulated through the induction of the pro-enzyme, either through increasing its expression or by 
altering its secretion from the cell. Since these processes can be enhanced by certain cellular factors, 
as discussed above, and given the evidence of an effect of APOE genotype on MMP-9 disposition, 
it was investigated in this Chapter whether apoE can influence MMP-9 expression and secretion 
in an isoform specific manner. 
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2.2 Materials and methods 
2.2.1 Materials 
Enzyme linked immunosorbent assay (ELISA) kits for mouse MMP-9 were purchased from 
Sciencell Research Laboratories (Carlsbad, CA, USA). Human Aβ(1-42) and ELISA kits for human 
MMP-9 were purchased from Invitrogen Corp. (Carlsbad, CA, USA). Human MMP-9 activity 
assays were purchased from QuickZyme Biosciences (Leiden, The Netherlands). Dextran was 
purchased from MilliporeSigma (St. Louis, MO, USA). Halt enzyme inhibitor cocktails, the 
bicinchoninic acid (BCA) protein assay and Hanks Balanced Salt Solution (HBSS) were purchased 
from Thermo Fisher Scientific (Waltham, MA, USA).  
2.2.2 Human cortex samples 
Human cortex samples (inferior frontal gyrus) were obtained from the autopsied brains of AD and 
non-demented subjects with different APOE genotypes as summarised in Table 1. The de-
identified human brain specimens were provided by the Banner Sun Health Research Institute 
Brain and Body Donation Program of Sun City, Arizona and the University of Maryland Brain and 
Tissue Bank which is a Brain and Tissue Repository of the NIH NeuroBioBank (Baltimore, MD) 
and the Mount Sinai NIH Brain and Tissue Repository (New York, NY).  
APOE Non-Demented Alzheimer’s Disease 
Mean age ± 
StDev 
N 
(M/F) 
Mean age ± 
StDev 
N 
(M/F) 
Age of 
Onset 
Amyloid 
burden 
2/2 79.0 ± 19.49 10(3/7) 82.67 ± 21.22 3(2/1) N/A N/A 
2/3 79.8 ± 10.84 10(4/6) 85.5 ± 10.05 10(3/7) 78.5 ± 3.45 11.4 ± 1.28 
3/3 79.8 ± 15.53 10(9/1) 84.5 ± 5.83 16(5/11) 76.9 ± 2.84 14.2 ± 0.25 
3/4 82.0 ± 9.02 10(7/3) 79.4 ± 10.18 17(10/7) 72.8 ± 3.14 12.9 ± 0.33 
4/4 51.6 ± 16.17 10(5/5) 80.8 ± 7.80 12(6/6) 72.9 ± 3.31 13.5 ± 0.51 
Abbreviations: APOE, apolipoprotein E genotype; StDev, Standard deviation; M, male; F, 
female. 
Table 1. Demographic details of human brain cortex samples. 
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The tissue was collected by various banks in accordance with the approved IRBs (Institutional 
Review Boards), and was received from the banks under the conditions below: 
The studies in this thesis did not constitute research involving human subjects as the studies did 
not involve intervention or interaction with living individuals or identifiable private information. 
The current studies utilised frozen human brain specimens acquired from various tissue banks. 
The investigator did not intervene nor interact with the subjects in obtaining the de-identified 
specimens.  The specimens were not linked to any protected health information and no identifiable 
private information was collected. 
University of Maryland Brain and Tissue Bank 
The University of Maryland Institutional Review Board 
IRB Protocol Number:  00042077 
 
Banner Sun Health Research Institute 
Western Institutional Review Board 
IRB Protocol Number:  20120821 
More details regarding the origins of the human samples are listed in the acknowledgements. 
2.2.3 Animals 
ApoE-TR mice were purchased from Taconic Biosciences (Rensselaer, NY) and allowed to adapt 
to the vivarium for 2 weeks prior to any experimental procedures. The apoE-TR mice were created 
by targeted replacement of the endogenous murine APOE gene with human APOE2, APOE3 or 
APOE4 [330]. These mice retain the endogenous regulatory sequences required for apoE 
production and express the human apoE protein at physiological levels. The EFAD animals were 
provided by Dr. Mary Jo LaDu (University of Illinois at Chicago). To generate the EFAD mouse 
model, transgenic mice expressing 5 familial AD mutations (5xFAD, Tg6799 line) were crossed 
with apoE4, apoE3, and apoE2-TR mice, producing the E4FAD, E3FAD, and E2FAD mouse 
models respectively, as previously described [247]. Mice were housed under standard laboratory 
conditions (23±1˚C, 50±5% humidity, and a 12-hour light/dark cycle) with free access to food 
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and water throughout the study. All experiments using animals were performed under protocols 
approved by the Institutional Animal Care and Use Committee of the Roskamp Institute. 
2.2.4 Isolation of brain fractions 
Frozen human cortex samples and mouse brains were homogenised and the cerebrovasculature 
was isolated using a step-wise density gradient extraction process as previously described [182]. 
Briefly, human or mouse brain samples were homogenised in cold HBSS using a Dounce 
homogeniser. The homogenates were suspended in HBSS with 20% dextran and centrifuged for 
15 minutes at 6000g and 4 °C. The cerebrovascular pellet at the bottom of the tube was gently 
rinsed in HBSS and either collected with lysis buffer (mammalian protein extraction (M-PER) 
reagent + 1% ethylenediaminetetraacetic acid (EDTA) + 0.2% phenylmethylsulphonyl fluoride 
(PMSF) (Thermo Scientific, USA)) supplemented with Halt protease and phosphatase inhibitor 
cocktail (Thermo Scientific, USA) and stored at -80 °C prior to analysis, or immediately 
resuspended in endothelial cell medium and used for the ex vivo studies described below. 
2.2.5 Measurement of active and total MMP-9 levels in mouse and human 
cerebrovasculature 
Total MMP-9 levels in the cerebrovasculature and the homogenate from mouse and human brain 
samples were detected using an MMP-9 ELISA. Absorbance was detected using a BioTek 
Powerwave XS microplate apparatus at a wavelength of 450nm. A quantitative substrate-based 
MMP-9 activity assay (QuickZyme Biosciences) was used to measure active MMP-9 levels in the 
cerebrovasculature from human brain samples. This assay provides a measure of MMP-9 activity 
in a biological sample by capturing MMP-9 present in the sample using an antibody followed by 
the addition of a proenzyme as a substrate, which upon activation releases colour from a 
chromogenic peptide substrate. Absorbance was then detected using a BioTek Powerwave XS 
microplate apparatus at a wavelength of 405nm. MMP-9 levels were normalised to total protein 
content, as determined by the BCA assay. 
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2.2.6 AB-42 injected apoE-TR mice 
Using a standard process to limit aggregation, as previously described [222], [331], lyophilised Aβ 
peptides were solubilised in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to obtain a 
monomeric/dimeric sample and reduce the development of β-sheet structures. Briefly, 1 mg of 
each lyophilised peptide was dissolved in 1 ml of ice-cold HFIP. The peptides were left to air dry 
for 1 hour in a chemical fume hood followed by further drying in a speed-vac centrifuge for 30 
min. The resulting clear film was resuspended in 100% dimethyl sulfoxide (DMSO) to a 
concentration of 1 mM and stored at -80 °C. ApoE2, apoE3 and apoE4-TR mice were 
stereotaxically injected with 3 μl of monomeric 1 mM human Aβ(1–42) or 100% DMSO bilaterally 
into the caudate putamen of the brain (0.5 mm anterior to the bregma, 2 mm lateral to the midline, 
and 3 mm below the surface of the skull). Ten minutes after intracerebral administration of human 
Aβ(1–42), mice were euthanised and the brain (excluding the cerebellum) was extracted and 
immediately snap frozen in liquid nitrogen. To assess MMP-9 levels in the cerebrovasculature, 
mouse brains were processed to isolate various brain fractions, as described above. 
2.2.7 Zymographic analysis of EFAD spleen samples 
Lysis buffer (M-PER + 1% EDTA + 0.2% PMSF (Thermo Scientific, USA)) supplemented with 
Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, USA) was added to spleen 
samples collected from EFAD mice before they were homogenised via sonication (Sonic 
Dismembrator model 100, T). Samples were centrifuged to remove cell debris before analysis by 
gelatin zymography to determine pro and active MMP-9 levels. Equal protein quantities of each 
sample (50 µg) were incubated with Gelatin-Sepharose® 4B (GE Healthcare, Chicago IL) to 
concentrate MMP-9. Samples were incubated with the beads for 1-2 hr at room temperature with 
rotation, and then centrifuged at 6000 rpm for 2 min. Gelatinases were eluted in equal amounts 
(25 µL) of 1X Zymogram sample buffer (Bio-Rad, Hercules, CA, USA) before being separated on 
a 10% precast polyacrylamide gel with gelatin (Thermo Fisher Scientific, Waltham, MA, USA). 
The gel was incubated in Triton X-100 (Zymogram Renaturation Buffer, Thermo Fisher Scientific, 
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Waltham, MA, USA) for 30 minutes at room temperature with gentle agitation to renature the 
proteins. The gel was next incubated in development buffer containing 50 mM Tris-HCl, pH 7.5, 
200 mM NaCl, 5 mM CaCl2, 0.02% Brij-35 (Zymogram Development Buffer, Thermo Fisher 
Scientific, Waltham, MA, USA) for 18h at 37 °C to initiate enzyme activity. The gel was stained 
with 0.5% Coomassie blue (Bio-Rad, Hercules, CA, USA) for one hour and washed in destaining 
solution (45% deionised water, 45% methanol, 10% acetic acid) before being scanned with the 
Universal Hood II (Bio-Rad, Hercules, CA, USA). Bands of MMP-9 activity were visualised as 
clear lysis zones on the gel which were quantified by densitometry using Image Lab 6.1. 
2.2.8 Collection and enrichment of human lipidated apoE 
The mixed glial cultures were provided by Dr. Mary Jo LaDu (University of Illinois at Chicago). 
Cortical glial cultures were prepared from apoE2-TR, apoE3-TR, or apoE4-TR mice as previously 
described [332]. Briefly, mixed glial cells from 1–2-day-old neonatal apoE-TR pups were plated in 
150cm2 flasks (∼1½ brains per flask) in Dulbecco's Modified Eagle Medium (DMEM)/F12 
medium containing 10% foetal bovine serum (FBS), L-glutamine (2mM) and 1% 
penicillin/streptomycin. Medium was changed every 3-5 days [332], [333]. Upon confluency, 
cultures were collected and grown in 75cm2 flasks until confluent. Cells were washed and incubated 
with serum-free media for 72 hours [333]. Following the incubation, glial-conditioned media was 
collected and centrifuged at 1,000g for 3 min to remove any residual cells before being 
concentrated (10x) using the Vivaspin 15 centrifugal concentrator with a molecular weight cut-off 
of 10,000 Da (Sartorius Mechatronics Corp., Bohemia, NY). The resulting concentrate was 
analysed for apoE content using a human apoE ELISA as per the manufacturer’s instructions and 
used to treat human brain microvascular endothelial cells (HBMECs) in the in vitro studies 
described below. 
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2.2.9 Effect of APOE genotype on total secreted MMP-9 and secreted active MMP-9 in 
vitro 
HBMEC were seeded at 100,000 cells per cm2 onto fibronectin-coated 12-well plates in endothelial 
cell medium containing 5% FBS, 1% endothelial cell growth supplement and 1% 
penicillin/streptomycin solution. When approximately 90% confluent, cells were washed twice 
thoroughly in phosphate-buffered saline (PBS) before being treated with serum-free endothelial 
cell medium containing lipidated apoE2, apoE3 or apoE4 (25 ng/ml) collected from mixed glial 
cultures (as described above) and incubated for 1h at 37 °C and 5% CO2. Cells were then treated 
with PMA (1μM), human Aβ(1-42) (2μM) (known stimulators of MMP-9 secretion) or dimethyl 
sulfoxide (DMSO) (0.5%) for 18h at 37˚C and 5% CO2. After the incubation period, the 
conditioned extracellular media was collected, centrifuged to remove cell debris and analysed for 
total secreted MMP-9 using an ELISA and for endogenously active and total MMP-9 using a 
quantitative substrate-based MMP-9 activity assay (described above). 
2.2.10 Effect of APOE genotype on total secreted MMP-9 ex vivo 
Cerebrovasculature was isolated from apoE3-TR and apoE4-TR mice through a step-wise density 
gradient extraction process, as described above, and seeded at 2 million cells per cm2 in 48-well 
plates in serum-free endothelial cell medium. After a 4-hour incubation at 37˚C and 5% CO2, the 
media and cell debris was removed and serum-free endothelial cell medium containing PMA 
(1μM), human Aβ (1-42) (2μM) or DMSO (0.5%) was added to the cells. After 24 hours at 37˚C 
and 5% CO2, the conditioned media and cell lysates were collected, and the conditioned media was 
analysed for total secreted MMP-9 using an ELISA. 
2.2.11 Tissue processing 
All mice were humanely euthanised, and their brains were collected and fixed in 4% 
paraformaldehyde (PFA) for 48 h as previously described [334]. The hemispheres were processed 
in a Sakura Tissue-Tek VIP (Leica Biosystems Inc., IL, USA) vacuum infiltration processor before 
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being embedded in paraffin with the Sakura Tissue-Tek (Leica Biosystems Inc., IL, USA) and 
stored at 4 °C for 2 days for subsequent cutting with a Leica RM2235 microtome (Leica Biosystems 
Inc., IL, USA). All brains were cut at a thickness of 12 μm. Sagittal slices were mounted on glass 
slides and dried for 48 h at 37 °C for immunofluorescence staining and confocal imaging. 
2.2.12 Immunofluorescence 
Paraffin sections were washed in two baths of histoclear (National Diagnostics, USA) and 
progressively rehydrated with ethanol gradients and PBS (Sigma Aldrich, MO, USA). Brain 
sections were subjected to antigen retrieval for 7 min in glycine buffer (pH 3) at 100 °C. Sections 
were then blocked in PBS containing 100% SeaBlock (EastCoast Bio, MA, USA), 0.5mM glycine, 
0.3% Triton X-100, 0.05% Tween™ 20 for 1 h. Sections were incubated in PBS containing 10% 
SeaBlock, 0.33mM glycine, 0.3% Triton X-100, 0.05% Tween™ 20 and the respective panel of 
primary antibodies overnight at 4 °C. The following antibodies were used: ab38898 (anti-MMP-9, 
1:200, Abcam, Cambridge, MA, USA) and AF3628 (anti-platelet endothelial cell adhesion molecule 
(CD31/PECAM-1), 1:1000, Novus Biologicals, Centennial, CO, USA). After three washing steps 
in PBS for 5 min, sections were incubated in PBS containing 10% SeaBlock, 0.33mM glycine, 0.3% 
Triton X-100, 0.05% Tween™ 20 and the respective panel of secondary antibodies for 1 h in the 
dark at room temperature in a humidified chamber. The following secondary antibodies were used: 
donkey anti-rabbit, anti-goat conjugated to Alexa 488 and 568, respectively (1:1000, Life 
technologies). After three washing steps in PBS for 5 min, sections were mounted in Fluoroshield 
(Sigma Aldrich, MO, USA). All images were acquired using the confocal microscope LSM 800 
(Carl Zeiss AG, Germany), the ZEN Blue 2.3 (Carl Zeiss AG, Germany) software and a 20× 
objective. The acquisition settings were kept the same for all genotypes within the same 
experiment. For qualitative analysis of MMP-9 immunoreactivity, orthogonal projections of 
cortical brain regions from E3FAD and E4FAD mice (n = 4 for each genotype, all female mice, 6 
month of age) were analysed. Six images were generated for each mouse. Averages calculated from 
the six images were used for statistical analysis. 
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2.2.13 Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM). Data was checked for normality 
and statistical significance was determined by analysis of variance (ANOVA) followed by the two-
stage step-up method of Benjamini, Krieger and Yekutieli (BKY) unless otherwise stated. A p-
value lower than 0.05 was used to indicate a statistically significant difference. Statistical analyses 
were performed with GraphPad Prism 8. 
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2.3 Results 
2.3.1 MMP-9 expression and activity across APOE genotype in human 
cerebrovasculature 
Isolated cerebrovasculature from human brain tissue (AD and non-demented controls) showed 
MMP-9 expression was significantly higher (2-fold) in the cerebrovasculature from AD specimens 
compared to control samples (Fig. 2.1a). Upon stratification by APOE genotype, MMP-9 
expression in AD subjects was markedly elevated in ε4 carriers compared to non ε4 carriers, with 
the APOE3/4 genotype showing significantly higher MMP-9 expression levels compared to 
subjects with the APOE2/3 and APOE3/3 genotypes (*p<0.05), in addition to being significantly 
higher than the corresponding APOE3/4 control subjects (**p<0.01) (Fig. 2.1b). There was no 
such APOE genotype difference observed in the control samples. 
 
Figure 2.1: APOE genotype effect on total MMP-9 levels in the cerebrovasculature of human brain 
tissue in AD and control subjects. 
Levels of total MMP-9 were found to be elevated in (A) Alzheimer’s disease (AD) subjects compared to 
non-demented controls and (B) APOE4 carriers with AD. MMP-9 levels in the cerebrovasculature were 
determined using an ELISA. Values were normalised to total protein concentration and represent mean 
± SEM. (A) n = 49 (control) n = 55 (AD). **p<0.01 as determined by an unpaired t-test. (B) Control 
subjects: APOE2/2: N = 10, APOE2/3: N = 9, APOE3/3: N = 10, APOE3/4: N = 10, APOE4/4: N 
= 10. AD subjects: APOE2/2: N = 3, APOE2/3: N = 10, APOE3/3: N = 13, APOE3/4: N = 17, 
APOE4/4: N = 12. *p>0.05, **p<0.01, ***p<0.001, as determined by a two-way ANOVA and the BKY 
procedure. 
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To assess MMP-9 activity in relation to APOE genotype, the human brain specimens were 
analysed using a quantitative substrate-based MMP-9 activity assay which measures endogenously 
active MMP-9 within biological samples. The levels of endogenously active MMP-9 were increased 
in the AD specimens compared to non-demented controls (Fig. 2.2a). In terms of APOE, AD 
subjects with the APOE3/4 and APOE4/4 genotypes exhibited significantly higher levels of active 
MMP-9 compared with their corresponding control subjects. Furthermore, ε4 carriers with AD 
displayed significantly elevated levels of active MMP-9 compared to non-APOE4 AD subjects. 
Lastly, no APOE genotype differences were observed within the control population (Fig. 2.2b). 
 
Figure 2.2: APOE genotype effect on active MMP-9 levels in the cerebrovasculature of human 
brain tissue in AD and control subjects. 
Using a quantitative substrate-based MMP-9 activity assay, levels of endogenously active MMP-9 were 
found to be elevated in (A) Alzheimer’s disease (AD) subjects compared to non-demented controls and (B) 
APOE4 carriers with AD. Values were normalised to total protein concentration and represent mean ± 
SEM. (A) n = 44 (control) n = 48 (AD). *p<0.05 as determined by an unpaired t-test. (B) Control subjects: 
APOE2/2: N = 8, APOE2/3: N = 8, APOE3/3: N = 13, APOE3/4: N = 8, APOE4/4: N = 7. AD 
subjects: APOE2/2: N = 3, APOE2/3: N = 9, APOE3/3: N = 11, APOE3/4: N = 15, APOE4/4: N = 
10. *p<0.05 as determined by a two-way ANOVA and the BKY procedure. 
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2.3.2 MMP-9 expression across APOE genotype in EFAD mice 
For a global view of changes in MMP-9 levels in relation to APOE genotype in an AD 
environment, whole brain homogenate of EFAD mice was examined via ELISA. To investigate 
whether MMP-9 levels are altered at different stages of AD progression, tissue from mice aged 10, 
40 and 70 weeks was analysed. There were no differences in MMP-9 levels between E4FAD and 
E3FAD mice at any age point. While no differences in APOE genotype were detected, levels of 
MMP-9 were elevated in E4FAD mice at 70 weeks of age compared to 10 weeks of age (Fig. 2.3a). 
E2FAD mice could only be analysed at 40 weeks of age due to a lack of availability of this genotype, 
however again, no APOE genotype differences in MMP-9 were observed (Fig. 2.3b). 
 
 
 
Figure 2.3: MMP-9 expression in mouse homogenate tissue from EFAD mice at 10, 40 and 70 
weeks of age. 
Levels of MMP-9 were measured in the whole brain homogenate of (A) E3FAD and E4FAD mice at 10, 
40 and 70 weeks of age and (B) E2FAD, E3FAD and E4FAD mice at 40 weeks of age. MMP-9 levels were 
found to be higher in E4FAD mice at 70 weeks of age relative to 10 weeks of age. MMP-9 levels were 
determined using an ELISA. Values were normalised to total protein concentration and represent mean ± 
SEM (E2FAD: N=4, E3FAD & E4FAD: N=8 per age group). (B) *p<0.05 as determined by ANOVA 
and the BKY procedure. 
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Focusing this examination on cerebrovasculature tissue from EFAD mouse brains revealed that 
total MMP-9 levels were increased in E3FAD and E4FAD mice compared to E2FAD mice at 40 
weeks of age (**p<0.01) (Fig. 2.4b). Analysis of E3FAD and E4FAD mice at 10, 40 and 70 weeks 
of age by 2way ANOVA indicated a significant difference between APOE genotype (F (2, 41) = 
3.474, p < 0.05), however this was not significant following post hoc testing (Fig. 2.4a). 
To further probe potential APOE genotype differences in E3FAD and E4FAD mouse 
cerebrovasculature, MMP-9 levels were investigated specifically within brain endothelia using 
immunofluorescence and confocal microscopy. The brain cortices of 6-month-old E3FAD and 
E4FAD mice were analysed and MMP-9 immunoreactivity was detected in cortical endothelial 
cells (indicated by white arrows) (Fig. 2.5). There was a 56% increase in MMP-9 immunoreactivity 
in cortical endothelial cells from E4FAD mice compared to E3FAD mice (*p<0.05) (Fig. 2.5c). 
Furthermore, the total area of MMP-9 in the endothelial cells appeared to be greater in E4FAD 
compared to E3FAD mice, although this was not significant (p = 0.06) (Fig. 2.5d). For a measure 
of the physiological baseline levels of MMP-9 activity in EFAD mice, spleen samples were analysed 
via zymography. No differences were detected between E3FAD and E4FAD mice (Fig. 2.6a, b). 
 
Figure 2.4: MMP-9 expression in mouse cerebrovasculature tissue from EFAD mice at 10, 40 and 
70 weeks of age. 
Levels of MMP-9 in the cerebrovasculature were measured in (A) E3FAD and E4FAD mice at 10, 40 and 
70 weeks of age and (B) E2FAD, E3FAD and E4FAD mice at 40 weeks of age. MMP-9 levels were found 
to be higher in E3FAD and E4FAD mice relative to E2FAD mice at 40 weeks of age. MMP-9 levels were 
determined using an ELISA. Values were normalised to total protein concentration and represent mean ± 
SEM (E2FAD: N=4, E3FAD & E4FAD: N=8 per age group). **p<0.01 as determined by ANOVA and 
the BKY procedure. 
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Figure 2.5: MMP-9 immunoreactivity in cortices of E3FAD and E4FAD mice. 
Representative confocal images depicting 6-month-old female (A) E3FAD and (B) E4FAD mice stained 
with antibodies against CD31/PECAM-1 (red) and MMP-9 (green). Both E3FAD and E4FAD mice 
exhibited a prominent MMP-9 signal in endothelial cells surrounding blood vessels. (C) Quantification of 
MMP-9 immunofluorescent intensity within endothelial cells (CD31/PECAM-1). (D) Quantification of 
MMP-9 area within endothelial cells (CD31/PECAM-1). White arrows indicate regions of prominent 
MMP-9 signal. The scale bars represent 50μm. N=4. Values represent mean ± SEM. *p<0.05, as 
determined by an unpaired t-test. 
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Figure 2.7: MMP-9 expression in mouse cerebrovasculature tissue from apoE-TR mice following 
intracranial injection with DMSO or Aβ-42. 
Levels of MMP-9 were measured in the (A, C) cerebrovasculature and (B, D) whole brain homogenate of 
apoE2-TR, apoE3-TR, apoE4-TR, and WT mice at 6 months of age. Levels were measured following the 
intracranial injection of 3 µl (A, B) 100% DMSO or (C, D) Aβ-42 (1 mM in 100% DMSO). MMP-9 levels 
were determined using an ELISA. Values were normalised to total protein concentration and represent 
mean ± SEM (N = 3 per group). *p<0.05, **p<0.01, ***p<0.001 as determined by ANOVA and the BKY 
procedure. 
Figure 2.6: Levels of proMMP-9 in spleens of E3FAD and E4FAD mice. 
Spleen samples from 6-month-old female E3FAD and E4FAD mice were analysed for MMP-9 levels using 
gelatin zymography. (A) Gelatin zymography demonstrating proMMP-9 bands (92kDa) and faint 
proMMP-2 bands (72kDa). (B) Quantification of proMMP-9 zymogram bands. Values represent mean ± 
SEM. N=4. No significant differences as determined by an unpaired t-test. 
ProMMP-9 (92kDa) - 
ProMMP-2 (72kDa) - 
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2.3.3 MMP-9 expression across APOE genotype in apoE-TR mice 
Whole brain homogenate and cerebrovasculature of apoE-TR mice were also analysed for MMP-
9 levels. These mice had been intracranially injected with either DMSO or human Aβ-42 before 
euthanasia in prior studies performed by our group [182]. No changes in MMP-9 levels were 
detected in the cerebrovasculature of DMSO-treated mice, however global MMP-9 levels were 
elevated in the brain homogenate of apoE4-TR animals relative to WT, apoE2-TR and apoE3-TR 
mice (**p < 0.01) (Fig. 2.7a, b). In apoE-TR mice that had been injected intracranially with Aβ-
42, elevated MMP-9 levels were detected in the cerebrovasculature of apoE2-TR, apoE3-TR and 
apoE4-TR mice relative to WT mice (*p < 0.05, **p < 0.01) (Fig. 2.7c). Further APOE genotype 
differences were also detected in the brain homogenate; MMP-9 levels were elevated in apoE3-TR 
mice compared to WT mice and in apoE4-TR mice relative to WT and apoE2-TR mice (*p < 
0.05, **p < 0.01) (Fig. 2.7d). 
 
2.3.4 Effect of apoE isoform on MMP-9 secretion in HBMECs and apoE-TR mice 
To study MMP-9 secretion from cultured cells in vitro, HBMECs were treated with different 
lipidated apoE isoforms (previously concentrated from glia conditioned media) and either DMSO, 
PMA (to stimulate MMP-9 secretion) or Aβ-42 (to simulate an AD-like environment). The 
extracellular conditioned media from the HBMECs was examined using a quantitative substrate-
based MMP-9 activity which provides a measure of endogenously active MMP-9 in addition to 
proMMP-9, once it has been activated on the plate by 4-aminophenylmercuric acetate (APMA). 
In this analysis, total MMP-9 is the combination of active and proMMP-9. ApoE alone did not 
appear to impact total secreted MMP-9 levels in the extracellular media (Fig. 2.8c), however upon 
stimulation with PMA or insult with Aβ-42, apoE isoform differences were apparent as total 
MMP-9 levels were higher in the presence of apoE3 and apoE4 compared to apoE2 (*p<0.05, 
**p<0.01) (Fig. 2.8f, i). A similar effect was observed with the levels of proMMP-9, as treatment 
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with apoE2 and either PMA or Aβ-42 resulted in lower levels of proMMP-9 compared to apoE3 
and apoE4, with apoE4 demonstrating the highest levels (*p<0.05, **p<0.01) (Fig. 2.8e, h). Again, 
this effect was not observed with apoE alone (Fig. 2.8b). Lastly, in terms of the active enzyme, 
apoE isoform-dependent differences in active MMP-9 levels were detected when apoE was added 
alone and in combination with PMA. The levels of active MMP-9 were 2-fold higher following 
treatment with apoE3 and apoE4 relative to apoE2 (**p<0.01, ***p<0.001) (Fig. 2.8a, d). 
The extracellular media was also analysed with an MMP-9 ELISA, which measures all forms of 
MMP-9 (i.e. proMMP-9, active MMP-9, and enzyme/inhibitor complexes). The known stimulator 
of MMP-9 secretion, PMA, induced the appearance of MMP-9 in the extracellular media from 
HBMEC cultures (Fig. 2.9a). However, MMP-9 levels in the extracellular media were below the 
detection limit following treatment with apoE and DMSO or apoE and Aβ-42. HBMECs treated 
with either apoE2, apoE3 or apoE4 in addition to PMA did not induce further MMP-9 secretion 
compared to control (i.e., no apoE) and no change in MMP-9 levels was apparent between apoE 
isoforms (Fig. 2.9a). In an ex vivo model, the cerebrovasculature from apoE3-TR and apoE4-TR 
mice was isolated and treated with DMSO, PMA or Aβ-42. Elevated MMP-9 levels were detected 
in the extracellular media upon treatment with Aβ-42 however, MMP-9 levels in the extracellular 
media were below the detection limit following treatment with PMA or DMSO. No changes were 
evident between the different apoE isoforms following Aβ-42 treatment (Fig. 2.9b). 
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Figure 2.8: ApoE isoform differences in MMP-9 secretion in conditioned media from apoE-treated 
HBMECs. 
Using a quantitative substrate-based MMP-9 activity assay, levels of (A, D, G) endogenously active MMP-
9, (B, E, H) proMMP-9 and (C, F, I) total MMP-9 were analysed in the presence of apoE2, 3 or 4 in the 
conditioned extracellular media of HBMECs. Cells were stimulated with either (A, B, C) apoE alone (25 
ng/ml), (D, E, F) PMA (1 µM) and apoE (25 ng/ml) or (G, H, I) Aβ-42 (2 µM) and apoE (25 ng/ml). 
ApoE isoform effects on secreted proMMP-9 levels and total secreted MMP-9 were apparent upon 
stimulation/insult. Levels of active MMP-9 were elevated in an apoE isoform-dependent manner 
(apoE2<apoE3<apoE4) when added alone and after stimulation with PMA. Values represent mean ± 
SEM. (A, B, C) n = 14, (D, E, F) n = 10, (G, H, I) n = 8. $$p<0.01, $$$$p<0.0001 indicates significant 
differences relative to all other conditions and *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 indicates 
significant differences relative to indicated bars as determined by ANOVA and the BKY procedure. 
 
~ 62 ~ 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Impact of apoE isoform on MMP-9 secretion. 
Secreted MMP-9 was measured in the extracellular media of A) HBMECs treated with 1 µM PMA and 
either apoE2, apoE3, apoE4 (25 ng/ml) or no apoE (control) and B) freshly isolated cerebrovessels from 
APOE targeted replacement (apoE-TR) mice treated with 2 µM Aβ-42 to stimulate secretion. No change 
was detected between apoE isoforms. Values represent mean ± SEM. A) N=8. No significant differences 
as determined by a one-way ANOVA. B) apoE3-TR: N=5, apoE4-TR: N=4. No significant differences as 
determined by an unpaired t-test. 
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2.4 Discussion 
For a more thorough understanding of how APOE isoforms confer either an increased or 
decreased risk of developing AD, their influence on MMP-9, an enzyme previously implicated in 
the worsening of AD pathology [144], [200], [213], [214], [219], [220], was investigated. Previously 
our group reported that MMP-9 function was influenced by APOE genotype [222], however the 
underlying mechanisms by which APOE regulates MMP-9 remain unknown. In the present 
Chapter, the effect of APOE isoforms on MMP-9 expression levels and secretion from the cell 
(two stages at which MMP-9 can be regulated) were examined using human non-demented control 
and AD brain tissue, apoE mice with or without AD mutations, and human brain endothelial cells. 
In this Chapter, an increase in total MMP-9 in isolated cerebrovasculature from human AD cortex 
samples compared to non-demented controls is reported. This observation coincides with prior 
reporting that MMP-9 levels were increased in AD plasma and brain parenchyma [208], [309], 
[335]. In addition to MMP-9 expression, cerebrovascular MMP-9 function was measured by a 
quantitative substrate-based activity assay. Active MMP-9 was significantly elevated in AD subjects 
relative to non-demented controls, indicating the changes in MMP-9 expression levels observed 
above were functionally active. This data corresponds with zymography and western blot 
experiments described by Bruno et al. (2009b) which show increased active MMP-9 levels in the 
middle frontal gyrus of AD samples compared to control samples. Moreover, MMP-9 activity 
levels have been previously reported to be increased in individuals with mild cognitive impairment, 
indicating that MMP-9 might be involved in early pathogenesis of AD [210]. Indeed, higher MMP-
9 levels have been found alongside AD biomarkers in the CSF of cognitively healthy individuals 
[99], [211]. The magnitude of the expression and activity of MMP-9 secreted by brain endothelia 
is important as elevated levels can have detrimental effects such as disrupting BBB transport and 
altering Aβ clearance from the brain [144], [222]. 
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In addition to global differences in cerebrovascular MMP-9 expression and activity between 
human AD and control specimens, MMP-9 levels in the AD cerebrovasculature were shown to be 
dependent on APOE genotype, as cerebrovessels from individuals carrying the APOE4 allele had 
significantly higher total MMP-9 levels than APOE4 non-carriers. This coincides with previous 
studies which have found that MMP-9 levels are increased in brain endothelia in AD and that 
APOE4 carriers showed elevated levels compared to APOE3 carriers [144]. Correspondingly, the 
levels of active MMP-9 in the cerebrovasculature were also higher in the APOE4 carriers with AD 
compared to APOE4 non-carriers with AD. ApoE isoforms have been previously found to 
modulate the expression and activity of certain enzymes involved in AD. For example, apoE4 but 
not apoE3 resulted in the reduced expression of the α-secretase, a desintegrin and 
metalloproteinase domain containing protein 10 (ADAM10), which is involved in the non-
amyloidogenic processing of APP [336]. Moreover, in terms of function, ADAM10 activity was 
found to be significantly lower in apoE4 samples compared to apoE2 [337]. Overall, 
downregulation of ADAM10 is associated with elevated Aβ levels in vitro and hence implicated in 
the pathogenesis of AD [337], [338]. Hence, modulation of MMP-9 by apoE may have similar 
implications in AD pathology. 
Notably, the age of onset, years of dementia, or amyloid plaque load did not correlate with MMP-
9 levels in these human samples. It is also important to note the limitations of the human dataset 
used for these experiments as, 1) the sample size of the APOE2/2 AD group is small, due to the 
exceedingly low incidence of AD in APOE2 homozygotes [121], and similarly 2) the mean age of 
the APOE4/4 non-demented control group is younger, as APOE4/4 individuals develop AD at 
an earlier age than other APOE genotypes [121], making it difficult to obtain autopsied brain 
specimens at ages consistent with the other APOE groups. That having been said, it does not 
appear these factors are driving the current observations as, for example, the APOE3/4 
heterozygous groups were more closely age-matched and MMP-9 levels were still significantly 
elevated in the APOE3/4 AD samples compared to the APOE3/4 control group and the non 
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APOE4 groups, suggesting an effect of APOE genotype on cerebrovascular MMP-9 levels in AD, 
as discussed above. 
In looking more closely at the data above, it appears that neither AD or APOE4 alone are driving 
the increase in MMP-9, but only the combination of APOE4 and AD pathology leads to elevated 
MMP-9 levels in the brain. In this regard, there was no APOE genotype effect on MMP-9 levels 
in the non-demented samples and, likewise, in the non APOE4 groups there was no difference in 
MMP-9 levels between the AD and non-demented samples. Relatedly, Saarela et al. (2004) 
discovered an interaction between a polymorphism of the MMP-3 gene (MMP3*5A) and the 
APOE4 allele which increases the overall risk of AD to a greater extent than with either allele 
alone. The detrimental effects of the APOE4 isoform in the progression of AD is well-defined, 
however the underlying mechanism has yet to be fully established. Aβ, proinflammatory cytokines 
and oxidative damage are elevated in AD [313] and APOE4 carriers [340]–[342] and these factors 
have been previously shown to influence MMP-9 levels [222], [312], [314], [315], [343]. 
Furthermore, oxidative stress has been linked to the activation of MMP-9 [344]. Hence, while 
MMP-9 levels may be mediated through these pathological features, only the combination of the 
AD environment and the APOE4 backdrop appears to be necessary to significantly elevate MMP-
9 levels in the brain. 
ApoE4 has been shown to undergo nuclear translocation, binding to double-stranded DNA with 
high affinity and functioning as a transcription factor, thereby directly influencing gene expression 
[336], [345], [346]. A recent paper by Huang and colleagues (2017) described an apoE isoform-
dependent alteration of APP transcription/expression via the DLK-MKK7-ERK1/2 pathway 
which leads to modified Aβ production with a potency rank order of apoE4>apoE3>apoE2. Not 
only does this provide a reason for the increased levels of APP and Aβ in APOE4 carriers but it 
also indicates apoE could regulate the transcription of MMP-9 and other gene targets. ApoE has 
also been shown to affect protein expression levels indirectly. By stimulating the release of nitric 
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oxide, apoE3 but not apoE4 inhibited the TNF-α-mediated up-regulation of vascular cell adhesion 
molecule-1 (VCAM1), a receptor implicated in the acceleration of the aging process [348]–[350]. 
Theendakara et al., (2016) found that apoE4 downregulates certain protective genes which resulted 
in the upregulation of TNF-α, nuclear factor κ-light-chain-enhancer of activated B cells (NFκB) 
and other inflammatory factors which have been previously implicated in the upregulation of 
MMP-9 [351]–[354], thus representing a more indirect mechanism by which the APOE4 genotype 
may impact MMP-9 expression levels. 
As the above analyses were performed in autopsied human brain specimens at an advanced or end 
stage of AD, subsequent experiments evaluated MMP-9 levels in relation to age or disease 
progression in the context of APOE genotype. This was assessed in the EFAD mouse model with 
mice at 10, 40, and 70 weeks of age, which reflect different stages of AD-related pathology [247]. 
Unfortunately, due to a lack of availability of the E2FAD genotype, only E2FAD tissue at 40 
weeks of age could be analysed. In the whole brain homogenate, there is an apparent age effect on 
MMP-9 levels between the 70-week-old and 10-week-old E4FAD mice. This is consistent with 
data which shows increased MMP-9 levels in age-related pathologies including AD [355] and may 
be due to the increased Aβ and proinflammatory cytokines which are heightened with age in 
EFAD mice, particularly E4FAD animals [247]–[249] and, as discussed above, have been 
previously shown to influence MMP-9 levels [222], [312], [314], [315], [343]. 
As opposed to whole brain homogenate, APOE differences were identified in the 
cerebrovasculature of EFAD mice. Specifically, there were significantly lower MMP-9 levels in 
E2FAD cerebrovessels compared to the other APOE genotypes, however no difference was 
evident between the E3FAD and E4FAD animals. As APOE genotype differences often manifest 
over time, evaluations in these animals at more advanced ages may reveal greater differences in 
brain MMP-9 levels across genotypes, as was demonstrated in the human brain specimens, which 
were obviously collected at an advanced or late stage of disease during autopsy. There are 
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indications of this, as a greater difference in cerebrovascular MMP-9 levels between the E4FAD 
and E3FAD animals was observed at 70 weeks of age compared to mice at 40 weeks of age or 
younger. In endothelial cells, using high-resolution laser scanning microscopy, the MMP-9 signal 
was particularly prominent in brain endothelial cells (CD-31/PECAM-1) surrounding blood 
vessels in the cortices of 6-month-old E3FAD and E4FAD mice, consistent with prior reporting 
[316]–[318], [356]. While no change in cerebrovascular MMP-9 expression levels was identified 
between E3FAD and E4FAD animals via ELISA, differences in MMP-9 immunoreactivity in the 
brain endothelia of these animals were apparent via confocal microscopy. This may be attributable 
to a greater expression of MMP-9 in endothelial cells specifically, as opposed to whole 
cerebrovasculature, which is comprised of various other cells, receptors, and proteins [357], [358]. 
Collectively, these animal studies coincide with the observations in the human brain specimens 
that APOE genotype can influence brain MMP-9 levels in the context of AD. The observation 
that APOE differences were only apparent in the cerebrovasculature, and even more specifically 
within the endothelial cells, draws attention to the specific regulation of MMP-9 by APOE in this 
brain region. MMP-9 has been shown to have detrimental effects at the BBB level in 
neurodegenerative diseases, for example, by increasing the ectodomain shedding of lipoprotein 
receptors and attenuating Aβ-42 transit out of the brain [222]. As lower levels of total MMP-9 
were detected in E2FAD mice this could represent a possible mechanism whereby APOE2 
delegates neuroprotection in AD [114], [119], [120], or at the very least doesn’t exacerbate any 
ongoing pathological processes, like APOE4 may do [109], [118]. 
Since no APOE isoform-specific changes in MMP-9 levels were detected in the cerebrovasculature 
from non-demented human control samples, this was investigated further in apoE mice with no 
AD mutations. The small number of mice used in these studies (N = 3) should be noted and the 
results interpreted with caution. No changes were detected between apoE2-TR, apoE3-TR, and 
apoE4-TR mice, coinciding with the human studies and suggesting an AD phenotype is necessary 
to result in APOE-specific changes in MMP-9, at least in the cerebrovasculature. Conversely, 
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MMP-9 levels have been previously found to be increased in the cerebrovessels of apoE4-TR 
relative to apoE3-TR and apoE2-TR mouse brains [219]. This disparity may be explained by the 
different detection technique used to measure levels of MMP-9 in the apoE-TR mouse brains in 
the prior reporting, i.e. multiphoton microscopy of DQ-gelatin. Since this technique measures 
MMP-9 activity, it could be that the apoE isoforms may be differentially interfering with the 
proteolytic activity of MMP-9 and accordingly, its ability to degrade the gelatin substrate, which 
may be a regulatory mechanism of apoE that is independent of AD pathology. The direct influence 
of apoE isoforms on MMP9 function will be investigated in detail in Chapter 3. 
Interestingly, when looking at the whole brain, MMP-9 levels were increased in apoE4-TR mice 
compared to apoE2-TR and apoE3-TR and WT mice. This may be due to the regulation of MMP-
9 by APOE in specific areas in the brain other than the cerebrovasculature. Stomrud et al. (2010) 
found that cognitively healthy individuals with risk markers for AD development, e.g. AD-
supportive CSF biomarker levels of Aβ42 or the presence of the APOE4 allele, had higher CSF 
MMP-9 levels compared to healthy individuals without these risk markers. Hence, there may be 
APOE-related changes in MMP-9 levels elsewhere in the brain which occur in the absence of AD 
pathology. Yet, it appears that AD pathology can still enhance these effects given that the addition 
of Aβ-42 (injected intracranially) in the current studies lead to further APOE differences in MMP-
9 levels in whole brain homogenate (WT<apoE3-TR, apoE2-TR<apoE4-TR). 
As mentioned earlier, MMP-9 is secreted as an inactive proenzyme from cells including brain 
endothelia [193], [316]–[318]. To determine whether the observed changes in brain MMP-9 levels 
could be due to alterations in the release of MMP-9 from the cell, experiments were conducted to 
investigate whether apoE impacts cellular MMP-9 secretion. Due to the prominent role of MMP-
9 at the BBB and our prior report of MMP-9 influencing lipoprotein receptor shedding and Aβ-
42 transit from the brain [222], the release of MMP-9 from cultured human brain endothelial cells 
and isolated cerebrovasculature from apoE-TR mice was examined. Upon stimulation with PMA 
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or Aβ-42, treatment with the apoE2 isoform significantly reduced MMP-9 secretion in the 
extracellular media relative to apoE3 or apoE4, which correlates with the findings in the E2FAD 
animals where cerebrovascular MMP-9 protein levels were substantially reduced versus the other 
APOE genotypes. In understanding the nature of these observations, the reported higher binding 
affinity of apoE2 for monomeric Aβ may explain the ability of apoE2 to mitigate the influence of 
Aβ on MMP-9 secretion, in comparison to other apoE isoforms [359], [360]. Furthermore, apoE2 
has been shown to prevent the conversion of monomeric Aβ into oligomeric species [134], [361], 
which are known to induce MMP-9 levels to a greater extent than other forms of Aβ [362], and 
may further describe the findings in the E2FAD animals. In these secretion studies, an apoE 
isoform-specific influence on MMP-9 levels was more evident after stimulation/insult with PMA 
or Aβ-42. These findings are consistent with the above MMP-9 expression data in the human 
brains which indicate APOE isoform-mediated changes in MMP-9 levels are only apparent upon 
insult, e.g., AD. Moreover, these observations are consistent with a “two-hit” hypothesis in which 
two factors are deemed necessary to propagate disease pathogenesis, in this case AD and the 
APOE4 genotype driving MMP-9 levels in the brain [363]–[365]. 
While differences in total secreted MMP-9 (i.e. pro and active MMP-9) were observed when the 
extracellular media was analysed with a substrate-based activity assay, the ELISA analysis of total 
MMP-9 levels (i.e. proMMP-9, active MMP-9 and enzyme/inhibitor complexes) did not identify 
changes in MMP-9 levels between apoE isoforms. Likewise, following treatment with Aβ-42, no 
apoE isoform differences in the levels of total MMP-9 in the extracellular media of the isolated 
apoE-TR cerebrovasculature were identified. This incongruence suggests that there may be a shift 
in the amount of free MMP-9 vs enzyme/inhibitor complexes secreted into the media [366]. For 
instance, there may be more MMP-9 complexed with TIMP-1, a natural inhibitor of MMP-9, 
present in the apoE2-treated media, as opposed to free MMP-9. These enzyme/inhibitor 
complexes can be detected by the ELISA analysis but not the substrate-based activity assay. Higher 
MMP-9/TIMP-1 ratios and lower TIMP-1 levels have been reported in AD, however not much 
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is known about the effect of apoE on TIMP-1 levels [367], [368]. These findings highlight the 
importance of recognising methodological differences when evaluating different MMP-9 assays 
[362]. Alternatively, the apoE2 in the media may be directly interacting with MMP-9, inhibiting its 
ability to degrade the substrate in the assay. This is discussed in further detail in Chapter 3.  
Collectively, the data presented in this Chapter indicates that APOE influences total MMP-9 
expression levels in AD human and EFAD mouse cerebrovascular tissue and also impacts levels 
of pro and active MMP-9 levels in conditioned media from HBMECs. ApoE may also be affecting 
other aspects of MMP-9 regulation such as the conversion from proMMP-9 to active MMP-9 or 
MMP-9 activity directly. The effect of apoE isoforms on these regulatory processes will be 
investigated in Chapter 3. 
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Chapter 3: Functional regulation of MMP-9 by apoE: conversion, binding, 
colocalisation and enzymatic activity 
3.1 Introduction 
In Chapter 2, the levels of active MMP-9 were shown to be increased in APOE4 carriers with AD. 
This elevation of active MMP-9 may be a consequence of overall raised MMP-9 expression levels, 
but they could also be due to the influence of apoE on the regulatory mechanisms of MMP-9. In 
addition to regulation via protein synthesis, MMPs are known to be highly regulated once they 
have been secreted from the cell [318]. Post-secretional regulation of MMP-9 includes conversion 
of the proenzyme to active MMP-9 and inhibition of proteolytic activity. Parts of the data and 
conclusions presented in this Chapter have been peer-reviewed and published [319]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Activation of the gelatinase, MMP-9. 
Like other MMPs, MMP-9 contains a pro-domain, catalytic domain, hinge region and hemopexin domain, 
however it also contains three fibronectin type II repeats in the catalytic domain. MMP-9 is produced as 
proMMP-9, a zymogen which requires activation through catalytic conversion and cleavage of the pro-
domain to expose the Zn2+ dependent active site (as described by Page-McCaw et al. (2007) [197]). 
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The proenzyme has molecular mass of 92 kDa which contains an N-terminal pro-domain that 
blocks the Zn2+ dependent active site (Fig. 3.1) [369]. The active MMP-9 enzyme is formed by an 
autocatalytic conversion through a “cysteine switch” mechanism which results in the removal of a 
10 kDa N-terminal pro-region [335], [370], [371]. Several activators of MMP-9 have been identified 
including MMP-2 [230], MMP-3 [231], MMP-7 [232], MMP-10 [233], MMP-13 [234], and the 
serine protease trypsin [235]. Increased MMP-9 activation is seen following inflammation [200], 
[372], for instance NF-κB signalling in human endothelial cells has been shown to affect the 
activation of MMP-9 [353], [373], [374]. MMP-9 is typically processed into the well-established 82-
kDa active species, in some instances via an inactive 86 kDa intermediate form [231], [369], [375]. 
APMA, a mercurial compound and a known MMP activator, can also convert proMMP-9 to the 
82 kDa active form [376]. Once activated, MMPs can be inhibited by TIMPs [377]. MMP-9 
inhibitors such as TIMP1 and various synthetic inhibitors usually bind to the Zn2+ active site, thus 
preventing activity [378]. A recent paper describes an MMP-9 inhibitor which prevents the 
conversion of the latent proenzyme, unlike most inhibitors which target the traditional active site, 
thus enabling a higher specificity to MMP-9 over other MMPs [375]. 
As discussed in Chapters 1 and 2, APOE is a major genetic risk factor for AD. The risk of 
developing AD is 4- and 8-fold higher in an individual carrying one or two APOE4 alleles 
respectively compared to APOE3 homozygotes [109], [118]. Conversely, APOE2 is regarded as 
protective against AD pathology, reducing risk by nearly half [114], [119], [120]. While considerable 
research has been conducted to define the detrimental effects of the APOE4 isoform that confer 
this heightened risk, the picture is incomplete. Each of the three major isoforms of APOE differ 
only at one or two positions; while APOE3 has cysteine at position 112 and arginine at position 
158, APOE2 has cysteine at both positions and APOE4 has arginine at both positions [111]. This 
drastically alters the structure and function of the apoE proteins and can affect their binding 
abilities. For instance, the apoE isoforms differ in their binding affinities to LDLR; apoE3 and 
apoE4 bind to LDLR with high affinity whereas apoE2 binding was not as strong [379], [380]. 
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Given that many MMP-9 inhibitors function through binding to MMP-9 in some way [375], 
experiments were conducted to assess if apoE could bind to MMP-9 and whether the apoE 
isoforms would exhibit different binding affinities. Determining if the apoE isoforms can bind to 
MMP-9 will not only indicate whether they can interact physiologically, but also give an indication 
as to whether apoE would be able to modulate MMP-9 directly. In this Chapter, the direct 
interactions between apoE and MMP-9 were investigated through binding association studies and 
localisation analyses in the brains of EFAD mice. In addition, the potential consequences of these 
interactions, namely the effect of apoE on MMP-9 conversion and activity, were determined. 
Investigating apoE behaviour in both its lipid‐free and lipid‐bound state is necessary to improve 
our understanding of its function in the context of AD pathology as apoE lipidation status has 
been shown to have an effect on its interactions, for instance with Aβ and its consequent 
aggregation, deposition and clearance [125], [381]–[384]. Therefore, apoE lipidation status was 
considered when studying the binding of apoE to MMP-9 and the resulting impact on MMP-9 
conversion to its active form. 
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3.2 Materials and methods 
3.2.1 Materials 
APMA, recombinant human MMP-9, and dextran were purchased from MilliporeSigma (St. Louis, 
MO, USA). Recombinant apoE was purchased from BioVision (Milpitas, CA). ELISA kits for 
LRP1 and LDLR were purchased from Cedarlane Labs (Burlington, NC, USA). ELISA kits for 
human apoE were purchased from MBL International (Woburn, MA). Halt enzyme inhibitor 
cocktails, the BCA protein assay and HBSS were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). 
3.2.2 Human cortex samples 
Human cortex samples (inferior frontal gyrus) were obtained from the autopsied brains of AD and 
non-demented subjects with different APOE genotypes as described in Chapter 2.2.2. 
3.2.3 Animals 
ApoE-TR mice and EFAD mice were used in the present studies. A description of these models 
and the housing conditions of the animals is presented in Chapter 2.2.3. 
3.2.4 Isolation of brain fractions 
Frozen human cortex samples and mouse brains were homogenised and the cerebrovasculature 
was isolated using a step-wise density gradient extraction process as previously described [182] and 
as summarised in Chapter 2.2.4. Following the separation of the cerebrovasculature, the remaining 
parenchyma and soluble brain fraction were centrifuged for a further 10 minutes to separate these 
two fractions. The parenchyma was resuspended in HBSS and centrifuged for a final 5 minutes 
before the pellet was collected in lysis buffer. All fractions were stored at -80 °C prior to analysis. 
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3.2.5 Collection and enrichment of human lipidated apoE 
The mixed glial cultures were provided by Dr. Mary Jo LaDu (University of Illinois at Chicago). 
Cortical glial cultures were prepared from apoE2-TR, apoE3-TR, or apoE4-TR mice as previously 
described [332] and as summarised in Chapter 2.2.8. 
3.2.6 Artificial lipidation of apoE 
Recombinant apoE was artificially lipidated as previously described using a protocol adapted from 
prior reporting [385]. Liposome preparation: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC, Avanti Polar Lipids, Alabaster, AL) and un-esterified cholesterol (Avanti Polar Lipids, 
Alabaster, AL) were mixed in a glass vial at a molar ratio of 90:5. This ratio was selected to mimic 
the physiological lipid composition of high-density lipoprotein (HDL)-like apoE particles. Lipids 
were resuspended in PBS at a concentration of 5 μg lipids/μl. The solution was mixed thoroughly 
by vortexing intermittently for 5-10 min (with 1-2 min intervals) to produce liposomes. Complete 
hydration of liposomes was achieved by incubating the solution at room temperature for 30 min 
and occasional vortex mixing. 
ApoE lipidation: sodium cholate (50 mg/ml, Sigma-Aldrich, St. Louis, MO) was slowly titrated 
into the liposome solution (2-3 volumes of sodium cholate for 1 volume of lipids). The solution 
turbidity cleared after 5 min of gentle vortex mixing (1 min interval) and the preparation was kept 
at room temperature for 30-60 min. Reconstituted apoE was then added to the liposome 
preparation (apoE:POPC:cholesterol, molar ratio of 1:90:5) and mixed gently for 5-10 min (1-2 
min interval). The solution was kept at room temperature for 1 h and dialysed (10 kDa cut-off 
membrane) against PBS for 4 h at room temperature (to promote removal of detergents), followed 
by 60-72 h at 4 °C. Samples were desalted and small molecular weight solutes were removed using 
PD-10 Desalting Columns (Sigma-Aldrich, St. Louis, MO). 
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3.2.7 Zymographic analysis of the impact of apoE on MMP-9 conversion to the active 
form 
Recombinant human MMP-9 (1 µg/ml) was incubated with recombinant, artificially lipidated, or 
glia-lipidated apoE2, apoE3 or apoE4 (25 ng/ml) for 45 minutes at 37 °C before being incubated 
with APMA (1 mM) for 45 minutes at 37 °C. Samples were then analysed by gelatin zymography 
to determine pro and active MMP-9 levels. For each sample, a total of 7.5 ng of total protein was 
loaded. The samples were separated on a 10% precast polyacrylamide gel with gelatin (Thermo 
Fisher Scientific, Waltham, MA) and developed as described in Chapter 2.2.7. 
3.2.8 Cell-free activity assay 
The effect of apoE isoforms on MMP-9 activity was assessed in a cell-free paradigm utilising a 
fluorescent substrate as per the manufacturers’ instructions (Anaspec, USA). Briefly, recombinant 
MMP-9 (5 nM) was incubated in the presence of lipidated apoE2, 3 and 4 (0-250 ng/ml) (collected 
from mixed glial cultures, described in Chapter 3.2.5) or SB-3CT (2-[[(4-
Phenoxyphenyl)sulfonyl]methyl]thiirane) (1 µM) and the fluorescent substrate for 1 hour at 37 °C 
before detection of fluorescence. To determine whether the substrate was metabolised by apoE 
itself, fluorescent substrate was incubated with differing concentrations of apoE alone in the 
absence of MMP-9. These values were used as background controls for each apoE isoform-MMP-
9 treatment combination. Fluorescence was measured at 340/490 nm excitation/emission 
wavelengths using a BioTek Synergy HT microplate reader. 
3.2.9 Binding studies 
The binding of MMP-9 to either recombinant apoE2, 3 and 4 or artificially lipidated apoE3 was 
evaluated using an Octet RED96 instrument equipped with Streptavidin biosensors purchased 
from ForteBio (Menlo Park, CA). Biotinylated recombinant human active MMP-9 in PBS (2 
μg/ml) was immobilised to the streptavidin biosensors for 1800 seconds and washed three times 
for 60 seconds in PBS at 1,000 rpm using the Octet platform. The Octet analysis was performed 
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at room temperature under a continuous agitation at 1,000 rpm. Each of the apoE isoforms were 
then loaded at multiple concentrations (10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml, 0.5 μg/ml, 0.25 
μg/ml) to separate sensors then allowed to dissociate in PBS (apoE2 association time: 1200s, 
dissociation time: 1200s, apoE3 association time: 1800s, dissociation time: 3800s, apoE4 
association time: 1200s, dissociation time: 1200s). Individual binding affinities were assessed by 
measuring the dissociation constant (KD) determined from the steady state. 
3.2.10 Tissue processing 
All mice were humanely euthanised, and their brains were collected and fixed in 4% 
paraformaldehyde for 48 h as previously described [334] and as summarised in Chapter 2.2.11. 
3.2.11 Immunofluorescence 
The protocol used for immunofluorescence staining is described in Chapter 2.2.12. Briefly, tissue 
sections were deparaffinised, rehydrated, and subjected to antigen retrieval for 7 min in glycine 
buffer (pH 3) at 100 °C before blocking in 100% SeaBlock (EastCoast Bio, MA, USA), 0.5mM 
glycine, 0.3% Triton X-100, 0.05% Tween™ 20 for 1 h. Sections were incubated in PBS containing 
10% SeaBlock, 0.33mM glycine, 0.3% Triton X-100, 0.05% Tween™ 20 and the respective panel 
of primary antibodies overnight at 4 °C. The following antibodies were used: ab38898 (anti-MMP-
9, 1:200, Abcam, Cambridge, MA, USA), ab1907 (anti-apoE [E6D7], 1:200, Abcam, Cambridge, 
MA, USA), AF3628 (anti-CD31/PECAM-1, 1:1000, Novus Biologicals, Centennial, CO, USA). 
After three washing steps in PBS for 5 min, sections were incubated in PBS containing 10% 
SeaBlock, 0.33mM glycine, 0.3% Triton X-100, 0.05% Tween™ 20 and the respective panel of 
secondary antibodies for 1 h in the dark at room temperature in a humidified chamber. The 
following secondary antibodies were used: donkey anti-rabbit, anti-goat, anti-mouse conjugated to 
Alexa 488, 568 and 647, respectively (1:1000, Life technologies). For qualitative analysis of the 
colocalisation between MMP-9 and apoE, orthogonal projections of cortical brain regions from 
E3FAD and E4FAD mice (n = 4 for each genotype, all female mice, 6 month of age) were 
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analysed. Six images were generated for each mouse. Averages calculated from the six images were 
used for statistical analysis. 
3.2.12 Statistical analysis 
Data are expressed as mean ± SEM. Data was checked for normality and statistical significance 
was determined by ANOVA followed by the two-stage step-up method of Benjamini, Krieger and 
Yekutieli unless otherwise stated. A p-value lower than 0.05 was used to indicate a statistically 
significant difference. Statistical analyses were performed with GraphPad Prism 8. 
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3.3 Results 
3.3.1 Binding interactions between apoE and MMP-9 
Kinetic binding studies using biolayer interferometry were conducted using the ForteBio Octet 
RED96 instrument. Active MMP-9 was able to bind to all isoforms of recombinant apoE in the 
association step (Fig. 3.2a, c, e), but the subsequent dissociation in PBS was limited, even when 
the dissociation time was extended, as shown with the apoE3 isoform (Fig. 3.2c). The dissociation 
constant (KD) was measured from the steady state analysis for each isoform (Fig. 3.2b, d, f). 
ApoE4 displayed a larger KD than both apoE3 and apoE2 (4.5-fold and 3.7-fold higher 
respectively) signifying a weaker binding interaction between MMP-9 and apoE4 compared to the 
other apoE isoforms (Fig. 3.2g, h). Artificially lipidated apoE3 did not bind to MMP-9 (Fig. 3.3). 
3.3.2 Effect of apoE isoform on pro MMP-9 conversion to activated MMP-9 
In assessing the effect of apoE isoforms on the conversion of proMMP-9 to the active form of 
MMP-9, as anticipated, both proMMP-9 (92 kDa) and active MMP-9 (82 kDa) bands could be 
detected using zymography following treatment of recombinant proMMP-9 with APMA (Fig. 3.4a, 
c, e), which has been previously shown to convert proMMP-9 into its active form [335], [370]. 
With respect to apoE, conversion of MMP-9 was increased by 25% and 62% in the presence of 
recombinant apoE4 compared to apoE2 and apoE3 respectively, following APMA activation 
(***p<0.001) (Fig. 3.4a, b). However, following incubation of MMP-9 with glia-lipidated apoE, 
the greatest conversion of proMMP-9 to active MMP-9 was observed in the presence of apoE2 
(Fig. 3.4c, d). Lastly, concerning apoE that had been artificially lipidated, no differences between 
apoE isoforms were identified (Fig. 3.4e, f). 
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Figure 3.2: Kinetic binding studies of MMP-9 and apoE2, apoE3 or apoE4 using Bio-Layer 
Interferometry. 
Biotinylated recombinant human MMP-9 was immobilised to streptavidin biosensors (1800 seconds). 
Recombinant apoE was then added in increasing concentrations (dark blue: 0.25 µg/ml, red: 0.5 µg/ml, 
light blue: 1 µg/ml, green: 2.5 µg/ml, orange: 5 µg/ml, purple: 10 µg/ml) to separate sensors then allowed 
to dissociate in PBS (A: apoE2. Association time: 1200s, Dissociation time: 1200s, B: apoE3. Association 
time: 1800s, Dissociation time: 4000s, C: apoE4. Association time: 1200s, Dissociation time: 1200s). 
Individual binding affinities were assessed by measuring the dissociation constant (KD) (G, H) determined 
from the steady state (D: apoE2, E: apoE3, F: apoE4). ApoE4 demonstrated the weakest binding affinity; 
the KD for apoE4 was greater compared to apoE3 and apoE2. Values represent mean ± SEM. N=5-6. 
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Figure 3.3: Figure 14: Kinetic binding studies of MMP-9 and artificially lipidated apoE3 using Bio-
Layer Interferometry. 
Biotinylated recombinant human MMP-9 was immobilised to streptavidin biosensors (1800 seconds). (A) 
Artificially lipidated apoE3 was then added in increasing concentrations (dark blue: 0.25 µg/ml, red: 0.5 
µg/ml, light blue: 1 µg/ml, green: 2.5 µg/ml, orange: 5 µg/ml, purple: 10 µg/ml) to separate sensors then 
allowed to dissociate in PBS (Association time: 1800s, Dissociation time: 4000s). (B) Steady state analysis 
showed limited binding of MMP-9 to artificially lipidated apoE3. 
 
 
 
Figure 3.4: Effect of apoE isoform on the conversion of MMP-9 to the active form. 
Recombinant human MMP-9 was incubated with 25 ng/ml (A, B) recombinant (C, D) glia-lipidated (GCM) 
or (E, F) artificially lipidated recombinant human apoE2, 3 or 4 or no apoE (control) before being activated 
with APMA (1 mM). (A, C, E) Gelatin zymography demonstrating pro and active MMP-9 bands. (B, D, F) 
Quantification of zymogram bands (ratio of active to proMMP-9). (B) n = 17, (D) n = 13, (F) n = 5-6.  
Values represent mean ± SEM. *p<0.05, ***p<0.001, ****P<0.0001 as determined by a one-way ANOVA 
and the BKY procedure. 
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3.3.3 Effect of apoE isoform on MMP-9 activity 
Using a cell-free MMP-9 activity assay, each apoE isoform significantly attenuated MMP-9 activity 
in a dose-dependent manner compared to control conditions (MMP-9 alone) (Fig. 3.5). 
Furthermore, apoE isoform-specific differences in modulating MMP-9 activity were observed at 
each apoE concentration on the order of apoE2>apoE3>apoE4. However, while apoE4 did 
impact MMP-9 function, apoE2 and apoE3 were considerably more effective than apoE4 in 
modulating MMP-9 activity. At 250 ng/ml apoE2 and apoE3 resulted in an 82% and 77% 
reduction in MMP-9 activity with respect to control, respectively, compared to a 48% reduction 
by apoE4, which equates to a 3-fold difference between apoE2 and apoE4 at this concentration 
(****p<0.0001). 
3.3.4 Localisation of apoE and MMP-9 in brain endothelia 
Having shown that MMP-9 can directly bind to apoE in a cell-free environment, experiments were 
conducted to investigate this interaction in a physiological setting by using immunofluorescence 
and confocal microscopy. Brain cortices of 6-month-old E3FAD and E4FAD mice were analysed 
for MMP-9 immunoreactivity in cortical endothelial cells (Fig. 3.6a, b). A high proportion of apoE 
was confined to amyloid plaques leading to higher overall levels of apoE in E4FAD mice 
compared to E3FAD (Fig. 3.6e). When apoE confined to amyloid plaques was excluded from the 
analysis, levels of apoE were no different between E3FAD and E4FAD mice (Fig. 3.6f). While 
levels of CD-31 or plaque-free apoE did not differ between APOE genotypes (Fig. 3.6f, h), there 
was a 56% increase in MMP-9 immunoreactivity in cortical endothelial cells from E4FAD mice 
compared to E3FAD mice, as discussed in Chapter 2.4 (*p<0.05) (Fig. 3.6c). Importantly, there 
were several areas where MMP-9 and apoE predominantly overlapped (indicated by white arrows) 
and interaction was significantly higher in E3FAD mouse cortices relative to E4FAD (*p<0.05) 
(Fig. 3.6g). 
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Figure 3.5: Differential modulation of MMP-9 activity by apoE isoforms. 
MMP-9 activity was significantly modulated by apoE in an isoform and dose-dependent manner 
(apoE2>apoE3>apoE4). Differences between each of the apoE isoforms were statistically significant at 
concentrations ≥ 5 ng/ml. Treatment of 1 µM SB-3CT was included as a positive control and showed 
considerable attenuation of MMP-9 activity. Values represent mean ± SEM (N = 3) and are expressed as 
fluorescent units. Statistical significance was determined by two-way ANOVA followed by the BKY 
procedure. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Asterisk symbols above bars indicates 
significant differences compared to MMP-9 alone. Asterisk symbols above brackets indicates significant 
differences from other apoE isoforms at that concentration. 
 
 
 
 
 
 
 
 
 
 
~ 84 ~ 
 
 
Figure 3.6: MMP-9 and apoE immunoreactivities in cortices of E3FAD and E4FAD mice. 
Representative confocal images depicting 6-month-old female (A) E3FAD and (B) E4FAD mice stained 
with antibodies against CD31/PECAM-1 (red), apoE (E6D7, purple) MMP-9 (green). Both E3FAD and 
E4FAD mice exhibited a prominent MMP-9 signal that overlapped with apoE in endothelial cells 
surrounding blood vessels (indicated by white arrows). (C) Quantification of MMP-9 immunofluorescent 
intensity within endothelial cells (CD31/PECAM-1). (D) Quantification of MMP-9 area within endothelial 
cells (CD31/PECAM-1). (E) Quantification of total apoE immunofluorescent intensity. (F) Quantification 
of apoE immunofluorescent intensity within endothelial cells. (G) Percentage overlap of MMP-9 and apoE 
areas normalised to total MMP-9 area. (H) Quantification of the area covered by endothelial cells 
(CD31/PECAM-1). The scale bars represent 50μm. N=4. Values represent mean ± SEM. *p<0.05, as 
determined by unpaired t-tests. 
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3.3.5 Differences in lipoprotein receptor levels in human brain tissue 
LRP1 levels were analysed in the soluble brain fraction, cerebrovasculature and whole brain 
homogenate of human AD and non-demented control subjects (Fig. 3.7). Levels of LRP1 were 
decreased in the whole brain homogenate and cerebrovasculature of AD subjects and further 
differences were detected across APOE genotype (APOE4>APOE3>APOE2) (Fig. 3.7a, b, e, f). 
No changes in LRP1 levels were observed in the soluble brain fraction (Fig. 3.7c, d). These results 
are unpublished data from our team and derived from the dissertation thesis of Dr. Ben 
Shackleton. 
3.3.6 Differences in lipoprotein receptor levels in EFAD mouse brain 
The levels of the lipoprotein receptors LRP1 and LDLR were analysed in the soluble brain fraction, 
cerebrovasculature and whole brain homogenate of E3FAD and E4FAD mice at 40 and 70 weeks 
of age (Fig. 3.8). Levels of LDLR in the cerebrovasculature were increased in E4FAD mice relative 
to E3FAD mice at 40 weeks of age but then were decreased in both genotypes at 70 weeks of age 
(Fig. 3.8b). While the levels of LDLR did not differ between APOE genotypes or by age in the 
soluble brain fraction or the whole brain homogenate (Fig. 3.8a, c), levels of LRP1 were elevated 
in the soluble brain fraction of E4FAD mice at 70 weeks of age compared to 40 weeks of age (Fig. 
3.8d). However, there were no differences in LRP1 levels in the cerebrovasculature or the whole 
brain homogenate in either E3FAD or E4FAD mice (Fig. 3.8e, f). 
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Figure 3.7: Expression of LRP1 in human cortex samples. 
(A) Expression of LRP1 in the total homogenate was decreased in AD vs non-demented control subjects. (B) 
This was APOE genotype-dependent; non-demented APOE4/4 individuals displayed increased LRP1 levels 
relative to non-demented APOE3/3 and APOE2/2 subjects and compared to APOE4/4 AD subjects. No 
changes in LRP1 expression were detected between (C) AD and control subjects nor with regards to (D) APOE 
genotype. (E) Expression of LRP1 in the cerebrovasculature was decreased in AD vs non-demented control 
subjects. (F) This was also APOE genotype-dependent; non-demented APOE4/4 individuals displayed 
increased LRP1 levels relative to non-demented APOE2/2 subjects and compared to APOE4/4 AD subjects. 
Values represent mean ± SEM (N = 2 for AD APOE2/2 subjects, N = 10 for all other genotype/disease 
groups). Statistical significance was determined by two-way ANOVA followed by Tukey’s post-hoc analysis. 
*p<0.05, **p<0.01, ****p<0.0001. These results are unpublished data from our group and derived from the 
dissertation thesis of Dr. Ben Shackleton. 
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Figure 3.8: Expression of LRP1 and LDLR in 40-week-old and 70-week-old EFAD mouse brain. 
Expression of LDLR was not different in E3FAD compared to E4FAD mice or in 40-week-old compared 
to 70-week-old mice in (A) the soluble brain fraction or (C) the whole brain homogenate. (B) Levels of 
LDLR were increased in E4FAD relative to E3FAD mice in the cerebrovasculature of 40-week-old mice 
and both genotypes showed decreased levels in 70-week-old mice. Expression of LRP1 was not different 
in E3FAD compared to E4FAD mice or in 40-week-old compared to 70-week-old mice in (E) the 
cerebrovasculature or (F) the whole brain homogenate. (D) Levels of LRP1 were increased in E4FAD at 
70 weeks of age compared to 40 weeks of age. Values represent mean ± SEM (N = 4). Statistical significance 
was determined by two-way ANOVA followed by the BKY procedure. *p<0.05, ***p<0.001. 
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3.4 Discussion 
MMP-9 undergoes extensive regulation following secretion from the cell [318]. Expressed as a 
proenzyme, it must undergo proteolytic cleavage before becoming active [228], [229]. Inhibitors 
of MMP-9 have been shown to be able to prevent this cleavage and thus modulate the activation 
of MMP-9 [375]. Moreover, once in its active form, MMP-9 activity can be inhibited by both 
endogenous and synthetic inhibitors [378]. In this Chapter, apoE was shown to impact the 
conversion of MMP-9 to its active form and in addition have a direct effect on its activity. 
Furthermore, there were isoform-specific differences in this regulation. 
Since the discovery that the APOE4 allele is a high-risk genetic factor for AD, researchers have 
been investigating the mechanisms underlying its detrimental effects through the use of 
recombinant or delipidated apoE, which provide a relatively uncomplicated means of assessing 
apoE function [386]. To obtain a direct measure of the influence of apoE on the conversion of 
proMMP-9 to the active form, proMMP-9 was incubated with APMA (a known MMP-9 activator) 
in the presence of each apoE isoform [335], [370]. The incubation of proMMP-9 with recombinant 
apoE4 resulted in a greater degree of conversion relative to apoE2 and apoE3, suggesting that 
apoE may regulate MMP-9 disposition by modulating proMMP-9 conversion to the active enzyme. 
Biolayer interferometry experiments demonstrated that the binding affinity of recombinant apoE4 
to MMP-9 was 3-times weaker than the other isoforms, which may describe the enhanced 
conversion of proMMP-9 to active MMP-9 in the presence of apoE4. In other words, apoE4 may 
be less able to modulate the catalytic cleavage of proMMP-9 to active MMP-9, which has 
previously been shown for other proteins [235], [375], [387]. 
While recombinant apoE has its advantages, lipidation status has been shown to influence the 
degree to which apoE binds to receptors and other proteins [383], [388]. In the current studies, 
artificially lipidated apoE, generated by using a ratio of cholesterol and POPC selected to mimic 
the physiological lipid composition of HDL-like apoE particles [385], was used to investigate the 
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potential differences in binding affinity that may occur following lipidation of apoE, However, 
limited binding was observed between MMP-9 and this apoE species. While this is a common 
approach used by laboratories to generate lipidated apoE, the method used to artificially lipidate 
apoE may not be reflective of the natural lipid composition and could have resulted in the binding 
sites being blocked by the lipid particles. Correspondingly, as a lack of binding seemingly occurred 
between MMP-9 and these artificially lipidated apoE species, this could describe why no changes 
were detected between any of the artificially lipidated apoE isoforms when these species were 
incubated with MMP-9 and APMA in the conversion studies. 
While these studies with recombinant apoE, both delipidated and artificially lipidated, provide 
important information regarding apoE in the context of AD, they may not be completely relevant 
to physiological conditions inside the brain. ApoE produced in the brain is expressed primarily by 
glia [112], [389]–[392] so using human apoE generated from the mixed glial cultures of apoE-TR 
mice in these studies provided a more physiologically relevant source of lipidated apoE by which 
to examine the effect of apoE on MMP-9 regulation. Interestingly, a significantly higher degree of 
conversion was observed in the presence of the glia-lipidated apoE2 compared to apoE3 and 
apoE4. A limitation of this study is that the glia-generated lipidated apoE was collected from 
conditioned media, so there may be confounding influences from other glial-secreted proteins in 
these preparations which would need to be determined through further analysis of the glia 
conditioned media. For example, apoE4 is associated with an increased pro-inflammatory response 
compared to apoE2 and apoE3, leading to elevated levels of cytokines [138], [393], [394], though, 
this has been shown to vary depending on cell type; the release of pro-inflammatory cytokines 
(TNF-α, nitric oxide, IL‐1β, or IL‐6) from microglia after lipopolysaccharide stimulation follows 
the pattern (apoE4>apoE3>apoE2), but this order is reversed with astrocytes [395]–[397]. 
However, in cells that have not been activated by lipopolysaccharide or other methods of 
stimulation, baseline levels of cytokines in the media are often too low to be detected [138], [395], 
[397]. Therefore, while it’s possible that increased proinflammatory factors in the conditioned 
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media from apoE2-TR mixed glial cultures, such as increased NFκB levels, is impacting MMP-9 
conversion levels [353], [373], [374], they are often in such low abundance in the extracellular media 
under non-stimulated conditions that their potential influence is likely negligible [138], [395], [397]. 
It should also be noted that the glia-lipidated apoE2 was sourced from apoE2 homozygous mice, 
which develop type III hyperlipidaemia, a chronic pro-inflammatory state that may confound the 
interpretation of results [243]. 
It has been shown that lipidation status has a profound impact on apoE function [398], which 
likely contributed to the diverse effects of recombinant, glia-lipidated and artificially lipidated apoE 
on MMP-9 conversion. This is consistent with previous studies demonstrating that various apoE 
preparations can yield dramatically different results [248], [383], [388], [398], [399]. The role and 
nature of apoE lipidation in health and disease are critical topics the field has been trying to 
reconcile for some time, which include the extent and composition of lipidation between apoE 
isoforms, changes during aging and disease, and differences between central and peripheral apoE, 
etc. As so little is known about the makeup of apoE particles under physiological conditions, the 
identification of appropriate lipidated preparations to study apoE and its function has proved to 
be challenging. The varied responses elicited by the different apoE preparations in the current 
studies highlight the need to identify physiologically relevant preparations of apoE, in order to 
more appropriately and reproducibly evaluate apoE function. Future in vitro experiments could 
utilise immortalised cell lines from primary glial cultures derived from apoE-TR mice for the 
production and purification of large quantities of apoE-containing lipoproteins [400]. Owing to 
the potential confounding influence of hyperlipidaemia in apoE2 homozygous mice, it may be 
necessary to instead use apoE2/3 heterozygous mice to avoid any lipid and cholesterol disruptions 
related to this condition. 
In terms of MMP-9 activity, while an increased ratio of active:proMMP-9 was observed in the 
presence of the glia-lipidated apoE2 isoform, this did not translate to increased activity of MMP-
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9. In fact, the presence of glia-lipidated apoE2 resulted in the largest inhibition of MMP-9 activity 
in a cell-free activity assay versus the other apoE isoforms. These supposedly contradicting results 
could be caused by the binding mechanism of each of the apoE isoforms. For instance, the 
different binding site or conformation adopted by the apoE2 isoform may enable the cleavage of 
MMP-9 by APMA however prevent MMP-9 from being able to bind and degrade substrates. 
MMP-9 can be inhibited by multiple mechanisms: binding of the inhibitor to proMMP-9 prevents 
conversion to the active form, whereas its binding to active MMP-9 allosterically inhibits MMP-9 
activity. Lipidated apoE2 could conceivably be more suited to bind to active MMP-9, and 
subsequently inhibit its activity [401], [402]. 
I could not assess the binding affinities of each of the glia-lipidated apoE isoforms due to the 
presence of other proteins in the media which could interfere with the binding of apoE to MMP-
9 or could bind to MMP-9 instead of apoE. To assess this in future studies, apoE would need to 
be isolated and purified before analysis. In the present studies, it was not possible to generate a 
sufficient amount of the necessary concentration of apoE from the primary glial cultures to 
perform these studies. Binding differences due to apoE lipidation state may arise from the 
conformational changes of apoE upon binding to lipids [403]–[406], which may also reveal 
underlying isoform-dependent differences. Although understanding the structure and the ensuing 
function of the apoE isoforms remains challenging due to the dynamic nature of their 
conformations, apoE4 is more likely to adopt a conformation that is considered pathological [407]. 
An important aspect of apoE4 structure is the orientation of Arg-61 which promotes domain 
interaction by interacting with Glu-255 within the lipid binding region, leading to a more compact 
conformation of apoE4 compared to the other isoforms [408], [409]. The binding affinities of each 
glia-lipidated apoE isoform to MMP-9 may follow a similar pattern to the delipidated, recombinant 
apoE (i.e. reduced binding with apoE4), as was reported in a study assessing the effect of lipidation 
status on the binding of apoE to TREM2, another risk factor for the development of AD; glia-
lipidated apoE demonstrated similar binding affinities to delipidated recombinant apoE [116]. 
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Alternatively, the effect of apoE lipidation status on the binding affinity to MMP-9 may be similar 
to that reported for the binding of apoE to Aβ, where lipidated apoE resulted in increased binding 
affinity and the emergence of apoE isoform differences [383]. 
Accordingly, the observed differences of the apoE isoforms on MMP-9 activity may be a result of 
the differences in the binding affinities of each apoE isoform to MMP-9, i.e., the greater the 
binding, the greater the inhibition of MMP-9 activity. This would suggest that apoE is directly 
inhibiting the enzymatic activity of MMP-9. ApoE is able to regulate the activity of enzymes 
involved in lipid metabolism [410] and APOE4 carriers have been previously shown to have altered 
global enzyme activity [341], [411], [412]. One mechanism by which apoE can alter the activities 
of enzymes is by binding to their receptors [347], [413], [414], while not much has been reported 
regarding the ability of apoE to inhibit enzymatic activity directly. Recently, apoE has been shown 
to bind and inhibit a key activator in the classical complement cascade, the C1q protein, thus 
inhibiting this inflammatory mechanism which plays a role in AD pathology [415], [416] and 
providing a clear example of a direct inhibitory role for apoE in AD. 
The significant and dose-dependent inhibition of MMP-9 activity observed in the presence of each 
apoE isoform indicates an interaction between apoE and MMP-9. In addition to the binding 
studies, further evidence for this association was identified in a more physiological setting using 
high-resolution laser scanning microscopy. MMP-9 and apoE immunoreactivities clearly 
overlapped in numerous areas of the cortex of EFAD animals. The finding that apoE4 appeared 
to associate with MMP-9 to a lesser extent than apoE3 as a smaller fraction of MMP-9 was found 
to colocalise with apoE4 compared to apoE3, could be indicative of a weaker interaction between 
apoE4 and MMP-9. These studies are consistent with the kinetic binding studies above, which 
demonstrated a lower binding affinity of apoE4 to MMP-9, compared to other apoE isoforms. 
Collectively, these results suggest a physiologically relevant interaction between MMP-9 and apoE 
in the brain cortices of E3FAD and E4FAD mice. 
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Previously our group showed that inhibiting the proteolytic activity of MMP-9 reduces the 
lipoprotein receptors LRP1 and LDLR shedding and increases the clearance of Aβ through the 
BBB [182], [222]. As described in Chapter 2 and recently [319], MMP-9 expression and activity are 
elevated in AD cerebrovasculature relative to control subjects, which may have contributed to the 
reduced LRP1 expression observed in AD cerebrovasculature in the current studies. This data is 
consistent with prior reports showing LRP1 levels to be reduced in human AD brains [417], [418]. 
What has not been thoroughly investigated is the effect of APOE genotype on lipoprotein receptor 
levels in AD. Intriguingly, the present studies showed lipoprotein receptor levels were APOE 
genotype-dependent with the highest expression levels found in E4FAD mice and APOE4/4 
individuals, most notably in the cerebrovasculature. Research conducted by Tachibana et al. (2019) 
demonstrated that LRP1 participates more in the clearance of Aβ in the context of the APOE3 
genotype whereas with the APOE4 genotype, LRP1 tends to contribute more to Aβ seeding [418], 
[419]. Given that the seeding of Aβ into oligomeric and insoluble species, which accumulate in 
extracellular Aβ plaques, has been shown to accelerate Aβ pathology [420], [421], the elevated 
levels of LRP1 exhibited by individuals with the APOE4 genotype reported in this Chapter may 
ultimately be detrimental and contribute to AD pathology. ApoE4 has been shown to have a 
critical impact on the seeding of Aβ in the early stages of the disease before symptoms are apparent 
[422], [423], which may describe the increased LRP1 levels observed in the APOE4/4 non-
demented controls. 
While prior research from our group has shown that the APOE4 isoform is associated with 
increased shedding of LRP1 and LDLR in vitro and in apoE4-TR mice [182], the lower levels of 
LRP1 seen in the cerebrovasculature of human subjects did not translate to elevated levels of the 
soluble lipoprotein receptor in the brain. This is possibly due to soluble LRP1 binding to Aβ or 
other proteins and masking the epitope [177]–[181]. Similarly, no APOE isoform differences were 
apparent between E3FAD and E4FAD mice in the soluble brain fraction, however LRP1 levels 
did increase in E4FAD mice in 70-week-old relative to 40-week-old mice, which could be a result 
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of increased Aβ levels or inflammation in these mice promoting receptor shedding [177], [182], 
[424], [425]. 
Collectively, the results presented in Chapters 2 and 3 indicate that apoE influences MMP-9 
disposition in the brain in an isoform-dependent manner, as displayed in Figure 3.9. ApoE was 
shown to influence both the levels of MMP-9 in conditioned media from brain endothelia and the 
conversion of proMMP-9 to active MMP-9, as well as dose-dependently inhibit MMP-9 activity. 
Importantly, overall, apoE4 was the least effective in modulating these processes compared to 
other apoE isoforms, which may be due to a weaker binding affinity and association with MMP-
9. Both the human and animal AD brain specimens exhibited APOE isoform specific differences 
in MMP-9 levels, particularly in the cerebrovasculature. The elevated MMP-9 levels in APOE4 AD 
subjects may describe our prior work showing an effect of APOE genotype on lipoprotein receptor 
proteolysis and Aβ elimination across the BBB [122], [182], which are mediated by MMP-9 [222]. 
As such, targeting MMP-9 may be an effective strategy to mitigate AD pathophysiology, 
particularly for individuals with an APOE4 genotype. 
 
Figure 3.9 ApoE isoforms differentially regulate MMP-9 disposition. 
A summary schematic depicting the results presented in Chapters 2 and 3, which demonstrate that apoE 
can influence multiple aspects of MMP-9 disposition in AD in an isoform-dependent fashion. 
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Chapter 4: Modulation of MMP-9 activity and expression in AD mice 
4.1 Introduction 
Elevated MMP-9 levels have been reported in numerous neurological and inflammatory disease 
states including AD [200], [208], [309], cerebral amyloid angiopathy [227], TBI [426], [427], 
amyotrophic lateral sclerosis [428], multiple sclerosis [429], [430], ischaemia [203], [204], 
intracerebral haemorrhage [431] and cardiovascular disease [193], [199]. Genetic knock out of the 
MMP-9 gene in mice has enabled the study of MMP-9 function in these pathological disease states. 
It has been demonstrated that MMP9KO mice were protected against cerebral ischemia [205] and 
TBI [206], reportedly due to the prevention of MMP-9 activity at the BBB. Pharmacologic 
inhibition of MMPs has been shown to attenuate tissue damage and oedema in cerebral focal 
ischemia [166], [432] and ameliorate neutrophil infiltration, oxidative stress, oedema and 
degenerating neurons in intracerebral haemorrhage [431]. In a transgenic mouse model of AD, 
minocycline treatment diminished inducible nitric oxide synthase and activation of microglia whilst 
ameliorating cognitive dysfunction which was attributed in part to the inhibition of MMP-9 [310]. 
MMP-9 has been found to play a causal role in Aβ-induced cognitive impairment and neurotoxicity 
[212]. While the injection of Aβ increases MMP-9 expression and induces hippocampal damage 
coupled with learning and memory deficits [212], [433]–[435], this was alleviated by MMP-9 
inhibitors and diminished in MMP9KO mice [212]. 
Owing to the elevated MMP-9 levels in AD brains and the reduced ability of apoE4 to modulate 
MMP-9 disposition reported previously [319] and described in Chapters 2 and 3, the therapeutic 
value of reducing MMP-9 activity in E4FAD mice was investigated in this Chapter. For these 
studies, SB-3CT, which has been recognised as a selective MMP-2 and MMP-9 inhibitor [204], 
[436]–[438], was used to reduce MMP-9 activity. This compound readily crosses the BBB and was 
developed to circumvent the adverse effects associated with broad-spectrum MMP inhibitors 
[439], [440]. SB-3CT treatment for seven days has been reported to reduce neuronal laminin 
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degradation and protect neurons from ischemic cell death [436]. Furthermore, in a TBI model, 
SB-3CT treatment preserved hippocampal neurons from neurodegeneration and attenuated 
accompanying behavioural deficits [441]. This inhibitor has also demonstrated beneficial effects in 
animal models of stroke, subarachnoid haemorrhage and spinal cord injury [442]–[444]. While SB-
3CT has shown efficacy in numerous neurological diseases, its effectiveness in AD has not been 
determined. A previous study investigated one aspect of AD pathology involving the shedding of 
pericyte NG2, a proteoglycan known to play a regulatory role in the maintenance of vascular 
integrity. While toxic oligomeric Aβ increased levels of activated MMP-9 which then enhanced the 
shedding of NG2 in primary human pericyte cultures, this was inhibited in the presence of SB-
3CT [362]. 
Pharmacological inhibition of MMP-9 activity offers a potential approach for the treatment of AD, 
providing information about the timing and length of duration required for treatment. In addition 
to this approach, 5xFAD/MMP9KO mice were generated to investigate the effect of MMP-9 
knockout from birth by crossing MMP9KO mice with 5xFAD mice. Many mouse models of AD, 
including 5xFAD mice, exhibit elevated levels of MMP-9 compared to WT mice, which may be 
contributing to the progression of AD pathology [445], [446]. Preventing this aberrant expression 
through the genetic manipulation of MMP-9 provides a more definitive approach to evaluating the 
role of MMP-9 in AD, separate from the influence of APOE isoforms. In this Chapter, the effects 
of MMP-9 inhibition and MMP-9 knockout on measures of behaviour (anxiety, sociability, social 
recognition memory and spatial memory), amyloid pathology and lipoprotein receptor shedding 
were assessed (Fig. 4.1). 
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4.2 Materials and methods 
4.2.1 Materials 
The MMP-9 inhibitor, SB-3CT, was purchased from Tocris Bioscience (Minneapolis, MN, USA). 
ELISA kits for mouse MMP-9 were purchased from Sciencell Research Laboratories (Carlsbad, 
CA, USA). ELISA kits for LRP1 and LDLR receptors were purchased from Cedarlane Labs 
(Burlington, NC, USA). Halt enzyme inhibitor cocktails, the BCA protein assay, HBSS and ELISA 
kits for human Aβ-40 and Aβ-42 were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). Dextran and guanidine hydrochloride were purchased from MilliporeSigma (St. Louis, MO, 
USA). 
4.2.2 Animals 
4.2.2.1 5xFAD mice 
5xFAD mice are APP/PS1 double transgenic mice that co-express five FAD mutations and 
additively increase Aβ-42 production resulting in a mouse model of AD with accelerated plaque 
development and elevated levels of cerebral Aβ-42 [236]. Of the three lines originally generated, 
the Tg6799 line expresses the highest levels of mutant APP and is the most widely used. The mice 
used in this study were on a congenic C57BL/6 background as opposed to the original hybrid 
B6SJL background and were hemizygous for the APP and PSEN1 transgenes. Extracellular 
amyloid plaques can be detected in the hippocampus, cortex and thalamus of these mice at 2 
months of age and thioflavin-S-positive plaques appear between 2 and 4 months of age in the 
frontal, parietal and entorhinal cortices and the dentate gyrus [237], [238]. Mice exhibit progressive 
cerebral amyloid angiopathy from around 3 months of age [237]. Amyloid pathology is more severe 
in female compared to male mice [236], [239]. Spatial working memory is impaired starting from 
3-6 months of age and is exacerbated with age. Anxiety decreases progressively with age from 3-6 
months in this strain of mice as determined by the elevated plus maze [240]. 
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4.2.2.2 EFAD mice 
ApoE-TR mice were purchased from Taconic Biosciences (Rensselaer, NY) and allowed to adapt 
to the vivarium for 2 weeks prior to any experimental procedures. The apoE-TR mice were created 
by targeted replacement of the endogenous murine APOE gene with human APOE2, APOE3 or 
APOE4 [330]. These mice retain the endogenous regulatory sequences required for apoE 
production and express the human apoE protein at physiological levels. The EFAD animals were 
provided by Dr. Mary Jo LaDu (University of Illinois at Chicago). To generate the EFAD mouse 
model, 5xFAD mice (Tg6799 line) were crossed with apoE4, apoE3, and apoE2-TR mice, 
producing the E4FAD, E3FAD, and E2FAD mouse models respectively, as previously described 
[247]. The EFAD mice remain homozygous for the APOE allele and heterozygous for the 5xFAD 
mutations. Overall, the EFAD mice display a less severe AD phenotype compared to the 5xFAD 
line; they develop plaques in the subiculum and cortex at four months of age as opposed to two 
months in the 5xFAD line [247]. EFAD mice display age-dependent Aβ accumulation and deficits 
in cognitive function, both of which are APOE-specific; E4FAD mice demonstrate the greatest 
deficits in cognitive function and developed more Aβ pathology compared to E3FAD and E2FAD 
mice [247], [251]. Amyloid pathology is greater in female mice than male mice [250]. In this 
Chapter, inhibition of MMP-9 activity by treatment with SB-3CT was assessed in E4FAD mice. 
4.2.2.3 MMP9KO mice 
MMP9KO mice and their C57BL/6 controls were purchased from the Jackson Laboratory (JAX 
stock #007084, Bar Harbor, ME, USA) [447] and allowed to adapt to the vivarium for 2 weeks 
prior to any breeding or experimental procedures. MMP9KO mice were generated as previously 
described and are viable, fertile and shown to survive for at least 24 months [198]. No MMP-9 
activity is detected in spleen cell lysates from these mice [198], a finding which was confirmed in 
the MMP9KO mice used in the current studies through the zymographic analysis of spleen cell 
lysates. Moreover, tail snips were assessed through Transnetyx, Inc. (Cordova, TN, USA) which 
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confirmed the absence of the MMP-9 gene. While long bones (tibia, femur) are initially 10% 
shorter in MMP9KO mice due to delayed apoptosis, vascularisation, and ossification, this is 
resolved by remodelling by 8 weeks of age [198]. 
4.2.2.4 Generation of the 5xFAD/MMP9KO mice 
The genetic manipulation of MMP-9 levels was investigated by crossing MMP9KO mice with 
5xFAD mice. Both strains of mice were on a C57BL/6 background. 5xFAD mice, hemizygous 
for the APP and PSEN1 transgenes were initially crossed with MMP9KO mice which were null 
for the MMP-9 gene. The resulting litter were all heterozygous for the MMP-9 gene, half were 
positive for the 5xFAD mutations (5xFAD/MMP9KO-het) and half were negative 
(WT/MMP9KO-het). The 5xFAD/MMP9KO-het mice were then backcrossed with the 
MMP9KO mice to generate 5xFAD/MMP9KO, WT/MMP9KO (MMP9KO), 
5xFAD/MMP9KO-het and WT/MMP9KO-het mice. The presence or absence of genes was 
determined through the assessment of tail snips by Transnetyx, Inc. (Cordova, TN, USA). 
Concurrent breeding of 5xFAD and WT mice generated the cohort of 5xFAD and WT control 
mice used for the study. Gender matched, 6-month-old WT, 5xFAD, 5xFAD/MMP9KO, 
5xFAD/MMP9KO-het and MMP9KO mice were used in this study (n=12, (6 x males, 6 x 
females). 5xFAD/MMP9KO-het mice were only used for pathological analysis. 
4.2.2.5 Housing 
Mice were housed under standard laboratory conditions (23 ± 1 ˚C, 50 ± 5% humidity, and a 12-
hour light/dark cycle) with free access to food and water throughout the study. Mice were multi-
housed through the elevated plus maze (EPM), open field test (OFT) and three-chamber tests. All 
experiments using animals were performed under protocols approved by the Institutional Animal 
Care and Use Committee of the Roskamp Institute. 
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4.2.3 In vivo treatment with SB-3CT in E4FAD mice 
SB-3CT has been shown to cross the BBB following intraperitoneal injection in mice [440]. In this 
study, 4-month-old E4FAD mice were injected intraperitoneally with either SB-3CT (25mg/kg) 
dissolved in 25% DMSO/65% Polyethylene glycol (PEG)-40/10% water or vehicle (25% 
DMSO/65% PEG-40/10% water alone) for 5 consecutive days per week for a total of 1 month. 
This duration was chosen to assess the effect of extended MMP-9 inhibition. Previously, seven 
days of treatment with this concentration of SB-3CT effectively inhibited MMP-9 in a mouse 
model of focal cerebral ischemia [436]. An intraperitoneal route of delivery was chosen for SB-
3CT as the inhibitor has been shown to be effectively delivered to the brain via this route in 
previous studies [204], [436]. In total, 28 animals were treated, divided into two groups balanced 
for gender and weight (E4FAD-vehicle, n=14 (5 x males, 9 x females), E4FAD-SB-3CT, n=14 (5 
x males, 9 x females)). Male and female mice weighed on average 32.41 ± 0.97 g and 21.57 ± 0.21 
g, respectively. SB-3CT treatment was adjusted for weight (25mg/kg). 
4.2.4 Study design 
 
Figure 4.1: Study design for the 4-week pharmacological MMP-9 inhibition and MMP-9 gene 
deletion in vivo analysis. 
(A) Study 1. MMP-9 was pharmacologically inhibited in E4FAD mice through a 4-week treatment with 
vehicle or SB-3CT (25 mg/kg), injected intraperitoneally (IP). (B) Study 2. MMP9KO mice were crossed 
with 5xFAD mice to create 5xFAD/MMP9KO mice, which were tested alongside WT, 5xFAD and 
MMP9KO mice. Behavioural analysis consisted of the EPM, OFT, three chamber test and the RAWM. 
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Daily intraperitoneal injections of vehicle or SB-3CT (25 mg/kg) were administered to 4-month-
old E4FAD mice, for a period of 4 weeks (Fig. 4.1a). Behavioural analysis began following 2 weeks 
of injections and mice were euthanised after 4 weeks for pathological analysis. WT, 5xFAD, 
5xFAD/MMP9KO and MMP9KO mice were tested for behavioural changes at 22 weeks of age 
and euthanised aged 26 weeks along with 5xFAD/MMP9KO-het mice for pathological analysis 
(Fig. 4.1b). 
4.2.5 Behavioural analysis 
4.2.5.1 Evaluation of anxiety-related behaviour and motor activity in mice 
Motor function and anxiety were assessed in E4FAD mice after 2 weeks of treatment of either 
SB-3CT (25mg/kg) or vehicle, and in WT, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice using 
the elevated plus maze and the open field test. The EPM consists of an elevated area (0.5m) with 
two open arms and two closed arms with 15 cm high walls and an open roof (similar arms are 
opposite each other) [448]. Mice were individually placed in the centre of the maze and movements 
were tracked using the EthoVision software for 5 minutes (Noldus, VA, USA). Mice were scored 
based on the number of entries into closed vs open arms and the time spent in closed vs open 
arms. An increase in open arm activity indicates anti-anxiety behaviour [449]. The OFT is a 
common measure of exploratory behaviour and general activity in mice [450]–[452]. The mice 
were individually placed into an enclosure with surrounding walls and an open roof and 
movements were tracked using the EthoVision software for 10 minutes (Noldus, VA, USA). Mice 
were scored based on the number of entries into the centre, middle and outer edges of the arena 
and the time spent in these three areas. An increase in duration/number of entries into the centre 
area indicates anti-anxiety behaviour [450]–[452]. The distanced travelled by the animal in the OFT 
provides a measure of motor activity [450], [451]. 
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4.2.5.2 Assessment of social interaction and social memory in mice 
The three-chamber test was used in these studies to measure cognition in the form of general 
sociability and interest in social novelty [453] in E4FAD mice following 2.5 weeks of SB-3CT 
treatment, and in WT, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice. Mice are typically social 
animals, preferring to spend more time with other mice, and have a natural tendency to investigate 
a novel mouse rather than a familiar one [454]. In this test, mice were placed individually into the 
centre chamber of a box arena with three equally sized chambers and openings between the 
chambers. A schematic of the setup is displayed in Figures 4.3 and 4.10. The two side chambers 
contained a wire cup through which the subject mouse can have indirect interaction with the novel 
and familiar mice. This test consisted of three 10-minute experimental sessions with different 
setups. In all sessions, the subject mouse could explore the whole arena. In the first session 
(habituation) the two side chambers remained empty to give the mice time to explore and become 
familiar with the arena. In the second session (test for social interaction), a mouse was added to 
the wire cup in one side chamber. In the third session (test for social memory), a novel mouse was 
placed in the wire cup in the opposite side chamber to the now familiar mouse. Positions of the 
novel and familiar mice were changed between trials to avoid side bias. The principle of the test is 
to present the subject mouse with a choice to spend time in any of the three compartments in the 
box arena during each of these experimental sessions and interact with mice that may be present 
[453]. Time spent in each chamber, time spent in the immediate area surrounding the wire cup, 
and the number of entries into each area were recorded. The test for social interaction measured 
the time spent with another mouse compared to time spent alone in an identical but empty 
chamber. The test for social memory measured the preference for a novel vs familiar mouse [453]. 
4.2.5.3 Assessment of spatial memory in mice 
Spatial memory and learning was assessed in E4FAD mice after 3 weeks of treatment with either 
vehicle or SB-3CT, and in WT, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice using the radial 
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arm water maze (RAWM) [455]. The RAWM has been shown to be a sensitive measure for 
detecting learning ability and memory deficits in mice [456]–[458]. The mice underwent nine trials 
per day for a total of five consecutive days. The RAWM consists of a circular water-filled maze 
with six arms extending from an open central area that are distinguishable by unique visual cues 
on the end of each arm. A schematic of the setup is displayed in Figures 4.4 and 4.12. The mice 
were placed into one of the five entry arms (alternated between trials) and the task was to find the 
hidden platform in the sixth arm (goal arm), which remained constant. Each trial ended after one 
minute and errors were calculated after tracking the movements using the EthoVision software 
(Noldus, VA, USA). Entry into an incorrect arm was scored as an error. The total number of 
incorrect errors made per trial before finding the hidden platform reflects reference memory, while 
the number of incorrect re-entries (multiple entries into the same arm) indicates working memory. 
By the last day of trials, mice that have correctly learned the location of the hidden platform 
demonstrate errors of 1 or less and show improvement between trials [455]. Latency to reach the 
hidden platform was also recorded and analysed. 
4.2.6 Isolation of brain fractions 
Mouse brains were homogenised and the cerebrovasculature, parenchyma and soluble brain 
fraction were isolated using a step-wise density gradient extraction process as previously described 
[182]. Briefly, mouse brain samples were homogenised in cold HBSS using a Dounce homogeniser. 
The homogenates were suspended in HBSS with 20% dextran and centrifuged for 15 minutes at 
6000g and 4 °C. The cerebrovascular pellet at the bottom of the tube was gently rinsed in HBSS 
and collected with lysis buffer (M-PER + 1% EDTA + 0.2% PMSF (Thermo Scientific, USA)) 
supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, USA). 
The remaining parenchyma and soluble brain fraction were centrifuged for a further 10 minutes 
to separate these two fractions. The parenchyma was resuspended in HBSS and centrifuged for a 
final 5 minutes before the pellet was collected in lysis buffer. All fractions were stored at -80 °C 
prior to analysis. 
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4.2.7 Guanidine extraction 
Levels of soluble and insoluble Aβ40 and Aβ42 were analysed in the brain. Briefly, half of the 
parenchyma material was homogenised by sonication in lysis buffer (M-PER + 1% EDTA + 0.2% 
PMSF (Thermo Scientific, USA)) supplemented with Halt protease and phosphatase inhibitor 
cocktail (Thermo Scientific, USA) on ice before centrifugation at 15000g for 30 minutes at 4 °C.  
The resulting supernatant was mixed with an equal amount of 5M guanidine in TRIS buffer 
generating the guanidine soluble (GS) fraction. For the guanidine insoluble (GI) fraction, the pellet 
was resolubilised in lysis buffer and combined with an equal amount of 5M guanidine solution. 
Both GS and GI fractions were subsequently incubated at room temperature for 1 hour and were 
mixed every 15 minutes. The GI fraction was centrifuged for another 30 minutes at 15000g, 4 °C 
to remove debris. All samples were stored at -80 °C prior to analysis. Quantification of Aβ40 and 
Aβ42 in the GS, GI, whole parenchyma, cerebrovascular and plasma fractions was carried out 
using an ELISA for human Aβ40 and Aβ42 (Invitrogen, USA). 
4.2.8 Zymographic analysis of EFAD spleen samples 
Spleen samples from SB-3CT and placebo-treated E4FAD mice were analysed for MMP-9 content 
through zymographic analysis as described in Chapter 2.2.7. 
4.2.9 Statistical analysis 
Data are expressed as mean ± SEM. Data was checked for normality and statistical significance 
was determined by ANOVA followed by the two-stage step-up method of Benjamini, Krieger and 
Yekutieli unless otherwise stated. A p-value lower than 0.05 was used to indicate a statistically 
significant difference. Statistical analyses were performed with GraphPad Prism 8. 
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4.3 Results 
4.3.1 Pharmacological inhibition of MMP-9 activity with SB-3CT in E4FAD mice 
4.3.1.1 SB-3CT treatment influenced anxiety levels but not motor activity in E4FAD mice 
The EPM and the OFT revealed there were no differences in total distance travelled or average 
velocity between the SB-3CT-treated and vehicle-treated mice (Fig. 4.2b, c, e, f), indicating the 
drug treatment does not alter locomotor activity. Furthermore, while no effects in anxiety were 
demonstrated in the OFT (Fig. 4.2a), SB-3CT-treated mice spent significantly more time in the 
closed arm compared to control animals in the EPM (*p<0.05) (Fig. 4.2b). There were no gender 
differences observed in either the EPM or the OFT. 
4.3.1.2 SB-3CT treatment did not impact social interaction, social memory, or spatial memory 
E4FAD mice treated with either SB-3CT or vehicle showed no preference for the chamber or 
proximal zone containing a mouse compared to an empty cage in the three-chamber test (Fig. 4.3a, 
b). Furthermore, there were no differences between either group in the time spent with a novel 
mouse compared to a familiar mouse (Fig. 4.3c, d). There were no gender differences observed in 
the three-chamber test. In the RAWM, again no differences between the SB-3CT or vehicle-treated 
mice were observed in the number of incorrect entries made before finding the hidden platform 
(Fig. 4.4b), the latency to find the platform (Fig. 4.4c), the average distance travelled per trial (Fig. 
4.4d) or the average velocity (Fig. 4.4e). Overall mice in both treatment groups continued to learn 
and improve each of the 5 days, making few incorrect entries and finding the hidden platform 
quickly. A schematic of the RAWM is shown in Figure 4.4a. When stratified for gender, male mice 
treated with SB-3CT displayed a slightly reduced latency to find the hidden platform, however this 
was not significant (Fig. 4.5c). 
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Figure 4.2: Anxiety-related behaviour and locomotor activity in the OFT and the EPM. 
SB-3CT and vehicle-treated E4FAD mice were tested using (A, B, C) the OFT and (D, E, F), the EPM. 
(A) For the OFT, the duration spent in the outer, middle and centre areas of the circular arena was measured 
along with (B) the total distance travelled and (C) the average velocity. (D) For the EPM, the duration spent 
in the closed and open arms was measured together with (E) the total distance travelled and (F) the average 
velocity. Values represent mean ± SEM (N = 14). Statistical significance was determined by (A, D) two-
way ANOVA followed by the BKY procedure and (B, C, E, F) an unpaired t-test. *p<0.05. 
~ 107 ~ 
 
 
Figure 4.3: Testing social interaction and social memory using the three-chamber test. 
SB-3CT and vehicle-treated E4FAD mice were tested for (A, B) social interaction (one mouse vs empty 
cage) and (C, D) social memory (novel mouse vs familiar mouse) in the three-chamber test. Time spent in 
(A, C) the whole chamber containing the mouse/empty cage and (B, D) the proximal zone surrounding 
the cages was measured (areas shown in green in each accompanying schematic). Values represent mean ± 
SEM (N = 14). No statistical significance was identified in any measures by a two-way ANOVA. 
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Figure 4.4: Spatial memory testing using the RAWM. 
SB-3CT and vehicle-treated E4FAD mice were tested for their ability to find the hidden platform in the 
RAWM. (A) A schematic of the maze layout is displayed. Mice were tested in nine trials per day for 5 days. 
(B) The number of incorrect entries made and (C) the time taken to find the maze were recorded and 
analysed. (D) The total distance travelled per trial and (E) the average velocity while swimming was also 
evaluated. Values represent mean ± SEM (N = 14). No statistical significance was identified in any of the 
parameters by a two-way ANOVA. 
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Figure 4.5: Spatial memory testing of male mice using the RAWM. 
SB-3CT and vehicle-treated male E4FAD mice were tested for their ability to find the hidden platform in 
the RAWM. (A) A schematic of the maze layout is displayed. Mice were tested in nine trials per day for 5 
days. (B) The number of incorrect entries made and (C) the time taken to find the maze were recorded and 
analysed. (D) The total distance travelled per trial and (E) the average velocity while swimming was also 
evaluated. Values represent mean ± SEM (N = 5). No statistical significance was identified in any of the 
parameters by a two-way ANOVA. 
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4.3.1.3 Amyloid levels remained similar for SB-3CT and vehicle-treated E4FAD mice 
Aβ-40 and Aβ-42 levels were evaluated in the brain parenchyma fractions of SB-3CT and vehicle-
treated E4FAD mice. The whole parenchyma brain fraction was analysed in addition to the 
guanidine soluble and insoluble parenchyma fractions. In addition, Aβ-42 levels were analysed in 
the cerebrovasculature of each mouse. While no differences in Aβ-40 and Aβ-42 levels were 
detected in any fraction, amyloid levels were typically higher in female mice compared to male 
mice (*p<0.05, **p<0.01, ***p<0.001) (Fig. 4.6). 
4.3.1.4 LDLR and LRP1 levels were unchanged across treatment groups in E4FAD mice 
LDLR and LRP1 were measured in the cerebrovasculature and soluble brain fraction of SB-3CT 
and vehicle-treated E4FAD mice (Fig. 4.7). Levels of both receptors remained unchanged in both 
brain fractions of SB-3CT and vehicle-treated mice (Fig. 4.7a, b, c, d). There were no gender 
differences observed in the analysis of LRP1 or LDLR. 
4.3.1.5 Pro and total MMP-9 levels were unaltered by SB-3CT treatment 
To examine the effects of the MMP-9 inhibitor (SB-3CT) on MMP-9 activity, the spleens of each 
mouse were examined via zymography (Fig. 4.8a, b), owing to the high expression levels of MMP-
9 in this tissue type [459]–[461]. Of note, neither pro nor active MMP-9 levels were high enough 
in the mouse brain tissue samples to be detected via zymographic analysis. ProMMP-9 levels were 
detected in the spleens of the mice; however, no differences were identified between mice treated 
with SB-3CT or vehicle (Fig. 4.8a, b). Furthermore, to investigate whether total MMP-9 expression 
levels in the brain were altered by SB-3CT treatment, cerebrovasculature and parenchyma brain 
samples were analysed for MMP-9 in an ELISA. No differences in total MMP-9 levels were 
identified between SB-3CT and vehicle-treated mice in either fraction (Fig. 4.8c, d). 
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Figure 4.6: Analysis of Aβ-40 and Aβ-42 levels in the cerebrovasculature, whole parenchyma and 
the GS and GI parenchyma brain fractions. 
Aβ-40 levels were examined in the (A) whole parenchyma, (B) GS parenchyma and (C) GI parenchyma of 
E4FAD mice. Aβ-42 levels were examined in the (D) cerebrovasculature, (E) whole parenchyma, (F) GS 
parenchyma and (G) GI parenchyma of E4FAD mice. Males and females were analysed separately due to 
large differences in amyloid levels. Values represent mean ± SEM (females: N = 9 per group, males: N= 5 
per group). Statistical significance was determined by two-way ANOVA followed by the BKY procedure. 
*p<0.05, **p<0.01 ***p<0.001. 
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Figure 4.7: Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain 
fraction. 
Levels of the (A, B) LDLR receptor and (C, D) LRP1 receptor were analysed in the (A, C) soluble brain 
fraction and (B, D) the cerebrovasculature of SB-3CT and vehicle-treated E4FAD mice. Values represent 
mean ± SEM (females: N = 9 per group, males: N= 5 per group). No statistically significant differences in 
LDLR or LRP1 levels were identified between vehicle or SB-3CT-treated mice in either brain fraction by a 
two-way ANOVA. 
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Figure 4.8: Analysis of MMP-9 levels in SB-3CT and vehicle-treated E4FAD mice. 
(A, B) Levels of proMMP-9 were examined in spleen samples from SB-3CT and vehicle-treated mice by 
zymography. (A) Zymography gel showing bands of proMMP-9 in SB-3CT-treated and control animals. 
(B) Quantification of zymographic analysis. (C, D) Levels of total MMP-9 as measured by ELISA analysis 
of the (C) cerebrovasculature and (D) the whole brain parenchyma of SB-3CT and vehicle-treated E4FAD 
mice. Values represent mean ± SEM (females: N = 9 per group, males: N= 5 per group). No statistical 
significance was identified in any fraction by a two-way ANOVA. 
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4.3.2 Genetic manipulation of MMP-9 in 5xFAD mice 
4.3.2.1 Anxiety and motor function differ between 5xFAD and 5xFAD/MMP9KO mice 
The OFT demonstrated that 5xFAD mice exhibit reduced anxiety compared to all other genotypes 
(Fig. 4.9a). WT, 5xFAD/MMP9KO and MMP9KO mice spent more time close to the walls in the 
outer area of the arena, while 5xFAD mice spent significantly less time in this area (**p<0.01). 
Instead, 5xFAD mice spent significantly more time in the middle area of the arena, away from the 
walls, than the other genotypes (*p<0.05) (Fig. 4.9a). Results showing the time spent in the closed 
and open arms of the EPM indicate that 5xFAD mice spent less time in the closed arms compared 
to MMP9KO mice (*p<0.05) (Fig. 4.9d). In the OFT, the total distance travelled, and the average 
velocity were both reduced in 5xFAD/MMP9KO compared to 5xFAD and WT mice (*p<0.05, 
**p<0.01) (Fig. 4.9b, c). In the EPM, these parameters were both increased in 5xFAD mice 
compared to 5xFAD/MMP9KO and MMP9KO mice (*p<0.05) (Fig. 4.9e, f). There were no 
gender differences observed in either the EPM or the OFT. 
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Figure 4.9: Anxiety-related behaviour and locomotor activity in the OFT and the EPM. 
Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were tested using (A, B, C) the OFT and (D, 
E, F), the EPM. (A) For the OFT, the duration spent in the outer, middle, and centre areas of the circular 
arena was measured along with (B) the total distance travelled and (C) the average velocity. (D) For the 
EPM, the duration spent in the closed and open arms was measured together with (E) the total distance 
travelled and (F) the average velocity. Values represent mean ± SEM (N = 12). Statistical significance was 
determined by (A, D) two-way ANOVA and (B, C, E, F) one-way ANOVA followed by the BKY 
procedure. *p<0.05, **p<0.01. 
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4.3.2.2 Genetic deletion of the MMP-9 gene rescues social memory deficits in 5xFAD mice 
The EPM and OFT were followed by the three-chamber test to assess social interaction behaviour 
(general sociability) and interest in social novelty in each genotype group. Regarding sociability, all 
genotypes spent significantly more time in the chamber with another mouse compared to the 
chamber with an empty cage (*p<0.05, **p<0.01, ***p<0.001) (Fig. 4.10a). When examining the 
time spent in close proximity to the empty cage or the cage containing a mouse, again, all genotypes 
spent more time in the proximal zone surrounding the cage containing the mouse compared to 
the empty cage (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) (Fig. 4.10b). However, 5xFAD 
mice spent significantly less time interacting with the mouse compared to WT mice (p<0.05) (Fig. 
4.10b). Following the introduction of a novel mouse in the test for social memory, WT, 
5xFAD/MMP9KO and MMP9KO mice all spent significantly more time with the novel mouse 
compared to the familiar mouse. Conversely, 5xFAD mice did not show a significant preference 
for either the novel or the familiar mouse (Fig. 4.10c, d). Overall, 5xFAD mice showed a lack of 
social interaction and increased deficits in social memory as demonstrated by a greater disinterest 
in exploring the novel mouse compared to the empty cage, and the novel mouse compared to the 
familiar mouse, respectively. Notably, this was not observed in the 5xFAD/MMP9KO mice, 
which exhibited behaviour akin to the WT and MMP9KO mice (Fig. 4.10c, d). Further analysis of 
this data revealed that these observed differences were driven by the male mice in each group (Fig. 
4.11). When analysing the males alone, the previously observed differences were more pronounced 
and additional differences were identified. For example, when examining the proximal zone near 
the cages containing the mice, male 5xFAD/MMP9KO mice spent significantly more time with 
the novel mouse compared to the familiar mouse (*p<0.05) (Fig. 4.11d). 
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Figure 4.10: Testing social interaction and social memory using the three-chamber test. 
Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were tested for (A, B) social interaction (one 
mouse vs empty cage) and (C, D) social memory (novel mouse vs familiar mouse) in the three-chamber 
test. Time spent in (A, C) the whole chamber containing the mouse/empty cage and (B, D) the proximal 
zone surrounding the cages was measured (areas shown in green in each accompanying schematic). Values 
represent mean ± SEM (N = 12). Statistical significance was determined by a two-way ANOVA followed 
by the BKY procedure. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 4.11: Testing social interaction and social memory of male mice using the three-chamber 
test. 
Male wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were tested for (A, B) social interaction 
(one mouse vs empty cage) and (C, D) social memory (novel mouse vs familiar mouse) in the three-chamber 
test. Time spent in (A, C) the whole chamber containing the mouse/empty cage and (B, D) the proximal 
zone surrounding the cages was measured (areas shown in green in each accompanying schematic). Values 
represent mean ± SEM (N = 6). Statistical significance was determined by a two-way ANOVA followed 
by the BKY procedure. *p<0.05, **p<0.01, ***p<0.001. 
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4.3.2.3 No deficits in spatial memory were identified in 5xFAD or 5xFAD/MMP9KO mice 
The RAWM was used to investigate working and reference memory (Fig. 4.12a). Analysis of the 
WT, 5xFAD, 5xFAD/MMP9KO or MMP9KO mice in the RAWM revealed no differences in the 
number of incorrect entries made for any genotype (Fig. 4.12b). All genotypes made gradually 
fewer mistakes as the trials progressed and the time taken to reach the platform also decreased by 
day 5 of testing. Again, no differences between genotypes were identified (Fig. 4.12c). The number 
of incorrect re-entries (multiple entries into the same arm per trial) was also assessed however, 
after day 1, this type of error was no longer made. When examining the distance travelled and the 
average velocity, no differences were detected between any groups (Fig. 4.12d, e). Overall, this data 
indicates that all groups showed continued improvement over the 5 days of trials, making few 
mistakes, and finding the platform quickly, even the 5xFAD mice. There were no gender 
differences observed in the RAWM. 
4.3.2.4 Amyloid levels were similar across genotypes 
Aβ-40 and Aβ-42 levels were evaluated in the cerebrovasculature and the brain parenchyma 
fractions of 5xFAD, 5xFAD/MMP9KO and 5xFAD/MMP9KO-het mice (Fig. 4.13, 4.14). WT 
and MMP9KO mice were excluded from analysis due to negligible Aβ levels. The parenchyma 
brain fraction was also analysed for soluble and insoluble amyloid following extraction with 
guanidine hydrochloride. In addition, Aβ-40 levels were analysed in the plasma of each mouse (Fig. 
4.13). While no differences in Aβ-40 and Aβ-42 levels were detected in any fraction, amyloid levels 
were typically higher in female mice compared to male mice (*p<0.05, **p<0.01, ***p<0.001) 
(Fig. 4.13, 4.14). 
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Figure 4.12: Testing spatial memory using the RAWM. 
Wild type, 5xFAD, 5xFAD/MMP9KO and MMP9KO mice were tested for their ability to find the hidden 
platform in the RAWM. (A) A schematic of the maze layout is displayed. Mice were tested in nine trials per 
day for 5 days. (B) The number of incorrect entries made and (C) the time taken to find the maze were 
recorded and analysed. (D) The total distance travelled per trial and (E) the average velocity while swimming 
were also evaluated. Values represent mean ± SEM (N = 12). No statistical significance was identified in 
any of the parameters by a two-way ANOVA. 
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Figure 4.13: Analysis of Aβ-40 levels in the cerebrovasculature, plasma, whole parenchyma and the 
GS and GI parenchyma brain fractions. 
Aβ-40 levels were examined in the (A) cerebrovasculature, (B) whole parenchyma, (C) GS parenchyma, (D) 
GI parenchyma and (E) plasma of 5xFAD, 5xFAD/MMP9KO and 5xFAD/MMP9KO-het mice. Males 
and females were analysed separately due to large differences in amyloid levels. Values represent mean ± 
SEM (N = 6). Statistical significance was determined by two-way ANOVA followed by the BKY procedure. 
*p<0.05, **p<0.01, ***p<0.001. 
 
~ 122 ~ 
 
 
Figure 4.14: Analysis of Aβ-42 levels in the cerebrovasculature, whole parenchyma and the GS and 
GI parenchyma brain fractions. 
Aβ-40 levels were examined in the (A) cerebrovasculature, (B) whole parenchyma, (C) GS parenchyma and 
(D) GI parenchyma of 5xFAD, 5xFAD/MMP9KO and 5xFAD/MMP9KO-het mice. Males and females 
were analysed separately due to large differences in amyloid levels. Values represent mean ± SEM (N = 6). 
Statistical significance was determined by two-way ANOVA followed by the BKY procedure. **p<0.01, 
****p<0.0001. 
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4.3.2.5 LDLR and LRP1 levels 
The cerebrovasculature of WT, 5xFAD, 5xFAD/MMP9KO, 5xFAD/MMP9KO-het and 
MMP9KO mice was analysed for LDLR and LRP1 levels to determine the effect of MMP-9 gene 
deletion on lipoprotein receptor shedding (Fig. 4.15b, d). No differences were detected between 
any genotype. Similarly, no differences were observed in receptor levels in the soluble brain 
fraction in any group (Fig. 4.15a, b). All genotypes displayed similar levels of LDLR and LRP1 in 
both brain fractions (Fig. 4.15). There were no gender differences observed in the analysis of LRP1 
or LDLR. 
 
 
Figure 4.15: Analysis of LDLR and LRP1 levels in the cerebrovasculature and the soluble brain 
fraction. 
Levels of the (A, B) LDLR receptor and (C, D) LRP1 receptor were analysed in the (A, C) soluble brain 
fraction and (B, D) the cerebrovasculature of wild type, 5xFAD, 5xFAD/MMP9KO, 5xFAD/MMP9KO-
het and MMP9KO mice. Values represent mean ± SEM (N = 12). No statistically significant differences 
in LDLR or LRP1 levels were identified between any genotype in either brain fraction by a two-way 
ANOVA. 
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4.4 Discussion 
Following the identification of several mechanisms by which apoE regulates MMP-9 function 
along with the reduced ability of the apoE4 isoform to attenuate MMP-9 levels and activity in AD, 
the effect of MMP-9 inhibition was assessed in E4FAD mice. Both MMP-9 and apoE4 have been 
implicated in early AD pathology, before the onset of cognitive impairment [99], [210], [211], [422], 
[423]. Therefore, in the current studies, treatment with the MMP-9 inhibitor, SB-3CT, began in 4-
month-old E4FAD mice, an age at which these transgenic animals are in the early stages of plaque 
development [247]. The upregulation of MMP-9 in multiple degenerative and inflammatory disease 
states has prompted many to pursue therapies that reduce its detrimental effects. Increased MMP-
9 levels are apparent in AD [200], [208], [309], along with other neurological diseases [203], [204], 
[227], [426]–[431], where they have been shown to perpetuate disease progression. Studies have 
shown that the benefits of MMP-9 inhibition following the injection of Aβ in rodents include 
improved cognition [212], [310]. In the present studies, the influence of MMP-9 in AD was 
examined by crossing 5xFAD mice with MMP9KO mice. 
Behavioural and psychological symptoms are common in AD and can significantly impact social 
interactions, leading to social withdrawal [462]–[466]. The sociability of the mice used in the 
current studies was measured with the three-chamber test. While mice are generally social animals 
[454], the E4FAD mice did not display a preference for the mouse compared to the empty cage, 
indicating a reduced sociability. Similarly, though the 5xFAD mice did spend significantly more 
time with the mouse than the empty cage, it did so to a lesser degree than the WT mice, consistent 
with previous studies demonstrating reduced sociability in this mouse model progressing from 3 
months of age [467]. This reduced interest in social interaction in 5xFAD mice was not apparent 
in the 5xFAD/MMP9KO mice, suggesting that removal of the MMP-9 gene in this AD mouse 
model beneficially impacted sociability. Furthermore, when a novel mouse was introduced, the 
WT, MMP9KO and the 5xFAD/MMP9KO mice all spent significantly more time with it 
~ 125 ~ 
 
compared to the familiar mouse, however the 5xFAD mice did not, indicating an impairment in 
social recognition memory that has been previously reported for this AD mouse model [468]. 
Notably, this impairment was not observed when the MMP-9 gene was absent. The CA2 region 
of the hippocampus has been shown to be crucial for sociocognitive memory processing [469] and 
in 6-month-old 5xFAD mice, the hippocampus shows considerable amounts of Aβ [66]. Our 
previous research demonstrated that inhibition of MMP-9 mitigated the Aβ-induced lipoprotein 
receptor shedding in the brains of apoE4 mice in addition to increasing the clearance of 
intracranially injected Aβ from the brain to the periphery [222]. However, this does not appear to 
be the main mechanism underlying the improved social memory in the 5xFAD/MMP9KO mice 
since Aβ-40 and Aβ-42 levels in the parenchyma, cerebrovasculature and Aβ-40 levels in the 
plasma remained constant across genotypes. Moreover, the levels of the lipoprotein receptors were 
unchanged between the different genotypes, suggesting that there were no discernible effects on 
LRP1 and LDLR shedding. Although knocking out MMP-9 in the 5xFAD mice did not result in 
obvious shifts in Aβ, it may have prevented the involvement of MMP-9 in Aβ-induced cognitive 
deficits [212]. Mizoguchi et al. demonstrated that the injection of Aβ increases MMP-9 expression 
and that this increase is associated with the development of cognitive impairment and 
neurotoxicity [212]. Recognition memory, as measured by the novel object recognition test, was 
impaired in Aβ-injected WT mice but not MMP9KO mice or WT mice treated with an MMP 
inhibitor [212], coinciding with the current studies using the three-chamber test. Like other mouse 
models of AD, 5xFAD mice display increased levels of MMP-9 compared to WT mice [445], [446], 
which could be contributing to the observed deficits in social recognition memory in these mice. 
Thus MMP-9 could be a target to improve social memory. 
While it was anticipated that MMP-9 modulation would alter brain Aβ levels by facilitating 
lipoprotein receptor transit across the BBB, removing MMP-9 may prevent other harmful actions 
of the enzyme, and could explain the differences observed between the 5xFAD and the 
5xFAD/MMP9KO mice. For instance, the degradation of matrix proteins in the vascular basal 
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lamina by MMP-9, leading to the disruption of the BBB, has been suggested to contribute to the 
brain damage that occurs following cerebral ischemia [470]–[472], which has been shown to be 
attenuated by MMP-9 inhibition [166], [432]. Alternatively, the degradation of laminin or other 
matrix proteins by MMP-9 throughout the brain may disrupt cell–matrix interactions and play a 
role in neuronal cell death [206], which may be reduced following the deletion of MMP-9. In fact, 
inhibition of MMP-9 has been shown to reduce tissue damage, neutrophil infiltration, oxidative 
stress and degenerating neurons [166], [431], [432], all factors which could contribute to the 
impaired social memory in the 5xFAD mice [236], [240], [473]–[476]. 
MMPs, in particular MMP-9, have been suggested to have a generalised role in the maintenance 
of long-term potentiation (LTP) and the nonpathological synaptic plasticity and function in intact 
adult brains [477]–[480]. In previous studies MMP-9 inhibition has led to the disruption of late-
phase LTP [477]–[480]. However, excessive MMP-9 activity is deleterious to the cells and MMP-
9 inhibition has also been shown to enhance LTP under conditions of excessive and prolonged 
MMP-9 activity [481]. Under normal conditions MMP-9 activity is strictly regulated, and the 
transient proteolytic activity required for structural remodelling is focal and quickly terminated 
following its completion. Conversely, in pathological conditions, MMP-9 activity is widespread 
and sustained, leading to abnormal synaptic plasticity and impairments in cognitive function [481], 
[482], which may describe the deficits in social recognition memory observed in the 5xFAD but 
not the 5xFAD/MMP9KO mice.  
The modulation of MMP-9 in 5xFAD mice appeared to be more effective in male mice, which 
may be because they have inherently less pathology compared to female mice [236], [239]. This is 
consistent with the results from clinical studies, where treatments are most effective in the early 
stages of pathology [298], [299]. In contrast to social recognition memory, spatial recognition 
memory was not impacted by MMP-9 deletion or inhibition in the mice, however, male E4FAD 
mice treated with SB-3CT located the hidden platform slightly faster than the vehicle-treated mice 
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over the course of the 5 days. This finding was not statistically significant, possibly owing to the 
reduced number of mice in this subgroup analysis (N=5) [483], [484]. Spatial disorientation is 
frequently observed in AD with patients displaying impaired visuospatial memory [485]–[487]. 
Spatial recognition memory has been previously shown to be impaired in 4-month-old E4FAD 
mice using the two-trial Y-maze and the Morris Water Maze [251], however, in the RAWM used 
in these studies, the control E4FAD mice continued to learn each day, making few mistakes by 
day 5 and finding the platform quickly. Likewise, the performance of the 5xFAD mice at 6 months 
of age was similar to the WT mice and did not exhibit deficits in spatial memory. Deficits in spatial 
memory and recognition memory are both initial symptoms of AD [488], though spatial memory 
typically presents earlier in the spectrum of cognitive impairment than recognition memory [468], 
[489]–[492]. In contrast, in the current studies, the 6-month-old 5xFAD mice displayed 
impairment of social recognition memory but not spatial memory. While memory impairment in 
this 5xFAD mouse strain has been detected as young as 1 month of age through the Morris water 
maze [493], [494], others have found that 5xFAD mice display normal spatial memory function in 
this test until 7 months of age [238] or even up to 12 months of age [495]. Likewise, recognition 
memory has been shown to emerge at 4 months of age [495] in one study and at 9 months of age 
in another [468]. These results indicate that behaviour results can vary considerably by experiment 
and memory impairment can be specific to context, modality, and/or environment [467]. Because 
the E4FAD and the 5xFAD made few errors by day 5, it is difficult to discern whether the SB-
3CT treatment or the MMP-9 knockout had any impact on spatial memory in these studies. Future 
studies would need to assess the effect of both approaches in older mice with more apparent 
deficits in spatial memory, whilst taking into account potential differences in gender. 
It has been demonstrated that 5xFAD mice display reduced anxiety in the EPM compared to WT 
mice, as measured by increased time spent in the open arms compared to the closed arms [240], 
[496], [497], which coincides with the results from the present studies and reflects a tendency 
toward disinhibition. This disinhibition is one of the neuropsychiatric symptoms seen in AD 
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patients, manifesting as impulsive behaviour and the disregard for danger [498]–[500]. The 
preference for the open arms in the EPM by 5xFAD mice has been suggested to be caused by 
impaired tactile sensation from the vibrissae, which is thought to lead to overstimulation and 
consequent avoidance of the closed arms [468]. However, the 5xFAD mice also spent less time in 
the outer edges of the OFT where this factor has less influence. Conversely, the behaviour of the 
5xFAD/MMP9KO mice in the OFT and the EPM was similar to the WT mice, indicating that 
removing MMP-9 may have influenced anxiolytic behaviour in the 5xFAD mice. It is necessary to 
analyse locomotor behaviour of the mice in these tests since anxiety measures can be confounded 
by levels of activity [501]. The increased locomotor activity in the 5xFADs has also been previously 
documented and attributed to alterations in neurotransmitter levels [468], [502] in addition to 
decreased anxiety [503]. In the present studies 5xFAD/MMP9KO mice had significantly lower 
locomotor activity compared to the 5xFAD mice as measured by distanced moved and average 
velocity, suggesting that the MMP-9 gene may be influencing anxiety-related behaviours. MMP-9 
has previously been implicated in an increased susceptibility to anxiety disorders [504] as well as 
having elevated levels in other psychiatric illnesses [505]–[507]. Human genomics and proteomics 
studies have revealed that aberrant inflammatory responses, gene regulation and synaptic plasticity 
are the major players underlying neuropsychiatric disorders. Since MMP-9 has been implicated in 
both the inflammatory response and synaptic plasticity, and is tightly controlled by gene regulation, 
it may contribute to the development of psychiatric symptoms [507]. However, more research 
needs to be conducted to understand the precise mechanisms involved. 
The altered anxiety in E4FAD mice indicates that treatment with SB-3CT is having an effect, 
however due to limitations in the detection methods, the proteolytic activity of MMP-9 in the brain 
could not be measured. This in vivo finding is consistent with other reports owing to the rapid 
degradation of the activated MMP-9 enzyme [206]. The mechanism of action of the SB-3CT 
compound is to inhibit the activity of MMP-9, not the expression [508] and thus total MMP-9 
levels in the brains of the E4FAD mice remained unaltered. Therefore, while seven days of SB-
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3CT treatment through intraperitoneal injections has been previously shown to effectively inhibit 
MMP-9 [204], [436], it is not certain whether the observed effect on anxiety in the current studies 
was caused by the inhibition of MMP-9 activity or another effect of the drug. 
The inherent limitations of transgenic AD mouse models when investigating the underlying 
mechanisms and potential treatments for sporadic AD must be noted. 5xFAD mice are based on 
EOAD and co-express five FAD mutations, resulting in excessively high levels of Aβ-42, and 
therefore is not fully equipped to study the progression of sporadic AD, which represents >97% 
of the AD population [509], [510]. The inability to recapitulate sporadic AD in animal models due 
to the complex and heterogenous nature of the disease has hindered the development of suitable 
treatments. However, by combining common risk alleles, researchers are seeking to develop more 
translationally relevant mouse models that better reflect this more prevalent form of AD [509], 
[510]. One example of this is a new mouse strain that has been created by the MODEL-AD 
consortium which expresses two of the strongest genetic risk factors for LOAD, APOE and 
TREM2, alongside human Aβ [511], [512]. Additional LOAD risk alleles along with environmental 
risk factors will be added to this model in order to generate a phenotype which more closely aligns 
with that of sporadic AD [511], [512]. Furthermore, since AD is primarily an age-related disorder, 
a translatable model of the disease would need to include an age component to fully replicate the 
human AD condition. The use of more accurate animal models of LOAD would facilitate the 
testing of potential treatments and may result in different outcomes in preclinical studies owing to 
the different causes and progression of sporadic AD compared to EOAD. With respect to the 
current studies, using mouse models of sporadic AD would give a better indication of the effect 
of MMP-9 inhibition on the underlying mechanisms and the cognitive symptoms of AD, and its 
potential as a therapeutic target for this disorder. 
Collectively, the results from this Chapter indicate that reducing aberrant MMP-9 activity or 
expression has beneficial effects in transgenic AD mouse models, in particular on sociability, social 
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recognition memory and reduced anxiety disinhibition. Removing the MMP-9 gene in 5xFAD 
mice resulted in more apparent differences compared to pharmacological inhibition in E4FAD 
mice, which may be due to several factors. For instance, the increased length of time and earlier 
commencement (from birth) of impeding MMP-9’s harmful effects, and the lack of involvement 
of the APOE4 isoform may all contribute to the greater improvement in behaviour seen in the 
5xFAD/MMP9KO mice compared to the SB-3CT-treated E4FAD mice. Our prior work [222], 
[319] and the data presented in previous chapters appeared to indicate MMP-9 levels were elevated 
and harmful in AD, particularly when associated with the APOE4 isoform, and that MMP-9 
modulation would promote Aβ elimination from the brain. While this appears not to be the case 
in the current AD animal studies, MMP-9 did impact behaviour but seemingly through another 
mechanism. The results from these studies offer further evidence for an important role of MMP-
9 in the development of cognitive impairment and the AD phenotype. Inhibiting the harmful 
actions of MMP-9 may represent a promising therapeutic strategy for the treatment of AD and 
other neurological disorders. 
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Chapter 5: Conclusions 
Earlier work conducted by our group demonstrated that apoE influences the clearance of Aβ 
through the BBB in an isoform dependent manner by impacting the ectodomain shedding of LRP1 
and LDLR [182]. Our team found this regulation involved MMP-9, an enzyme implicated in AD 
pathology. MMP-9 treatment in brain endothelial cells and freshly isolated mouse cerebral vessels 
dose-dependently increased lipoprotein receptor shedding [222]. Furthermore, treatment with the 
MMP-9 inhibitor, SB-3CT, increased Aβ transit across the BBB in an in vitro model, and enhanced 
the clearance of intracranially injected Aβ from the brain to the periphery in apoE4-TR mice [222]. 
Therefore, our team hypothesised that apoE was influencing Aβ transit across the BBB through 
the regulation of MMP-9 and its ability to elicit lipoprotein receptor shedding. 
In this thesis, apoE was shown to modulate several regulatory mechanisms of MMP-9 in an apoE 
isoform-specific manner. A clear indication of this regulation was shown in Chapter 3, where apoE 
dose-dependently inhibited the activity of MMP-9 in a cell-free assay. ApoE2 showed the greatest 
inhibition of MMP-9 activity, while apoE4 displayed the weakest inhibition. Owing to the cell-free 
nature of this assay, it is plausible that apoE is directly interacting with MMP-9 to produce these 
effects. This theory is supported by the studies using biolayer interferometry, in which it is 
illustrated that recombinant apoE can bind to recombinant MMP-9 and that the apoE4 isoform 
demonstrated the weakest binding affinity. Furthermore, confocal microscopic analysis in EFAD 
animals showed that apoE and MMP-9 were associated within the same areas of brain endothelial 
cells, further alluding to an interaction between these two molecules within the brain. 
Notably, APOE isoform-specific differences in MMP-9 levels were detected in both human and 
mouse AD brain samples and these effects were more apparent upon insult, i.e. the presence of 
AD (APOE2<APOE3<APOE4). The results of these studies suggest that the combination of 
AD and APOE4 results in a greater elevation of MMP-9 levels in the brain. Deposition of Aβ in 
the AD brain has been reported to be higher in APOE4 carriers [131], [132] and our group and 
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others have shown that Aβ induces MMP-9 expression [212], [222], [343]. The combination of 
elevated MMP-9 levels and the APOE4 isoform could exacerbate the development of AD 
pathology through a vicious circle, where both restrict the clearance of Aβ from the brain to the 
periphery, contributing to the accumulation of Aβ in the brain, which in turn promotes further 
expression of MMP-9. 
In looking more broadly at the data in Chapters 2 and 3, MMP-9 cellular secretion in the presence 
of apoE2 and cerebrovascular MMP-9 levels in the E2FAD mice were substantially lower than the 
other apoE isoforms (apoE2<<apoE3=apoE4). The effect of apoE2 on cellular secretion and 
MMP-9 levels may be similar to that reported for the secretion of Aβ, where apoE2 significantly 
attenuated the production of APP and secretion of Aβ compared to the other apoE isoforms [347]. 
Conversely, the results from the MMP-9 activity and binding studies indicate apoE4 may be most 
relevant in the regulation of MMP-9 function. The binding affinity of apoE4 to MMP-9 and the 
influence of apoE4 on MMP-9 activity were considerably lower than the other isoforms 
(apoE2=apoE3>>apoE4). In total, while apoE can impact MMP-9 processing overall, the 
individual isoforms appear to do so through different mechanisms as our findings suggest apoE2 
is most effective in suppressing the production and/or cellular secretion of MMP-9, while apoE4 
is least effective in binding MMP-9 and modulating its activity [319]. 
Both MMP-9 and APOE4 have been implicated in early AD pathology, before the onset of 
cognitive impairment [99], [210], [211], [422], [423]. Therefore, therapeutic approaches targeting 
MMP-9 may require early administration to see the greatest benefits. SB-3CT has been shown to 
have beneficial effects in many neurological disorders including ischemia, TBI, stroke, 
subarachnoid haemorrhage and spinal cord injury [436], [441], [442], [444], [513] and in primary 
human pericyte cultures following the administration of toxic oligomeric Aβ [362]. In the current 
studies, while 30 days of SB-3CT treatment in E4FAD mice showed reduced anxiety disinhibition, 
no effects on cognition or amyloid pathology were observed. Owing to the limitations encountered 
~ 133 ~ 
 
in detecting active MMP-9 in the mouse brains, it is uncertain how much MMP-9 activity was 
inhibited in the treated mice. This would need to be rectified by using a more sensitive method to 
detect the active species of MMP-9, which is short lived and typically low in concentration [206]. 
Alternatively, to indirectly gauge the overall activity of MMP-9 in SB-3CT and vehicle-treated 
mouse brains, levels of MMP-9 substrates in the brain could be measured. In prior reporting, this 
dose of SB-3CT showed significant reductions in MMP-9 activity in the brain using a treatment 
paradigm more acute than that used in the present studies [436]. Thus, it seems likely MMP-9 was 
inhibited in the current studies, but a more chronic treatment paradigm may be necessary to 
overcome the AD phenotype, since SB-3CT treatment began in E4FAD mice at 4-months of age, 
at which time pathology is already apparent [237], [238]. 
In providing a more definitive method to investigate the role of MMP-9 in AD animals, a mouse 
model was created in which the MMP-9 gene was genetically removed in 5xFAD mice. Behaviour 
changes in these mice compared to the 5xFAD mice were more evident than the pharmacological 
inhibition studies. Notably, the absence of the MMP-9 gene in 5xFAD mice protected them against 
deficits in sociability and social recognition memory and restored anxiety disinhibition. While our 
prior work indicated that MMP-9 modulation may be beneficial due to the enhanced elimination 
of Aβ through the BBB [222], the data presented in Chapter 4 suggests that MMP-9 modulation 
did impact behaviour, but via another mechanism, as Aβ levels in the brain and plasma were 
unchanged. MMP-9 has been shown to be upregulated in 5xFAD mice compared to WT mice, 
and has been suggested to contribute, at least in part, to the detrimental effects observed in this 
mouse model including those relating to neuroinflammation and neurotoxicity [445], [446]. In that 
regard, the inhibition of MMP-9 in these mice may act to combat and reverse some of these effects, 
leading to memory improvement. 
As described in Chapter 1.4, to date, there is no disease-modifying therapy for AD patients, as the 
approved treatments merely treat symptoms of the disease instead of altering disease progression 
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and preventing cognitive decline. While these current drugs may provide transient benefits to 
patients by enhancing their cognitive abilities, this does not translate to long lasting improvements. 
Hence, disease modifying treatments are required for the successful treatment of AD. The 
investigation and advancement of alternative therapies to the ones currently used in the clinic 
remains an essential part of drug development. As indicated by the recent failures of amyloid-
directed therapies in the clinic, targeting Aβ may not be enough to fully resolve AD [514]. MMP-
9 inhibitors represent one therapeutic avenue that may help to alleviate behavioural deficits and 
restore normal brain function. As discussed in Chapter 4, this could potentially occur through an 
amyloid-independent mechanism. Due to the complex and diverse nature of AD pathology, 
inhibition of MMP-9 may be more beneficial in some individuals than others. In this regard, the 
inhibition of MMP-9 in APOE4 carriers may confer additional positive effects, owing to the higher 
levels and inefficient modulation of MMP-9 exhibited by this genotype.  
Initial trials with MMP inhibitors for the treatment of cancer yielded negative results, resulting in 
undesirable side effects such as musculoskeletal syndrome [515]–[517]. This was later found to be 
due to the broad-spectrum nature of these drugs and that inhibition of certain MMPs (MMP-2, 
MMP-9, MMP-13 and MT1-MMP) did not result in these adverse effects [518], [519]. Currently, 
there is one MMP inhibitor, doxycycline, which is FDA approved for periodontal disease treatment 
[515], [520] and there are other non-specific MMP inhibitors being tested in clinical trials as 
potential cancer treatments [201], [202]. The most recent generation of MMP inhibitors are more 
specific and display better pharmacokinetics resulting in less toxicity [515]. One such compound 
that has been recently discovered, JNJ0966, has been shown to be highly selective in its inhibition 
of MMP-9, and does not inhibit MMP-2, which is closely related [375]. These compounds offer 
renewed interest in MMP-9 inhibitors and their potential in AD and other disorders [515]. 
The data presented in Chapter 4 suggest that inhibition of MMP-9 in AD can lead to positive 
behaviour changes including the rescue of social recognition memory. Additionally, the studies 
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discussed in Chapter 1.2.3 signal that the inhibition of aberrant elevated MMP-9 expression and 
activity may be beneficial in numerous other diseases [194], [199], [200], [203], [204], [227], [426]–
[431]. The combined results from these studies suggest that inhibiting MMP-9 can lead to a wide 
array of effects including, for example, the attenuation of the immune response and the subsequent 
tissue damage in inflammatory conditions [199], [200], improvement of cardiac function [199] and 
the reduction of BBB dysfunction [203], neuronal apoptosis [204], epileptogenesis [426], myelin 
destruction [429], [430], cytokine activation [430], oxidative stress, oedema and neurodegeneration 
[431]. Consequently, the continued exploration of MMP-9 inhibitors as therapeutic agents may 
have broader applications than in AD alone. Likewise, as APOE genotype has been shown to 
influence the progression of many of these diseases [521]–[523], it follows that there may be 
interaction between apoE and MMP-9 in other disorders in which the inhibition of MMP-9 may 
be of a higher value in APOE4 carriers. 
APOE isoforms are a major genetic determinant of developing sporadic AD [109], [110], and are 
therefore undisputedly a prominent target in the advancement of therapies to combat AD. Hence 
it is crucial to understand the mechanisms involved in the development of cognitive impairment 
and the AD phenotype in depth, in particular with respect to APOE genotype, in order to 
formulate potential therapies [308]. In conclusion, the data presented in this thesis support a role 
of apoE in the modulation of MMP-9 disposition, particularly upon insult, i.e. the AD 
environment, and that apoE isoforms differ in their ability to regulate MMP-9 function 
(apoE2>apoE3>apoE4). Furthermore, the modulation of elevated MMP-9 expression and activity 
may be a promising therapeutic approach for AD and potentially other neurological disorders with 
aberrant MMP-9 activity and underlying behavioural deficits. 
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Chapter 6: Future directions 
In Chapter 3 of this thesis the binding affinities of each recombinant apoE isoform with MMP-9 
were investigated. However, due to the presence of potentially confounding proteins in the 
conditioned media containing glia-lipidated apoE, the binding affinities of these apoE species with 
MMP-9 could not be assessed. Considering that this source of apoE is more physiologically 
relevant than the delipidated recombinant apoE or the artificially lipidated apoE, it would be 
advantageous to determine whether the binding pattern follows that seen with recombinant apoE 
in the current studies (apoE2=apoE3>apoE4). Future studies would require a larger amount of 
the glia-conditioned apoE, or another source of physiologically lipidated apoE, so that it can be 
isolated and purified before analysis. For example, immortalised cell lines from primary glial 
cultures derived from apoE-TR mice could be used to generate large quantities of apoE-containing 
lipoproteins [400]. 
Further analysis of the in vivo samples will elucidate the impact of MMP-9 gene removal in the 
5xFAD mice. Brain hemispheres were collected from these mice and fixed in 4% PFA for tissue 
processing and extended investigation using immunofluorescence. This will help ascertain any 
pathological changes in the 5xFAD/MMP9KO mice which may be underlying the observed 
behavioural differences. As noted previously, this may involve changes in neurodegeneration, 
oxidative stress or neuroinflammation [166], [431], [445], [446]. The studies conducted by 
Mizoguchi et al., point to the direct involvement of MMP-9 in Aβ-induced cognitive deficits, since 
MMP-9 inhibition and knockout prevented the impairment of social recognition memory [524]. 
Therefore, a more detailed analysis of specific changes in the Aβ population following MMP-9 
removal, for instance shifts in the brain location, forms, or toxic species of Aβ, may be necessary 
to understand the influence of MMP-9 in these mechanisms. 
These studies with the MMP9KO mice provide a simplified view of the deleterious actions of 
MMP-9 in AD and the benefits associated with inhibiting it, without the complexity of apoE 
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isoforms. However, apoE-driven AD pathologies differ from pure amyloid pathologies [525], 
[526] and, as detailed in this thesis, apoE can modulate multiple aspects of MMP-9 regulation other 
than elevated expression and may still influence MMP-9 disposition after its induction. Hence, it 
would be interesting to build on these in vivo studies and cross MMP9KO mice with EFAD mice, 
to generate EFAD mice in which the MMP-9 gene is deleted. Another possibility would be to 
investigate the conditional knockout of MMP-9 in specific cells, for instance endothelial cells, to 
establish whether the release of MMP-9 in certain areas of the brain are more damaging. These 
experiments would examine the behaviour (spatial memory, learning, anxiety, and social memory), 
in addition to AD-related pathological changes on a molecular level, including Aβ disposition, 
using different detection methods such as ELISA, immunoblotting, and immunofluorescence 
microscopy. This study will provide us with more detailed information about the interactions 
between APOE and MMP-9 and the benefit of inhibiting MMP-9 in APOE4 carriers in particular, 
who represent a large proportion of AD patients. 
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